<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Endocrinology - QuizMaster Pro</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}


    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Cerebellum / qBank / Pathology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">172</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls>
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd" />
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z" />
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>
        let questionsData = [
  {
    "id": 53809,
    "choices": [
      {
        "id": 214709,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Activates a GPCR increasing cAMP. </span></span></span></p>"
      },
      {
        "id": 214710,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Directly activates PKC. </span></span></span></p>"
      },
      {
        "id": 214711,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Binds nuclear receptor. </span></span></span></p>"
      },
      {
        "id": 214712,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Interacts with tyrosine kinase receptor.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 30-year-old woman presents with complaints of polyuria (excessive urination), polydipsia (excessive thirst), and fatigue. Laboratory results reveal hyperglycemia and glucosuria. Which of the following best describes the mechanism of action of the hormone likely deficient in this patient?</span></span></span></p>",
    "unique_key": "Q5509148",
    "question_audio": null,
    "question_video": null,
    "map_id": 25404,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Interacts with tyrosine kinase receptor.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s symptoms are classic for diabetes mellitus, a condition characterized by insulin deficiency or resistance. Insulin is a peptide hormone (Group II) that binds to tyrosine kinase receptors on target cells. This binding triggers autophosphorylation of the receptor and subsequent activation of intracellular signaling cascades, leading to increased glucose uptake and utilization.<strong> </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Activates a GPCR increasing cAMP:</span></strong><span style=\"font-size:12.0pt\"> This mechanism is characteristic of some Group II hormones (e.g., glucagon), but not insulin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Directly activates PKC:</span></strong><span style=\"font-size:12.0pt\"> While PKC activation can occur downstream of insulin signaling, it is not the primary mechanism of action.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Binds nuclear receptor:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This mechanism is characteristic of Group I hormones (e.g., steroid hormones, thyroid hormones)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin interacts with tyrosine kinase receptors on target cells to mediate its effects.</span></span></span></p>",
    "correct_choice_id": 214712,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53849,
    "choices": [
      {
        "id": 214869,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Falsely low PRL levels can be due to macroprolactinemia.</span></span></span></p>"
      },
      {
        "id": 214870,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hook effect causes falsely elevated values of prolactin.</span></span></span></p>"
      },
      {
        "id": 214871,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Most common symptom in women is galactorrhea.</span></span></span></p>"
      },
      {
        "id": 214872,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Can be associated with reduced Bone Mineral Density.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is true regarding hyperprolactinemia?</span></span></p>",
    "unique_key": "Q9161599",
    "question_audio": null,
    "question_video": null,
    "map_id": 25435,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Can be associated with reduced Bone Mineral Density</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic hyperprolactinemia can reduce vertebral bone mineral density due to hypogonadism (since PRL suppresses GnRH release </span><span style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&agrave;</span></span><span style=\"font-size:12.0pt\"> it results in low FSH/LH and subsequent hypoestrogenism). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Falsely low PRL levels can be due to</span></strong><span style=\"font-size:12.0pt\"> <strong>macroprolactinemia</strong>: Macroprolactinemia is caused by aggregated forms of circulating PRL, which are usually biologically inactive. This can result in falsely increased PRL values.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hook effect causes falsely elevated values of prolactin:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Markedly elevated PRL levels (&gt;1000 &mu;g/L), can result in falsely low PRL values because of assay artifacts (the hook effect). Sample dilution is required to measure these high values accurately<strong> </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Most common symptom in women is galactorrhea:</span></strong><span style=\"font-size:12.0pt\"> Most common symptom in women is gonadal dysfunction (galctorrhea occurs in </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 80% women)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic hyperprolactinemia can reduce vertebral bone mineral density due to hypogonadism caused by prolactin suppressing GnRH release, resulting in low FSH/LH and subsequent hypoestrogenism.</span></span></span></p>",
    "correct_choice_id": 214872,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 53813,
    "choices": [
      {
        "id": 214725,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucocorticoid receptor (GR) </span></span></span></p>"
      },
      {
        "id": 214726,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thyroid hormone receptor (TR) </span></span></span></p>"
      },
      {
        "id": 214727,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vitamin D receptor (VDR) </span></span></span></p>"
      },
      {
        "id": 214728,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Retinoic acid receptor (RAR)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following steroid receptors primarily functions as a homodimer upon ligand binding?</span></span></p>",
    "unique_key": "Q3343886",
    "question_audio": null,
    "question_video": null,
    "map_id": 25408,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans. A) Glucocorticoid receptor (GR)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucocorticoid receptors (GRs) typically form homodimers upon binding to their ligand (cortisol). This homodimer then translocates to the nucleus, where it binds to specific DNA sequences called glucocorticoid response elements (GREs) to regulate gene expression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Thyroid hormone receptor (TR):</span></strong><span style=\"font-size:12.0pt\"> TRs typically form heterodimers with retinoid X receptors (RXRs).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Vitamin D receptor (VDR):</span></strong><span style=\"font-size:12.0pt\"> VDRs also primarily form heterodimers with RXRs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Retinoic acid receptor (RAR):</span></strong><span style=\"font-size:12.0pt\"> RARs predominantly form heterodimers with RXRs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Homodimer (Steroid) Receptors - ER, AR, PR, GR</span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cytoplasmic in location. Translocates to nucleus after binding to a ligand (also called as type 1 nuclear receptors)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ligands usually induce coactivator binding</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heterodimer Receptors - TR, VDR, RAR, PPAR</span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nuclear in location (also called as type 2 nuclear receptors)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ligand dissociates corepressors and induces coactivator binding</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Orphan Receptors - SF-1, DAX-1, HNF4&alpha;</span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nuclear in location and they do not have known agonists (bind to nuclear intermediates)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Action may be ligand independent &amp; can be homo-dimeric or hetero-dimeric</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-152909.png\" style=\"height:339px; width:500px\" /></span></span></span></p>",
    "correct_choice_id": 214725,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "Factual"
    ]
  },
  {
    "id": 53853,
    "choices": [
      {
        "id": 214885,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Octreotide </span></span></span></p>"
      },
      {
        "id": 214886,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Lanreotide </span></span></span></p>"
      },
      {
        "id": 214887,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Pegvisomant </span></span></span></p>"
      },
      {
        "id": 214888,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pasireotide</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 48-year-old woman with acromegaly is currently being treated with a drug but her growth hormone (GH) levels remain paradoxically elevated. Which of the following medications is she most likely taking?</span></span></p>",
    "unique_key": "Q4047374",
    "question_audio": null,
    "question_video": null,
    "map_id": 25439,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Pegvisomant</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pegvisomant is a GH receptor antagonist. It works by blocking the action of GH at its receptor, thereby reducing IGF-1 production and effectively treating the symptoms of acromegaly. However, it increases GH resistance and hence, GH levels may remain elevated. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Octreotide and Option B. Lanreotide:&nbsp;</span></strong><span style=\"font-size:12.0pt\">SRLs (somatostatin receptor ligand)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduces GH and IGF-1 levels and reduces pituitary tumor size in ~50% of patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All SRLs can cause GI side effects, glucose intolerance (or diabetes), cholesterol gall stones, asymptomatic bradycardia and hypothyroxinemia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Octreotide is available as LAR and oral forms. Lanreotide is available as slow release depot formulation. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pasireotide:</span></strong><span style=\"font-size:12.0pt\"> SRL specific for SST5 &ndash; can be used if resistant to octreotide or lanreotide. Higher prevalence of glucose intolerance and diabetes. Available as LAR.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pegvisomant, a GH receptor antagonist, can cause paradoxically elevated GH levels despite reducing IGF-1 production and treating symptoms of acromegaly.</span></span></span></p>",
    "correct_choice_id": 214887,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 53846,
    "choices": [
      {
        "id": 214857,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Surgical resection</span></span></span></p>"
      },
      {
        "id": 214858,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Radiotherapy </span></span></span></p>"
      },
      {
        "id": 214859,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GnRH analogs </span></span></span></p>"
      },
      {
        "id": 214860,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACTH</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 4-year-old child presents with precocious puberty, psychomotor delay, and laughing seizures. What is the first-line treatment?</span></span></p>",
    "unique_key": "Q1672044",
    "question_audio": null,
    "question_video": null,
    "map_id": 25432,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) GnRH analogs</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The symptoms suggest hypothalamic hamartoma, a benign tumor associated with a typical triad of&nbsp; precocious puberty, psychomotor delay, and gelastic (laughing) seizures. GnRH analogs suppress the HPG axis, halting precocious puberty.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Surgical resection:</span></strong><span style=\"font-size:12.0pt\"> Reserved for severe or refractory cases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Radiotherapy:</span></strong><span style=\"font-size:12.0pt\"> Not preferred in children due to long-term side effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. ACTH:</span></strong><span style=\"font-size:12.0pt\"> Not relevant to precocious puberty treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GnRH analogs are the first-line treatment for precocious puberty associated with hypothalamic hamartoma.</span></span></span></p>",
    "correct_choice_id": 214859,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 53818,
    "choices": [
      {
        "id": 214745,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal adult serum PRL levels are about 10&ndash;25 &micro;g/mL in women </span></span></span></p>"
      },
      {
        "id": 214746,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peak serum PRL levels (up to 30 &micro;g /mL) occur between 4:00 and 6:00 a.m </span></span></span></p>"
      },
      {
        "id": 214747,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Highest secretory peaks occurring during rapid eye movement (REM) sleep </span></span></span></p>"
      },
      {
        "id": 214748,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Circulating half-life of PRL is ~50 min</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are true about Prolactin except:</span></span></p>",
    "unique_key": "Q2966081",
    "question_audio": null,
    "question_video": null,
    "map_id": 25413,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans. C)</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Highest secretory peaks occurring during rapid eye movement (REM) sleep</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While prolactin levels do increase during sleep, the highest secretory peaks actually occur during the non-REM (NREM) stages, particularly slow-wave sleep. REM sleep is associated with a relative decrease in prolactin secretion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Normal adult serum PRL levels are about 10-25 ng/mL in women:</span></strong><span style=\"font-size:12.0pt\"> This is the typical range for non-pregnant women. Normal serum PRL levels in men are about 10-25 ng/mL. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Peak serum PRL levels (up to 30 &micro;g /mL) occur between 4:00 and 6:00 AM:</span></strong><span style=\"font-size:12.0pt\"> Prolactin levels follow a circadian rhythm, with the highest levels occurring during the early morning hours.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Circulating half-life of PRL is ~50 min:</span></strong><span style=\"font-size:12.0pt\"> Prolactin is relatively quickly cleared from the bloodstream, since it is a polypeptide.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Highest secretory peaks of prolactin occur during non-REM (NREM) sleep, not REM sleep.</span></span></span></p>",
    "correct_choice_id": 214747,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 53844,
    "choices": [
      {
        "id": 214849,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Anterior </span></span></span></p>"
      },
      {
        "id": 214850,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Central </span></span></span></p>"
      },
      {
        "id": 214851,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ventromedial </span></span></span></p>"
      },
      {
        "id": 214852,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Posterior</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 16-year-old boy has been diagnosed with craniopharyngioma. He also has hyperphagia and obesity. This is seen in damage to which of the hypothalamic nuclei? </span></span></p>",
    "unique_key": "Q5363827",
    "question_audio": null,
    "question_video": null,
    "map_id": 25430,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Ventromedial</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyperphagia (excessive eating) and obesity are characteristic symptoms of damage to the <strong>ventromedial nucleus (VMN)</strong> of the hypothalamus. The VMN is a key satiety center containing melanocortin receptors and regulated by leptin, insulin and POMC. Damage to this area can lead to a loss of satiety signals, resulting in overeating and obesity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Anterior:</span></strong><span style=\"font-size:12.0pt\"> Lesions result in Paradoxical vasoconstriction, tachycardia, and hyperthermia</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Central:</span></strong><span style=\"font-size:12.0pt\"> Lesions result in Excess sympathetic activity </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Posterior:</span></strong><span style=\"font-size:12.0pt\"> Lesions result in Periodic Hypothermia syndrome</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Damage to the ventromedial nucleus of the hypothalamus leads to hyperphagia and obesity due to loss of satiety signals.</span></span></span></p>",
    "correct_choice_id": 214851,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 53858,
    "choices": [
      {
        "id": 214905,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intravenous hypertonic saline (3%) </span></span></span></p>"
      },
      {
        "id": 214906,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fluid restriction </span></span></span></p>"
      },
      {
        "id": 214907,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Demeclocycline </span></span></span></p>"
      },
      {
        "id": 214908,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tolvaptan</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old male smoker presents with mild confusion and nausea. He has a serum sodium of 125 mEq/L and a urine osmolality of 450 mOsm/kg. His BP and JVP are normal. Which of the following is the most appropriate initial treatment for him?</span></span></p>",
    "unique_key": "Q4193613",
    "question_audio": null,
    "question_video": null,
    "map_id": 25444,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Fluid restriction</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The likely diagnosis is SIADH (history of smoking may suggest a possible small cell lung cancer). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For hyponatremia due to SIADH (without severe symptoms), the initial treatment of choice is fluid restriction. This helps correct hyponatremia by limiting water intake and allowing the body to naturally excrete excess water.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Intravenous hypertonic saline (3%):</span></strong><span style=\"font-size:12.0pt\"> This is reserved for severe hyponatremia (&lt;120 mEq/L) with significant neurological symptoms (coma, seizures)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Demeclocycline:</span></strong><span style=\"font-size:12.0pt\"> This is a tetracycline antibiotic that can be used for chronic SIADH but is not the initial treatment for mild cases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Tolvaptan:</span></strong><span style=\"font-size:12.0pt\"> This is a vasopressin receptor antagonist used for SIADH, but it is not the first-line treatment for mild cases due to its potential side effects and cost.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fluid restriction is the initial treatment of choice for hyponatremia due to SIADH without severe symptoms.</span></span></span></p>",
    "correct_choice_id": 214906,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 53842,
    "choices": [
      {
        "id": 214841,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pituitary adenomas frequently extend in a suprasellar direction. </span></span></span></p>"
      },
      {
        "id": 214842,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Headache is a common feature.</span></span></span></p>"
      },
      {
        "id": 214843,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Headache severity correlates with adenoma size or extension. </span></span></span></p>"
      },
      {
        "id": 214844,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Suprasellar extension can lead to visual loss.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 33-year-old lady presented with headache. MRI revealed a pituitary tumor. All of the following are true except?</span></span></p>",
    "unique_key": "Q6721071",
    "question_audio": null,
    "question_video": null,
    "map_id": 25428,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Headache severity correlates with adenoma size or extension.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Headaches are common features of small intrasellar tumors, even without suprasellar extension. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Because of the confined nature of the pituitary, small changes in intrasellar pressure stretch the dural plate; however, headache severity correlates poorly with adenoma size or extension.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pituitary adenomas frequently extend in a suprasellar direction:</span></strong><span style=\"font-size:12.0pt\"> Pituitary tumors often grow upwards towards the optic chiasm.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Headache is a common feature:</span></strong><span style=\"font-size:12.0pt\"> Headaches are a frequent symptom of pituitary tumors, often due to pressure effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Suprasellar extension can lead to visual loss:</span></strong><span style=\"font-size:12.0pt\"> Upward growth of a pituitary tumor can compress the optic chiasm, leading to visual field defects or loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Headache severity in pituitary adenomas does not correlate well with tumor size or extension.</span></span></span></p>",
    "correct_choice_id": 214843,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53820,
    "choices": [
      {
        "id": 214753,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic glucocorticoid excess decreases GH release. </span></span></span></p>"
      },
      {
        "id": 214754,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGF-1 inhibits GH. </span></span></span></p>"
      },
      {
        "id": 214755,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH stimulates lipolysis, leading to reduced lean body mass. </span></span></span></p>"
      },
      {
        "id": 214756,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGFBP3 is the major carrier protein for IGF-1.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is false regarding GH and IGF-1?</span></span></p>",
    "unique_key": "Q4099554",
    "question_audio": null,
    "question_video": null,
    "map_id": 25415,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) GH stimulates lipolysis, leading to reduced lean body mass.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH stimulates lipolysis (breakdown of fats), but this process actually leads to an increase in lean body mass and a decrease in fat mass.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chronic glucocorticoid excess decreases GH release:</span></strong><span style=\"font-size:12.0pt\"> Glucocorticoids can suppress GH secretion and can result in growth failure in children. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. IGF-1 inhibits GH:</span></strong><span style=\"font-size:12.0pt\"> IGF-1, which is produced in response to GH, acts as a negative feedback signal to inhibit further GH release.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. IGFBP3 is the major carrier protein for IGF-1:</span></strong><span style=\"font-size:12.0pt\"> IGFBP3 is the most abundant IGF-binding protein in circulation and plays a crucial role in regulating IGF-1 bioavailability and activity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Summary of GH and IGF-1:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">50% of anterior pituitary cell population is somatotrophs (that secrete GH)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH secretion is pulsatile and highest at night.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH secretion is increased by GHRH, ghrelin and decreased by somatostatin &amp; IGF-1. Chronic glucocorticoid use can suppress GH secretion and can result in growth failure in children. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH secretion declines with age&nbsp; (correlates with age related sarcopenia) and obesity (IGF-1 levels in obesity may be normal)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH induces insulin resistance, protein synthesis, nitrogen retention, lipolysis, and sodium and water retention. GH also promotes linear bone growth.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Most GH effects are mediated indirectly through somatomedins (IGF-1 is the most important somoatomedin).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGF-1 is the major somatomedin and primarily produced in the liver in response to GH. IGF-1 is bound to IGFBPs in circulation (most important is IGFBP3).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGF-1 side effects include hypoglycemia, hypotension, fluid retention, TMJ pain, and increased intracranial pressure and possibly can cause retinal damage and avascular femoral head necrosis. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH stimulates lipolysis, leading to an increase in lean body mass and a decrease in fat mass.</span></span></span></p>",
    "correct_choice_id": 214755,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 53841,
    "choices": [
      {
        "id": 214837,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Active neoplasm </span></span></span></p>"
      },
      {
        "id": 214838,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intracranial hypertension </span></span></span></p>"
      },
      {
        "id": 214839,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Uncontrolled diabetes</span></span></span></p>"
      },
      {
        "id": 214840,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypertension</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 41-year-old man with a history of cranial radiation is considered for GH therapy. Which of the following is NOT a contraindication? </span></span></p>",
    "unique_key": "Q2843550",
    "question_audio": null,
    "question_video": null,
    "map_id": 25427,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Hypertension.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While hypertension can be a consideration and requires monitoring during GH therapy, it is not an absolute contraindication. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Contraindications to GH therapy in adults are: active neoplasm, intracranial hypertension, uncontrolled diabetes, retinopathy</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Active neoplasm:</span></strong><span style=\"font-size:12.0pt\"> GH can potentially stimulate the growth of existing tumors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Intracranial hypertension:</span></strong><span style=\"font-size:12.0pt\"> GH can worsen intracranial pressure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Uncontrolled diabetes:</span></strong><span style=\"font-size:12.0pt\"> GH can impair glucose tolerance and worsen glycemic control.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypertension is not an absolute contraindication for GH therapy.</span></span></span></p>",
    "correct_choice_id": 214840,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 53835,
    "choices": [
      {
        "id": 214813,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pituitary apoplexy </span></span></span></p>"
      },
      {
        "id": 214814,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sheehan syndrome </span></span></span></p>"
      },
      {
        "id": 214815,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lymphocytic hypophysitis </span></span></span></p>"
      },
      {
        "id": 214816,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prolactinoma</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 32-year-old woman presents six weeks postpartum with headaches and visual disturbances. Her ESR is elevated, Prolactin levels are mildly increased, and MRI reveals a pituitary mass. Which of the following is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q7004971",
    "question_audio": null,
    "question_video": null,
    "map_id": 25421,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Lymphocytic hypophysitis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The likely diagnosis is lymphocytic hypophysitis, which commonly occurs in postpartum women. Most patients have elevated ESR, mildly elevated Prolactin levels and MRI findings usually resemble an adenoma. Usually has a good prognosis if treated early with glucocorticoids.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pituitary apoplexy:</span></strong><span style=\"font-size:12.0pt\"> It is an acute hemorrhagic or ischemic event in the pituitary and presents with sudden onset of severe headache, visual loss, and ophthalmoplegia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Sheehan syndrome:</span></strong><span style=\"font-size:12.0pt\"> This is postpartum hypopituitarism caused by ischemic necrosis of the pituitary gland, usually presenting with lactational failure. Prolactin levels would be low and high ESR in this case cannot be explained by Sheehan&rsquo;s syndrome</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Prolactinoma:</span></strong><span style=\"font-size:12.0pt\"> Close differential but high ESR points towards and inflammatory process than a prolactinoma. To differentiate &ndash; can consider a trial of glucocorticoids</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lymphocytic hypophysitis is a postpartum condition characterized by headaches, visual disturbances, elevated ESR, mildly increased prolactin levels, and MRI findings resembling a pituitary adenoma.</span></span></span></p>",
    "correct_choice_id": 214815,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53845,
    "choices": [
      {
        "id": 214853,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Pituitary adenoma </span></span></span></p>"
      },
      {
        "id": 214854,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Craniopharyngioma </span></span></span></p>"
      },
      {
        "id": 214855,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Germinoma </span></span></span></p>"
      },
      {
        "id": 214856,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pinealoma</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 15-year-old boy presents with headaches, visual field deficits, and growth retardation. CT scan of the head is shown. What is the most likely diagnosis?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-164409.png\" style=\"height:364px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q1423220",
    "question_audio": null,
    "question_video": null,
    "map_id": 25431,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Craniopharyngioma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The classic triad of symptoms: headaches, visual field deficits, and growth retardation (due to pituitary hormone deficiencies) with imaging typically showing suprasellar mass with calcifications suggests a diagnosis of craniopharyngioma. Craniopharyngiomas are benign tumors that arise from Rathke&#39;s pouch remnants.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pituitary adenoma:</span></strong><span style=\"font-size:12.0pt\"> While pituitary adenomas can cause similar symptoms, they are less likely to present with calcifications and typically arise within the pituitary gland itself, not in the suprasellar region.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Germinoma:</span></strong><span style=\"font-size:12.0pt\"> These tumors are more common in the pineal gland and usually present with Parinaud syndrome (upward gaze palsy, pupillary abnormalities) and obstructive hydrocephalus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pinealoma:</span></strong><span style=\"font-size:12.0pt\"> These tumors arise from the pineal gland and can also present with Parinaud syndrome and obstructive hydrocephalus. They are less likely to have a cystic appearance with calcifications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Important DD for sellar/suprasellar masses:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Craniopharyngioma: </span></strong></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Benign, suprasellar cystic masses derived from Rathke&#39;s pouch.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Presents with a triad of headaches, visual field deficits, and hypopituitarism.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Presents usually &lt; 20 years if age and the most common type is adamantinomatous (large, cystic, lobulated, locally invasive, and partially calcified, usually has CTNNB1 (&beta;-catenin gene mutations)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypopituitarism is seen in ~90% and diabetes insipidus in ~10%. So, most patients require lifelong pituitary hormone replacement.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Treatment: Surgical resection followed by radiation of residual tumor (Surgery alone is curative in only &lt;50% cases due to recurrences. Radiotherapy improves 10-year survival to 70-90% but slightly increases the risk of secondary malignancies).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BRAF inhibitors may be effective in some cases with BRAF V600E mutations (especially in the adult papillary types). </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Rathke&#39;s Cysts:</span></strong></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Occues due to failure of Rathke&#39;s pouch obliteration.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mostly asymptomatic. ~33% present in adulthood with compressive symptoms, diabetes insipidus, and hyperprolactinemia.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pathognomonic large dot sign in MRI</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-164911.png\" style=\"height:610px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Craniopharyngiomas commonly present with headaches, visual field deficits, and growth retardation, and are characterized by suprasellar masses with calcifications on imaging.</span></span></span></p>",
    "correct_choice_id": 214854,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 53811,
    "choices": [
      {
        "id": 214717,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">JAK-STAT pathway </span></span></span></p>"
      },
      {
        "id": 214718,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MAPK pathway </span></span></span></p>"
      },
      {
        "id": 214719,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PI3K/Akt pathway </span></span></span></p>"
      },
      {
        "id": 214720,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">cAMP/PKA pathway</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old patient presents with large hands, coarse face and headache. MRI shows a pituitary tumor. Which of the following signaling pathways is most likely activated by the hormone involved in the pathology?</span></span></p>",
    "unique_key": "Q6516191",
    "question_audio": null,
    "question_video": null,
    "map_id": 25406,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) JAK-STAT pathway</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient is suffering from acromegaly and it is due to Growth hormone (GH) excess. Growth hormone receptors belong to the class of cytokine receptors that primarily signal through the JAK-STAT pathway. This pathway leads to the activation of transcription factors involved in growth and metabolism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. MAPK pathway:</span></strong><span style=\"font-size:12.0pt\"> While GH can activate MAPK pathways, it&#39;s not the primary signaling mechanism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. PI3K/Akt pathway:</span></strong><span style=\"font-size:12.0pt\"> GH also activates the PI3K/Akt pathway, but it&#39;s not the primary pathway.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. cAMP/PKA pathway:</span></strong><span style=\"font-size:12.0pt\"> This pathway is primarily activated by G-protein coupled receptors, not GH receptors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Growth hormone (GH) primarily signals through the JAK-STAT pathway.</span></span></span></p>",
    "correct_choice_id": 214717,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53837,
    "choices": [
      {
        "id": 214821,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">III cranial nerve (CN) palsy </span></span></span></p>"
      },
      {
        "id": 214822,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypertension </span></span></span></p>"
      },
      {
        "id": 214823,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypoglycaemia </span></span></span></p>"
      },
      {
        "id": 214824,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Visual field defects</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman with a known pituitary adenoma presents to the emergency department with sudden onset of severe headache, visual disturbances, and vomiting. Which of the following is NOT an expected complication?</span></span></p>",
    "unique_key": "Q8957283",
    "question_audio": null,
    "question_video": null,
    "map_id": 25423,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Hypertension</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This is a case of pituitary apoplexy. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Causes:</span></strong><span style=\"font-size:12.0pt\"> Hemorrhage into a pre-existing adenoma (most common), Sheehan&#39;s syndrome</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Risk Factors:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Pituitary adenoma, Diabetes, Hypertension, Sickle cell disease, PPH/shock</span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Symptoms &amp; Complications:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Severe headache with meningeal irritation , visual field defects, Ophthalmoplegia (Most commonly III &gt; VI CN palsy</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Can cause Cardiovascular collapse and/or Loss of consciousness (in severe cases).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Severe hypoglycemia, Hypotension and shock, Death</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Diagnosis:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Pituitary CT or MRI (usually shows sellar mass with hemorrhage)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Management:</span></strong><span style=\"font-size:12.0pt\"> High dose glucocorticoids. Urgent surgery if LOC/ophthalmoplegia</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. III CN palsy:</span></strong><span style=\"font-size:12.0pt\"> Most common cranial nerve injured in apoplexy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hypoglycemia:</span></strong><span style=\"font-size:12.0pt\"> Hypopituitarism can result in secondary adrenal insufficiency, leading to low cortisol levels and hypoglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Visual field defects:</span></strong><span style=\"font-size:12.0pt\"> Compression of the optic chiasm by the pituitary mass can cause bitemporal hemianopsia or other visual field defects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypertension is not an expected complication of pituitary apoplexy.</span></span></span></p>",
    "correct_choice_id": 214822,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53810,
    "choices": [
      {
        "id": 214713,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">JAK-STAT pathway </span></span></span></p>"
      },
      {
        "id": 214714,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MAPK pathway </span></span></span></p>"
      },
      {
        "id": 214715,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PI3K/Akt pathway </span></span></span></p>"
      },
      {
        "id": 214716,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Smad pathway</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman presents with progressive muscle weakness and a distinctive heliotrope rash around her eyes. A muscle biopsy reveals endomysial inflammation and fibrosis. Which of the following signaling pathways is most likely implicated in the pathogenesis of her condition? </span></span></p>",
    "unique_key": "Q9363324",
    "question_audio": null,
    "question_video": null,
    "map_id": 25405,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Smad pathway </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation is consistent with dermatomyositis, an autoimmune inflammatory myopathy. Transforming growth factor beta (TGF-&beta;) plays a crucial role in the pathogenesis of dermatomyositis, and its signaling occurs through the Smad pathway, leading to fibrosis and muscle damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. JAK-STAT pathway:</span></strong><span style=\"font-size:12.0pt\"> This pathway is primarily involved in cytokine signaling and immune responses.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. MAPK pathway:</span></strong><span style=\"font-size:12.0pt\"> This pathway is involved in various cellular processes, including proliferation and differentiation, but is not the primary pathway implicated in dermatomyositis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. PI3K/Akt pathway:</span></strong><span style=\"font-size:12.0pt\"> This pathway is involved in cell survival and growth, but not the primary pathway implicated in dermatomyositis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Receptor Tyrosine Kinase -&nbsp; Insulin, IGF-I EGF, NGF</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cytokine Receptor Linked Kinase - GH, PRL</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serine Kinase - Activin, TGF-&beta;, MIS</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-150602.png\" style=\"height:342px; width:500px\" /></span></span></span></p>",
    "correct_choice_id": 214716,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "CriteriaBased"
    ]
  },
  {
    "id": 53855,
    "choices": [
      {
        "id": 214893,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Central diabetes insipidus (DI) </span></span></span></p>"
      },
      {
        "id": 214894,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nephrogenic DI </span></span></span></p>"
      },
      {
        "id": 214895,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primary polydipsia </span></span></span></p>"
      },
      {
        "id": 214896,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old male presents with complaints of excessive thirst (polydipsia) and frequent urination (polyuria), both during the day and at night. A 24-hour urine collection reveals a volume of 5 liters with an osmolality of 250 mOsm/L. Basal plasma ADH is 0.5pg/mL. MRI of the pituitary is shown. Which of the following is the most likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-170840.png\" style=\"height:299px; width:300px\" /></span></span></p>",
    "unique_key": "Q7635996",
    "question_audio": null,
    "question_video": null,
    "map_id": 25441,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Primary polydipsia (DI)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s high urine output (&gt;40 mL/kg/24 hours), low urine osmolality (&lt;300 mOsm/L), low ADH levels (&lt; 1 pg/mL) and intact posterior pituitary bright spot are all consistent with primary polydipsia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Central DI:</span></strong><span style=\"font-size:12.0pt\"> MRI would have revealed an absent posterior pituitary bright spot. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Nephrogenic DI:</span></strong><span style=\"font-size:12.0pt\"> This is caused by resistance to ADH in the kidneys, and would typically present with ADH level of &gt; 1pg/mL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. SIADH (Syndrome of Inappropriate Antidiuretic Hormone Secretion):</span></strong><span style=\"font-size:12.0pt\"> This would not cause polyuria and polydipsia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primary polydipsia is characterized by high urine output, low urine osmolality, low ADH levels, and an intact posterior pituitary bright spot on MRI.</span></span></span></p>",
    "correct_choice_id": 214895,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 53816,
    "choices": [
      {
        "id": 214737,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lactotrophs </span></span></span></p>"
      },
      {
        "id": 214738,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gonadotrophs </span></span></span></p>"
      },
      {
        "id": 214739,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thyrotrophs </span></span></span></p>"
      },
      {
        "id": 214740,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Corticotrophs</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following pituitary cell type would appear earliest in the fetus?</span></span></span></p>",
    "unique_key": "Q5782914",
    "question_audio": null,
    "question_video": null,
    "map_id": 25411,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Corticotrophs</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Corticotrophs, the cells responsible for producing adrenocorticotropic hormone (ACTH), are the earliest to appear in the fetal pituitary gland, at around 6 weeks of gestation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Lactotrophs:</span></strong><span style=\"font-size:12.0pt\"> These cells produce prolactin and appear around 12 weeks of gestation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Gonadotrophs:</span></strong><span style=\"font-size:12.0pt\"> These cells produce FSH and LH and also appear around 12 weeks of gestation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Thyrotrophs:</span></strong><span style=\"font-size:12.0pt\"> These cells produce TSH and also appear around 12 weeks of gestation. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-154029.png\" style=\"height:758px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Corticotrophs are the earliest pituitary cells to appear in the fetus, around 6 weeks of gestation.</span></span></span></p>",
    "correct_choice_id": 214740,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "Factual"
    ]
  },
  {
    "id": 53829,
    "choices": [
      {
        "id": 214789,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypothyroidism</span></span></span></p>"
      },
      {
        "id": 214790,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypogonadism</span></span></span></p>"
      },
      {
        "id": 214791,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyperprolactinemia</span></span></span></p>"
      },
      {
        "id": 214792,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH deficiency</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the most common feature of adult hypopituitarism?</span></span></p>",
    "unique_key": "Q8698550",
    "question_audio": null,
    "question_video": null,
    "map_id": 25420,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Hypogonadism</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypogonadism is the most common presenting feature of adult hypopituitarism even when other pituitary hormones are also deficient. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Hypothyroidism:</span></strong><span style=\"font-size:12.0pt\"> Common, but not as frequent as hypogonadism in adults</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Hyperprolactinemia:</span></strong><span style=\"font-size:12.0pt\"> Less common and usually associated with prolactinomas. Note that even hyperprolactinemia&rsquo;s are associated with hypogonadism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. GH deficiency:</span></strong><span style=\"font-size:12.0pt\"> Common, but not as frequent as hypogonadism in adults</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypogonadism is the most common presenting feature of adult hypopituitarism.</span></span></span></p>",
    "correct_choice_id": 214790,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 53852,
    "choices": [
      {
        "id": 214881,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Most common cause is GH cell adenoma</span></span></span></p>"
      },
      {
        "id": 214882,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">25% co-secrete prolactin</span></span></span></p>"
      },
      {
        "id": 214883,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Malignancies are the commonest cause of death</span></span></span></p>"
      },
      {
        "id": 214884,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Survival is 10 years lesser in acromegalics</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old man presents with features suggestive of acromegaly. Which of the following is incorrect?</span></span></p>",
    "unique_key": "Q7725314",
    "question_audio": null,
    "question_video": null,
    "map_id": 25438,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Malignancies are the commonest cause of death</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While acromegaly can be associated with an increased risk of certain malignancies, the most common cause of death in patients with acromegaly is cardiovascular disease. This is due to the multiple effects of excess growth hormone on the cardiovascular system, including hypertension, left ventricular hypertrophy, and increased risk of arrhythmias and heart failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Most common cause is GH cell adenoma:</span></strong><span style=\"font-size:12.0pt\"> Common causes of acromegaly are densely or sparsely granulated GH cell adenoma (60%) &gt; Mixed GH cell and PRL cell adenoma (25%), Mammosomatotrope cell adenoma (10%)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 25% co-secrete prolactin:</span></strong><span style=\"font-size:12.0pt\"> A significant proportion of GH-secreting tumors also co-secrete prolactin, leading to symptoms such as galactorrhea and menstrual irregularities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Survival is 10 years lesser in acromegalics:</span></strong><span style=\"font-size:12.0pt\"> Untreated acromegaly can significantly reduce life expectancy, primarily due to cardiovascular complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most common cause of death in patients with acromegaly is cardiovascular disease, not malignancies.</span></span></span></p>",
    "correct_choice_id": 214883,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 53847,
    "choices": [
      {
        "id": 214861,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MEN1 </span></span></span></p>"
      },
      {
        "id": 214862,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Carney complex</span></span></span></p>"
      },
      {
        "id": 214863,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MEN4 </span></span></span></p>"
      },
      {
        "id": 214864,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pallister hall syndrome</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All of the following are familial pituitary tumour syndromes except? </span></span></span></p>",
    "unique_key": "Q2087152",
    "question_audio": null,
    "question_video": null,
    "map_id": 25433,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Pallister-Hall syndrome.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pallister-Hall syndrome (due to mutations in GLI3 gene) is a rare genetic disorder characterized by various developmental abnormalities, including hypothalamic hamartoma, imperforate anus, and polydactyly. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While hypothalamic hamartomas can cause endocrine dysfunction, Pallister-Hall syndrome is not primarily considered a familial pituitary tumor syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. MEN1 (Multiple Endocrine Neoplasia type 1):</span></strong><span style=\"font-size:12.0pt\"> This syndrome is characterized by tumors of the parathyroid glands, pituitary gland, and pancreas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Carney complex:</span></strong><span style=\"font-size:12.0pt\"> This syndrome is associated with various tumors, including pituitary adenomas, cardiac myxomas, and pigmented skin lesions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. MEN4 (Multiple Endocrine Neoplasia type 4):</span></strong><span style=\"font-size:12.0pt\"> This rare syndrome is similar to MEN1 but is caused by mutations in a different gene (CDKN1B).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pallister-Hall syndrome, characterized by hypothalamic hamartoma, imperforate anus, and polydactyly, is not primarily a familial pituitary tumor syndrome.</span></span></span></p>",
    "correct_choice_id": 214864,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "Factual"
    ]
  },
  {
    "id": 53838,
    "choices": [
      {
        "id": 214825,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metyrapone test </span></span></span></p>"
      },
      {
        "id": 214826,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">l-Arginine test </span></span></span></p>"
      },
      {
        "id": 214827,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CRH test </span></span></span></p>"
      },
      {
        "id": 214828,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACTH stimulation test</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following tests are used for ACTH deficiency, except?</span></span></p>",
    "unique_key": "Q4778001",
    "question_audio": null,
    "question_video": null,
    "map_id": 25424,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) l-Arginine test</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The l-Arginine test is used to assess growth hormone (GH) reserve, not ACTH deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Metyrapone test:</span></strong><span style=\"font-size:12.0pt\"> Tests the integrity of the hypothalamic-pituitary-adrenal (HPA) axis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CRH test:</span></strong><span style=\"font-size:12.0pt\"> Directly stimulates the pituitary to release ACTH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. ACTH stimulation test:</span></strong><span style=\"font-size:12.0pt\"> Assesses the adrenal glands&#39; ability to respond to ACTH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Summary:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tests for ACTH deficiency: </span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACTH test (Standard &amp; low dose &ndash; test cortisol, level &gt; 21 &mu;g/dL is normal)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin tolerance test (test cortisol, level &gt; 20 &mu;g/dL is normal)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CRH test (test ACTH and cortisol, cortisol level &gt; 20 &mu;g/dL is normal). </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metyrapone test (test 11 deoxy cortisol and ACTH) &ndash; outdated, not in use.</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tests for GH deficiency: Insulin tolerance test, GHRH test, l-Arginine test, l-Dopa test, ghrelin test (macimoerlin test - ORAL) &amp; glucagon test. Facts on Adult GH deficiency -</span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin tolerance test is the 1<sup>st</sup> line test but C/I in diabetes, ischemic heart disease, cerebrovascular disease, epilepsy and elderly. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH &gt;3 &mu;g/L in response to hypoglycemia (&lt; 40mg/dL) is considered as the normal response (GH &lt; 3 &mu;g/L is suggestive of GH deficiency). </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adult GH deficiency is associated with changes in body composition (reduced lean body mass, increased fat mass with selective deposition of intraabdominal visceral fat, and increased waist-to-hip ratio), Hyperlipidemia, LV dysfunction, hypertension, and reduced bone mineral density.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adult hypopituitarism is associated with a 3x increase in CV mortality</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The l-Arginine test is used to assess growth hormone (GH) reserve, not ACTH deficiency.</span></span></span></p>",
    "correct_choice_id": 214826,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 53812,
    "choices": [
      {
        "id": 214721,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Familial hypocalciuric hypercalcemia (FHH) </span></span></span></p>"
      },
      {
        "id": 214722,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Familial hypocalciuric hypocalcemia </span></span></span></p>"
      },
      {
        "id": 214723,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neonatal severe hyperparathyroidism (NSHPT) </span></span></span></p>"
      },
      {
        "id": 214724,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Familial hypocalcemic hypercalciuria</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Genetic testing of a patient reveals a homozygous inactivating mutation in the calcium-sensing receptor (CaSR) gene. Which of the following is the most likely diagnosis?</span></span></span></p>",
    "unique_key": "Q7301258",
    "question_audio": null,
    "question_video": null,
    "map_id": 25407,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Neonatal severe hyperparathyroidism (NSHPT)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">NSHPT</span></strong><span style=\"font-size:12.0pt\"> is a rare autosomal recessive disorder caused by homozygous or compound heterozygous inactivating mutations in the CaSR gene. This leads to severe hypercalcemia due to unsuppressed PTH secretion, often resulting in life-threatening complications in newborns.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Familial hypocalciuric hypercalcemia (FHH):</span></strong><span style=\"font-size:12.0pt\"> FHH is a milder autosomal dominant condition caused by heterozygous CaSR mutations, characterized by mild hypercalcemia and low urinary calcium excretion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Familial hypocalciuric hypocalcemia:</span></strong><span style=\"font-size:12.0pt\"> This is not a recognized condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Familial hypocalcemic hypercalciuria:</span></strong><span style=\"font-size:12.0pt\"> This is caused by activating CaSR mutations, leading to hypocalcemia and high urinary calcium excretion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><u><span style=\"font-size:12.0pt\">: </span></u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Calcium sensing receptor defects &ndash;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Familial hypocalciuric hypercalcemia - AD, inactivating</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neonatal severe hyperparathyroidism- AR, inactivating</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Familial hypocalcemic hypercalciura- AD, activating</span></span></span></p>",
    "correct_choice_id": 214723,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 53848,
    "choices": [
      {
        "id": 214865,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Verapamil</span></span></span></p>"
      },
      {
        "id": 214866,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Methyldopa</span></span></span></p>"
      },
      {
        "id": 214867,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Risperidone</span></span></span></p>"
      },
      {
        "id": 214868,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metoclopramide</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following medications is most likely to cause a significant elevation in prolactin levels, often exceeding 200 &mu;g/L?</span></span></p>",
    "unique_key": "Q3057957",
    "question_audio": null,
    "question_video": null,
    "map_id": 25434,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Risperidone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PRL secreting pituitary adenomas (prolactinomas) are the most common cause of PRL levels &gt;200 &mu;g/L.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Other causes (drugs/ infiltrative disorders) that elevate PRL levels, usually have PRL in the range of 30&ndash;100 &mu;g/L. Risperidone, is an exception though since it can elevate PRL to levels exceeding 200 &mu;g/L.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Verapamil:</span></strong><span style=\"font-size:12.0pt\"> While verapamil is a calcium channel blocker and can mildly elevate prolactin levels, it typically doesn&#39;t cause levels exceeding 200 &mu;g/L.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Methyldopa:</span></strong><span style=\"font-size:12.0pt\"> Methyldopa is an antihypertensive that can also slightly increase prolactin, but not to the extent seen with risperidone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Metoclopramide:</span></strong><span style=\"font-size:12.0pt\"> Metoclopramide is a dopamine antagonist used for nausea and gastroparesis, and it can elevate prolactin, but typically not to levels above 200 &mu;g/L.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Risperidone can significantly elevate prolactin levels, often exceeding 200 &mu;g/L.</span></span></span></p>",
    "correct_choice_id": 214867,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 53856,
    "choices": [
      {
        "id": 214897,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Desmopressin (DDAVP) </span></span></span></p>"
      },
      {
        "id": 214898,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thiazides </span></span></span></p>"
      },
      {
        "id": 214899,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fluid restriction </span></span></span></p>"
      },
      {
        "id": 214900,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucocorticoids</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old female with a history of psychiatric illness presents with polyuria and polydipsia. A 24-hour urine collection reveals a volume of 4 liters with an osmolality of 200 mOsm/L. Basal plasma ADH is 1.4 pg/mL. Which of the following is the best treatment?</span></span></p>",
    "unique_key": "Q8254692",
    "question_audio": null,
    "question_video": null,
    "map_id": 25442,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Thiazides</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s clinical presentation, with polyuria, polydipsia, dilute urine and increased ADH (&gt; 1 pg/mL) suggests a diagnosis of nephrogenic diabetes insipidus (NDI). In NDI, use of thiazides (&plusmn; Indomethacin) improves ADH sensitivity and hence, the preferred treatment. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Desmopressin (DDAVP):</span></strong><span style=\"font-size:12.0pt\"> This is a synthetic analog of ADH and is used to treat central DI, where there is a deficiency of ADH. It would not be effective for NDI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Fluid restriction:</span></strong><span style=\"font-size:12.0pt\"> Can treat SIADH but can worsen hypernatremia in NDI. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Glucocorticoids:</span></strong><span style=\"font-size:12.0pt\"> Glucocorticoids are not indicated for the treatment of DI (can worsen DI by reducing ADH release)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thiazides are the preferred treatment for nephrogenic diabetes insipidus (NDI) as they improve ADH sensitivity and reduce polyuria.</span></span></p>",
    "correct_choice_id": 214898,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 53825,
    "choices": [
      {
        "id": 214773,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyposmia</span></span></span></p>"
      },
      {
        "id": 214774,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypogonadism </span></span></span></p>"
      },
      {
        "id": 214775,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mirror movements</span></span></span></p>"
      },
      {
        "id": 214776,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyperacusis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following clinical features is uncommon in Kallmann syndrome?</span></span></p>",
    "unique_key": "Q9024110",
    "question_audio": null,
    "question_video": null,
    "map_id": 25418,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Hyperacusis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Kallmann syndrome is a genetic disorder (usually due to KAL mutations, X-linked) and is characterized by GnRH deficiency and hyposmia/anosmia due to olfactory bulb hypoplasia or agenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Classically, the syndrome may also be associated with color blindness, optic atrophy, SNHL, cleft palate, renal abnormalities, cryptorchidism, and neurologic abnormalities such as mirror movements (mirror movements can also be seen in cerebral palsy, CVJ anomalies, ALS, Friedrich ataxia and phenylketonuria)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Hyposmia or anosmia:</span></strong><span style=\"font-size:12.0pt\"> This is a hallmark feature of Kallmann syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hypogonadism:</span></strong><span style=\"font-size:12.0pt\"> This is the primary hormonal manifestation of Kallmann syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Mirror movements (bimanual synkinesis):</span></strong><span style=\"font-size:12.0pt\"> This is a relatively common associated feature in Kallmann syndrome, although not always present.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyperacusis is uncommon in Kallmann syndrome, which primarily features hypogonadism and hyposmia/anosmia.</span></span></span></p>",
    "correct_choice_id": 214776,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53815,
    "choices": [
      {
        "id": 214733,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thyroid hormone controls </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 25% of basal metabolic rate</span></span></span></p>"
      },
      {
        "id": 214734,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aldosterone exerts a permissive action on other hormones. </span></span></span></p>"
      },
      {
        "id": 214735,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Parathyroid hormone (PTH) is a key regulator of calcium and phosphorus homeostasis. </span></span></span></p>"
      },
      {
        "id": 214736,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vasopressin (ADH) is involved in the control of serum osmolality.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is false?</span></span></p>",
    "unique_key": "Q8156990",
    "question_audio": null,
    "question_video": null,
    "map_id": 25410,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Aldosterone exerts a permissive action on other hormones.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Aldosterone</span></strong><span style=\"font-size:12.0pt\"> is a mineralocorticoid hormone primarily responsible for regulating sodium and potassium balance, which indirectly influences blood pressure and fluid volume. On the other hand, Cortisol exerts a permissive action, which is the ability of one hormone to enhance the responsiveness of a target organ to another hormone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Thyroid hormone:</span></strong><span style=\"font-size:12.0pt\"> Correct. Thyroid hormone does play a significant role in regulating basal metabolic rate, affecting energy expenditure and heat production. It controls </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\">25% of BMR in most tissues. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Parathyroid hormone (PTH):</span></strong><span style=\"font-size:12.0pt\"> Correct. PTH is the primary regulator of calcium and phosphorus homeostasis, acting on bone, kidney, and intestine to maintain normal levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Vasopressin (antidiuretic hormone):</span></strong><span style=\"font-size:12.0pt\"> Correct. Vasopressin regulates serum osmolality by controlling water reabsorption in the kidneys, thus maintaining fluid balance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aldosterone does not exert a permissive action on other hormones; this function is primarily attributed to cortisol.</span></span></span></p>",
    "correct_choice_id": 214734,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 52104,
    "choices": [
      {
        "id": 207917,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It binds to an intracellular receptor and acts as a transcription factor. </span></span></span></p>"
      },
      {
        "id": 207918,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is stored in vesicles and released by exocytosis. </span></span></span></p>"
      },
      {
        "id": 207919,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It utilizes cyclic AMP (cAMP) as a second messenger. </span></span></span></p>"
      },
      {
        "id": 207920,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is derived from cholesterol.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman presents with complaints of heat intolerance, weight loss, and palpitations. Physical examination reveals tachycardia, tremor, and exophthalmos. Which of the following statements is most likely true regarding the hormone responsible for her symptoms?</span></span></p>",
    "unique_key": "Q9998569",
    "question_audio": null,
    "question_video": null,
    "map_id": 25087,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) It binds to an intracellular receptor and acts as a transcription factor.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s symptoms and signs are characteristic of hyperthyroidism, most likely due to Graves&#39; disease. The primary hormone responsible for these manifestations is thyroxine (T4), which belongs to Group I hormones. Group I hormones are lipophilic and can readily cross the cell membrane to bind to intracellular receptors, ultimately affecting gene transcription.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. It is stored in vesicles and released by exocytosis:</span></strong><span style=\"font-size:12.0pt\"> This mechanism is characteristic of Group II hormones, such as peptide hormones and catecholamines.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. It utilizes cyclic AMP (cAMP) as a second messenger:</span></strong><span style=\"font-size:12.0pt\"> While cAMP is a common second messenger, it is primarily used by Group II hormones that bind to cell surface receptors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. It is derived from cholesterol:</span></strong><span style=\"font-size:12.0pt\"> This is true for steroid hormones, which are also Group I hormones. However, thyroid hormones are derived from tyrosine and iodine, not cholesterol.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thyroid hormones, like thyroxine (T4), bind to intracellular receptors and act as transcription factors.</span></span></span></p>",
    "correct_choice_id": 207917,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 53814,
    "choices": [
      {
        "id": 214729,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gs&alpha; </span></span></span></p>"
      },
      {
        "id": 214730,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TSH receptor </span></span></span></p>"
      },
      {
        "id": 214731,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">LH receptor </span></span></span></p>"
      },
      {
        "id": 214732,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GHRH receptor</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 4-year-old girl presents with precocious puberty, caf&eacute;-au-lait spots, and bone pain. Radiographs reveal multiple bone lesions consistent with fibrous dysplasia. A mutation in which of the following genes is most likely responsible for her condition?</span></span></p>",
    "unique_key": "Q2890212",
    "question_audio": null,
    "question_video": null,
    "map_id": 25409,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Gs&alpha;</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The girl&#39;s presentation is classic for McCune-Albright syndrome, a rare disorder caused by activating mutations in the Gs&alpha; gene. These mutations lead to constitutive activation of G protein-coupled receptors, resulting in excessive hormone production and the characteristic features of the syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. TSH receptor:</span></strong><span style=\"font-size:12.0pt\"> Mutations in the TSH receptor gene are associated with thyroid disorders, not McCune-Albright syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. LH receptor:</span></strong><span style=\"font-size:12.0pt\"> Mutations in the LH receptor gene can cause familial male-limited precocious puberty or Leydig cell hypoplasia, not McCune-Albright syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. GHRH receptor:</span></strong><span style=\"font-size:12.0pt\"> Mutations in the GHRH receptor gene are associated with isolated growth hormone deficiency or gigantism, not McCune-Albright syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><u><span style=\"font-size:12.0pt\">: </span></u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diseases due to Gs&alpha; mutations &ndash;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acromegaly (Gs&alpha; mutations in the GHRH pathway)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">McCune Albright Syndrome (mosaic Gs&alpha; mutations)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Albright&rsquo;s hereditary osteodystrophy (AHO)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pseudopseudohypoparathyroidism (PPHP)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pseudohypoparathyroidism types 1b, 1c, and 2</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 214729,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53817,
    "choices": [
      {
        "id": 214741,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">DAX-1</span></span></span></p>"
      },
      {
        "id": 214742,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">T-pit</span></span></span></p>"
      },
      {
        "id": 214743,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prop-1</span></span></span></p>"
      },
      {
        "id": 214744,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">WT-1</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following transcription factor is NOT required for the normal development of pituitary gland?</span></span></p>",
    "unique_key": "Q6995256",
    "question_audio": null,
    "question_video": null,
    "map_id": 25412,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) WT1</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While WT1 is a transcription factor involved in the development of several organs, including the kidneys and gonads, it is not directly implicated in pituitary gland development.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. DAX-1:</span></strong><span style=\"font-size:12.0pt\"> This is a nuclear receptor involved in sex determination, gonadotroph and adrenal gland development. Its absence can lead to pituitary hypoplasia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. T-pit (TBX19):</span></strong><span style=\"font-size:12.0pt\"> This T-box transcription factor is crucial for the differentiation of corticotrophs (ACTH-producing cells) in the pituitary gland.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. PROP-1:</span></strong><span style=\"font-size:12.0pt\"> This paired-like homeodomain transcription factor is essential for the development of somatotrophs, lactotrophs, and thyrotrophs in the pituitary gland. Mutations in PROP-1 can cause combined pituitary hormone deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">WT1 is not required for the normal development of the pituitary gland.</span></span></span></p>",
    "correct_choice_id": 214744,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "Factual"
    ]
  },
  {
    "id": 53819,
    "choices": [
      {
        "id": 214749,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyperglycemia </span></span></span></p>"
      },
      {
        "id": 214750,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypotension </span></span></span></p>"
      },
      {
        "id": 214751,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased intracranial pressure </span></span></span></p>"
      },
      {
        "id": 214752,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Temporomandibular joint pain</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Growth hormone increases IGF -1 production from the liver. Which of the following is incorrect regarding the effect of IGF-1?</span></span></p>",
    "unique_key": "Q9329393",
    "question_audio": null,
    "question_video": null,
    "map_id": 25414,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Hyperglycemia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGF-1 actually has insulin-like effects, promoting glucose uptake into cells and lowering blood glucose levels. Therefore, hyperglycemia (high blood sugar) would not be a direct effect of IGF-1 administration.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hypotension:</span></strong><span style=\"font-size:12.0pt\"> IGF-1 can cause vasodilation, leading to hypotension. IGF-1 can result in fluid retention as well. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increased intracranial pressure:</span></strong><span style=\"font-size:12.0pt\"> This is a rare but serious side effect of excessive IGF-1 levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Temporomandibular joint pain:</span></strong><span style=\"font-size:12.0pt\"> This is a known side effect of IGF-1 therapy, possibly related to its effects on cartilage growth.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGF-1 has insulin-like effects, promoting glucose uptake into cells and lowering blood glucose levels, thus not causing hyperglycemia.</span></span></span></p>",
    "correct_choice_id": 214749,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 53821,
    "choices": [
      {
        "id": 214757,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cortisol levels peak around midnight. </span></span></span></p>"
      },
      {
        "id": 214758,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACTH acts on melanocortin-2 receptors. </span></span></span></p>"
      },
      {
        "id": 214759,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inflammation decreases POMC expression. </span></span></span></p>"
      },
      {
        "id": 214760,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">An exaggerated response to ACTH is a feature of Addison&#39;s disease.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following statements is regarding ATCH and Cortisol is correct?</span></span></span></p>",
    "unique_key": "Q7633832",
    "question_audio": null,
    "question_video": null,
    "map_id": 25416,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) ACTH acts on melanocortin-2 receptors.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACTH binds to melanocortin-2 receptors (MC2R) on adrenocortical cells, stimulating cortisol production.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cortisol levels peak around midnight:</span></strong><span style=\"font-size:12.0pt\"> Cortisol levels follow a circadian rhythm, peaking in the morning (</span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 6 AM) and reaching a nadir around midnight.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Inflammation decreases POMC expression:</span></strong><span style=\"font-size:12.0pt\"> Inflammation/stress increases CRH and AVP release. CRH increased POMC (proopiomelanocortin) gene and ACTH production.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. An exaggerated response to ACTH is a feature of Addison&#39;s disease:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Addison&#39;s disease is characterized by primary adrenal insufficiency, leading to a <em>decreased</em> cortisol response to ACTH stimulation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACTH binds to melanocortin-2 receptors (MC2R) on adrenocortical cells, stimulating cortisol production.</span></span></span></p>",
    "correct_choice_id": 214758,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 53822,
    "choices": [
      {
        "id": 214761,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Kisspeptin regulates GnRH release </span></span></span></p>"
      },
      {
        "id": 214762,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Continuous GnRH suppresses FSH and LH</span></span></span></p>"
      },
      {
        "id": 214763,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TSH shares a common &alpha; subunit with LH and FSH</span></span></span></p>"
      },
      {
        "id": 214764,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucocorticoids stimulate TSH release</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is incorrect?</span></span></p>",
    "unique_key": "Q5507070",
    "question_audio": null,
    "question_video": null,
    "map_id": 25417,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Glucocorticoids stimulate TSH release.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucocorticoids, such as cortisol, inhibit TSH release. They act at the level of the hypothalamus and pituitary gland to suppress the hypothalamic-pituitary-thyroid (HPT) axis. This is part of the stress response, where energy resources are diverted away from growth and reproduction towards immediate survival needs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Kisspeptin plays a role in regulating GnRH release:</span></strong><span style=\"font-size:12.0pt\"> Brain Kisspeptin (from KISS1 gene) stimulates GnRH release, which in turn triggers the release of LH and FSH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Continuous GnRH administration suppresses FSH and LH release:</span></strong><span style=\"font-size:12.0pt\"> Continuous GnRH stimulation leads to downregulation of GnRH receptors on gonadotrophs, resulting in decreased FSH and LH secretion. This principle is utilized in GnRH agonist therapy for conditions like prostate cancer and endometriosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. TSH shares a common &alpha; subunit with LH and FSH:</span></strong><span style=\"font-size:12.0pt\"> The &alpha; subunit of TSH, LH, and FSH is identical, while their &beta; subunits confer specific biological activity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucocorticoids inhibit TSH release, not stimulate it.</span></span></span></p>",
    "correct_choice_id": 214764,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "Factual"
    ]
  },
  {
    "id": 53827,
    "choices": [
      {
        "id": 214781,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Growth failure</span></span></span></p>"
      },
      {
        "id": 214782,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypogonadism</span></span></span></p>"
      },
      {
        "id": 214783,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypothyroidism </span></span></span></p>"
      },
      {
        "id": 214784,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adrenal insufficiency</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 12-year-old boy has a history of medulloblastoma treated with cranial irradiation. Which of the following is the most common?</span></span></p>",
    "unique_key": "Q5126295",
    "question_audio": null,
    "question_video": null,
    "map_id": 25419,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Growth failure</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">2/3<sup>rd</sup> of patients develop hormone insufficiency after </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 50 Gy (5000 rad) of radiation</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Usually occurs over 5&ndash;15 years and usually reflects hypothalamic &gt; pituitary damage</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH deficiency is the most common (Pattern GH</span><span style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&agrave;</span></span><span style=\"font-size:12.0pt\"> FSH/LH </span><span style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&agrave;</span></span><span style=\"font-size:12.0pt\"> Thyroid </span><span style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&agrave;</span></span><span style=\"font-size:12.0pt\">ACTH)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hypogonadism:</span></strong><span style=\"font-size:12.0pt\"> While hypogonadism (deficiency of sex hormones) can also occur due to radiation therapy, it usually manifests later than growth failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Hypothyroidism:</span></strong><span style=\"font-size:12.0pt\"> Hypothyroidism (decreased thyroid hormone production) is another potential complication, but it is less common and often occurs later than growth failure and hypogonadism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Adrenal insufficiency:</span></strong><span style=\"font-size:12.0pt\"> Adrenal insufficiency is the least common endocrine complication following cranial irradiation and typically manifests much later than the other hormonal deficiencies.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Growth hormone deficiency is the most common endocrine disorder following cranial irradiation in children.</span></span></span></p>",
    "correct_choice_id": 214781,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53836,
    "choices": [
      {
        "id": 214817,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ipilimumab </span></span></span></p>"
      },
      {
        "id": 214818,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Pembrolizumab </span></span></span></p>"
      },
      {
        "id": 214819,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Nivolumab </span></span></span></p>"
      },
      {
        "id": 214820,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rituximab</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old male is being treated with immunotherapy. He presents with fatigue, headache, and visual disturbances. MRI reveals a pituitary mass. Which of the following medications is LEAST likely to be the cause of his symptoms?</span></span></p>",
    "unique_key": "Q8017697",
    "question_audio": null,
    "question_video": null,
    "map_id": 25422,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Rituximab</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ipilimumab, pembrolizumab, and nivolumab are immune checkpoint inhibitors that can cause hypophysitis (inflammation of the pituitary gland). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ipilimumab:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Pituitary cells express CTLA-4 and up to 20% of patients receiving CTLA-4 inhibitors (e.g., ipilimumab) develop hypophysitis<strong> </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Pembrolizumab:</span></strong><span style=\"font-size:12.0pt\"> Hypophysitis is also reported with PD-1/PD-L1 inhibitors (e.g., pembrolizumab and nivolumab) and may show delayed presentation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Nivolumab:</span></strong><span style=\"font-size:12.0pt\"> Hypophysitis is also reported with PD-1/PD-L1 inhibitors (e.g., pembrolizumab and nivolumab) and may show delayed presentation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rituximab is least likely to cause hypophysitis among the listed immunotherapy medications.</span></span></span></p>",
    "correct_choice_id": 214820,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 53839,
    "choices": [
      {
        "id": 214829,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">170 cms</span></span></span></p>"
      },
      {
        "id": 214830,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">176.5 cms</span></span></span></p>"
      },
      {
        "id": 214831,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">163.5 cms</span></span></span></p>"
      },
      {
        "id": 214832,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">168.5 cms</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 5-year-old boy presented with short stature. His father&rsquo;s height is 175 cms, mother&rsquo;s height is 165 cms. His mid parental height is?</span></span></p>",
    "unique_key": "Q2877059",
    "question_audio": null,
    "question_video": null,
    "map_id": 25425,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) 176.5 cms</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Final height can be predicted using standardized scales (Bayley-Pinneau or Tanner-Whitehouse) or estimated by adding 6.5 cm (boys) or subtracting 6.5 cm (girls) from the midparental height.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">175+165/2= 170; 170 + 6.5= 176.5</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Final height can be estimated by adding 6.5 cm to the midparental height for boys.</span></span></span></p>",
    "correct_choice_id": 214830,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "Factual"
    ]
  },
  {
    "id": 53840,
    "choices": [
      {
        "id": 214833,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low dose Growth Hormone</span></span></span></p>"
      },
      {
        "id": 214834,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High dose Growth Hormone</span></span></span></p>"
      },
      {
        "id": 214835,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGF-1</span></span></span></p>"
      },
      {
        "id": 214836,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High dose Corticosteroids</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following can be used to treat Laron dwarfism?</span></span></span></p>",
    "unique_key": "Q1180940",
    "question_audio": null,
    "question_video": null,
    "map_id": 25426,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) IGF-1</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Laron dwarfism, also known as growth hormone insensitivity, is a rare genetic disorder caused by a deficiency or malfunction of growth hormone receptors. IGF-1 (Insulin-like Growth Factor 1), a hormone stimulated by growth hormone, is the primary mediator of growth. Therefore, recombinant IGF-1 therapy is the standard treatment for Laron dwarfism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Low dose Growth Hormone:</span></strong><span style=\"font-size:12.0pt\"> Ineffective as the body cannot respond to GH due to receptor issues.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. High dose Growth Hormone:</span></strong><span style=\"font-size:12.0pt\"> Ineffective and potentially harmful, as the body cannot utilize excess GH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. High dose Corticosteroids:</span></strong><span style=\"font-size:12.0pt\"> Long term corticosteroids can reduce GH release and impair growth in children.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Laron dwarfism is treated with IGF-1 (Insulin-like Growth Factor 1).</span></span></span></p>",
    "correct_choice_id": 214835,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 53843,
    "choices": [
      {
        "id": 214845,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Raised ICP</span></span></span></p>"
      },
      {
        "id": 214846,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Permanent DI</span></span></span></p>"
      },
      {
        "id": 214847,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypopituitarism</span></span></span></p>"
      },
      {
        "id": 214848,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vision loss</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 36-year-old man with acromegaly underwent transsphenoidal surgery (TSS). All of the following are complications except?</span></span></p>",
    "unique_key": "Q8842012",
    "question_audio": null,
    "question_video": null,
    "map_id": 25429,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Raised ICP (Intracranial Pressure)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TSS complications &ndash;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Operative mortality rate is </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 1%.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Transient DI and hypopituitarism in </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 20%.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Permanent DI, CN damage, nasal septal perforation, visual disturbances in </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 10%. Permanent side effects are rare after surgery for microadenomas.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CSF leaks (leading to intracranial hypotension) in </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 4% of patients.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rare complications: carotid artery injury, loss of vision, hypothalamic damage, and meningitis </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Permanent DI (Diabetes Insipidus):</span></strong><span style=\"font-size:12.0pt\"> Can occur due to damage to the posterior pituitary or pituitary stalk during surgery, leading to a deficiency of antidiuretic hormone (ADH).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Hypopituitarism:</span></strong><span style=\"font-size:12.0pt\"> Can occur due to damage or removal of pituitary tissue, leading to deficiencies in various pituitary hormones.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Vision loss:</span></strong><span style=\"font-size:12.0pt\"> Can occur due to compression or damage to the optic chiasm or nerves during surgery.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Raised intracranial pressure (ICP) is not a common complication of transsphenoidal surgery (TSS) for acromegaly.</span></span></span></p>",
    "correct_choice_id": 214845,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53850,
    "choices": [
      {
        "id": 214873,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prolactinoma</span></span></span></p>"
      },
      {
        "id": 214874,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-functioning pituitary adenoma</span></span></span></p>"
      },
      {
        "id": 214875,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACTH secreting adenoma</span></span></span></p>"
      },
      {
        "id": 214876,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TSHoma</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the most common type of pituitary adenoma?</span></span></p>",
    "unique_key": "Q2151742",
    "question_audio": null,
    "question_video": null,
    "map_id": 25436,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Nonfunctioning pituitary adenomas</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 43% of pituitary adenomas are nonfunctioning pituitary adenomas, which do not produce excess hormones. Prolactinomas are the most common type of <em>functional</em> pituitary adenoma (prevalence </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 40%) but nonfunctioning adenomas are more prevalent overall. Also </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 80% of macroadenomas are non-functioning.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Prolactinomas:&nbsp;</span></strong><span style=\"font-size:12.0pt\">These are the most common <em>functional</em> pituitary adenoma, but not the most common overall.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. ACTH secreting</span></strong><span style=\"font-size:12.0pt\"> <strong>adenoma</strong>: These tumors are less common than prolactinomas and nonfunctioning adenomas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. TSHoma:</span></strong><span style=\"font-size:12.0pt\"> These tumors are extremely rare and in-fact the least common. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Most common type of pituitary adenoma is non functioning pituitary adenoma</span></span></span></p>",
    "correct_choice_id": 214874,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53851,
    "choices": [
      {
        "id": 214877,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fasting insulin levels </span></span></span></p>"
      },
      {
        "id": 214878,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral glucose tolerance test </span></span></span></p>"
      },
      {
        "id": 214879,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum IGF-1 </span></span></span></p>"
      },
      {
        "id": 214880,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin tolerance test</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">45-year-old male presents with gradual enlargement of his hands and feet, coarsening of facial features, and excessive sweating. He also reports frequent headaches and joint pain. Which of the following tests would be the initial screening test for this patient?</span></span></p>",
    "unique_key": "Q2929049",
    "question_audio": null,
    "question_video": null,
    "map_id": 25437,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Serum IGF-1</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum IGF-1 is the most reliable initial screening test for acromegaly. IGF-1 is produced in the liver in response to growth hormone (GH) and its levels are more stable than GH levels, which fluctuate throughout the day. Elevated IGF-1 levels are highly suggestive of GH excess.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Fasting insulin levels:</span></strong><span style=\"font-size:12.0pt\"> While insulin levels may be increased in acromegaly due to insulin resistance, it is neither a screening nor a confirmatory test. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Oral glucose tolerance test:</span></strong><span style=\"font-size:12.0pt\"> It is confirmatory test for GH excess, not a screening test. The diagnosis of acromegaly is confirmed by demonstrating the failure of GH suppression to &lt; 0.4 &mu;g/L (or &lt; 0.05 &mu;g/L with newer assays) within 1&ndash;2 h of an oral glucose load (75 g).&nbsp; About 20% of patients exhibit a paradoxical GH rise after glucose.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Insulin tolerance test:</span></strong><span style=\"font-size:12.0pt\"> It is primarily used for confirming GH deficiency. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum IGF-1 is the most reliable initial screening test for acromegaly due to its stable levels compared to fluctuating growth hormone levels.</span></span></span></p>",
    "correct_choice_id": 214879,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 53854,
    "choices": [
      {
        "id": 214889,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Smoking</span></span></span></p>"
      },
      {
        "id": 214890,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low glucose</span></span></span></p>"
      },
      {
        "id": 214891,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Low angiotensin II levels</span></span></p>"
      },
      {
        "id": 214892,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low glucocorticoids</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT a trigger for ADH release? </span></span></p>",
    "unique_key": "Q3720389",
    "question_audio": null,
    "question_video": null,
    "map_id": 25440,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Low angiotensin II levels</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Angiotensin II is a potent stimulator of ADH release. Low levels of angiotensin II would therefore not trigger ADH release but rather suppress it.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Other triggers: Nausea, acute hypoglycemia, glucocorticoid deficiency, smoking, and, possibly, hyperangiotensinemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">FACTS ON ADH:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ADH secretion is determined by &lsquo;osmoreceptors&rsquo; (anteromedial hypothalamus). </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Usual setpoint for ADH release = S.osm of ~275 mosmol/L and S.Na of 135 ~ meq/L. <em>Set point for thirst ~3% higher than ADH setpoint.</em></span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Set point decreases in the luteal phase (~1%) and pregnancy (~3%).<br />\r\n\tAlso, note that in pregnancy ADH clearance is increased (3x - 4x) due to placental N-terminal peptidase (which corresponds to physiologic polyuria, a.k.a gestational DI)</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ADH actions: Antidiuresis (V2), Vasoconstriction &amp; vWF/FVIII release (V1A), ACTH release (V1B)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Site of ADH action in the kidney = Principal cells (Distal nephron &ndash; especially the medullary collecting duct)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Maximum diuresis achievable (if no ADH) = ~50mOsm/L (UO ~0.2mL/kg/min, SG &lt; 1)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Maximum antidiuresis (Max ADH 1-3 pg/mL) = = ~1200mOsm/L (UO = ~0.35mL/kg/min)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Smoking:</span></strong><span style=\"font-size:12.0pt\"> Nicotine in cigarettes can stimulate ADH release.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Low blood glucose:</span></strong><span style=\"font-size:12.0pt\"> Hypoglycemia can trigger ADH release as part of a stress response.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Low glucocorticoid levels:</span></strong><span style=\"font-size:12.0pt\"> Glucocorticoids (like cortisol) inhibit ADH release. Hence deficiency would trigger ADH release.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low levels of angiotensin II do not trigger ADH release but rather suppress it, as angiotensin II is a potent stimulator of ADH release.</span></span></span></p>",
    "correct_choice_id": 214891,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53857,
    "choices": [
      {
        "id": 214901,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low serum albumin </span></span></span></p>"
      },
      {
        "id": 214902,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypokalemia</span></span></span></p>"
      },
      {
        "id": 214903,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated BUN</span></span></span></p>"
      },
      {
        "id": 214904,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low serum uric acid</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old woman with a history of lung cancer presents with confusion, lethargy, and muscle cramps. Laboratory results revealed a serum sodium of 120 mEq/L and serum osmolality of 260 mOsm/kg. Urine osmolality is 450 mOsm/kg, and urine sodium is 40 mEq/L. BP is 120/80 mm Hg and her JVP is normal. Which of the following laboratory findings is consistent with a diagnosis?</span></span></p>",
    "unique_key": "Q5641386",
    "question_audio": null,
    "question_video": null,
    "map_id": 25443,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Low serum uric acid</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In this case, the patient presents with euvolemic hypo-osmolar hyponatremia, accompanied by increased urine osmolality (&gt; 100 mOsm/L) and elevated urine sodium (&gt; 25 mEq/L). These findings suggest a diagnosis of SIADH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Classic Features of SIADH: </span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clinical euvolemia.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased: S.Na, S. Osmolality.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased U.Osmolality and U.Na.</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Other features of SIADH: </span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased: BUN, Cr, Uric acid, Urate and Plasma renin activity.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal: Cortisol, T4, albumin and Potassium.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Low serum albumin:</span></strong><span style=\"font-size:12.0pt\"> Serum albumin may be low in hypervolemic hyponatremia and may be slight high in hypovolemic hyponatremia. In SIADH it would be normal. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hypokalemia:</span></strong><span style=\"font-size:12.0pt\"> In SIADH, serum potassium would be normal. It may be reduced in hyper and hypovolemic hyponatremia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Elevated BUN:</span></strong><span style=\"font-size:12.0pt\"> BUN is generally normal/low in SIADH. It may be elevated in hypervolemic and hypovolemic hyponatremia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low serum uric acid is a characteristic finding in SIADH, along with euvolemic hyponatremia, low serum osmolality, and high urine osmolality and sodium.</span></span></span></p>",
    "correct_choice_id": 214904,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19984,
    "choices": [
      {
        "id": 79897,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GATA6 mutations </span></span></span></p>"
      },
      {
        "id": 79898,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucokinase mutations </span></span></span></p>"
      },
      {
        "id": 79899,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ABCC8 activating mutations </span></span></span></p>"
      },
      {
        "id": 79900,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">mtDNA mutations</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the most common cause of pancreatic agenesis?</span></span></p>",
    "unique_key": "Q5270252",
    "question_audio": null,
    "question_video": null,
    "map_id": 19957,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) GATA6 mutations</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GATA6 is a transcription factor essential for pancreatic development. Mutations in the GATA6 gene are the most common known genetic cause of pancreatic agenesis, a condition where the pancreas fails to develop during embryogenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Glucokinase mutations:</span></strong><span style=\"font-size:12.0pt\"> Heterozygous mutations are associated with maturity-onset diabetes of the young (MODY) type 2, characterized by mild, stable hyperglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Homozygous mutations are associated with severe neonatal diabetes.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. ABCC8 activating mutations:</span></strong><span style=\"font-size:12.0pt\"> These mutations cause a form of neonatal diabetes that can be treated with sulfonylureas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. mtDNA mutations:</span></strong><span style=\"font-size:12.0pt\"> Mutations in mitochondrial DNA can cause a rare form of diabetes associated with deafness, but not typically pancreatic agenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GATA6 mutations are the most common cause of pancreatic agenesis.</span></span></span></p>",
    "correct_choice_id": 79897,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53899,
    "choices": [
      {
        "id": 215069,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alzheimer&rsquo;s disease </span></span></span></p>"
      },
      {
        "id": 215070,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gout </span></span></span></p>"
      },
      {
        "id": 215071,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-alcoholic fatty liver disease </span></span></span></p>"
      },
      {
        "id": 215072,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Polycystic ovarian syndrome</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with metabolic syndrome are at higher risk for all of the following EXCEPT:</span></span></span></p>",
    "unique_key": "Q1303613",
    "question_audio": null,
    "question_video": null,
    "map_id": 25494,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Alzheimer&#39;s disease</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While there is some evidence suggesting a potential link between metabolic syndrome and an increased risk of Alzheimer&#39;s disease, the association is not as strong or well-established as the link between metabolic syndrome and the other options listed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Gout:</span></strong><span style=\"font-size:12.0pt\"> The metabolic syndrome is associated with increased uric acid levels, a key risk factor for gout.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Nonalcoholic fatty liver disease (NAFLD):</span></strong><span style=\"font-size:12.0pt\"> Insulin resistance, a central feature of metabolic syndrome, is strongly linked to the development of NAFLD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Polycystic ovarian syndrome (PCOS):</span></strong><span style=\"font-size:12.0pt\"> Insulin resistance is also a key factor in the development of PCOS, and metabolic syndrome is frequently seen in women with PCOS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metabolic syndrome is linked with gout, non-alcoholic fatty liver disease, and polycystic ovarian syndrome but not strongly with Alzheimer&#39;s disease.</span></span></span></p>",
    "correct_choice_id": 215069,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53909,
    "choices": [
      {
        "id": 215105,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pharmacotherapy </span></span></span></p>"
      },
      {
        "id": 215106,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bariatric surgery</span></span></span></p>"
      },
      {
        "id": 215107,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diet, exercise, and behavioral therapy </span></span></span></p>"
      },
      {
        "id": 215108,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No intervention needed</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 32-year-old woman with a BMI of 31 kg/m&sup2; and no obesity-related comorbidities is seeking advice on weight management. What is the most appropriate initial intervention for this patient?</span></span></p>",
    "unique_key": "Q5070152",
    "question_audio": null,
    "question_video": null,
    "map_id": 25503,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Diet, exercise, and behavioral therapy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A BMI of 31 kg/m&sup2; falls into the obesity class I category. The most appropriate initial intervention for individuals with obesity class I and no comorbidities is lifestyle modification, which includes diet, exercise, and behavioral therapy. These interventions aim to create a calorie deficit and promote sustainable weight loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pharmacotherapy:</span></strong><span style=\"font-size:12.0pt\"> While pharmacotherapy can be an adjunct to lifestyle modification for weight loss, it is not the first-line treatment for patients with obesity class I without comorbidities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Bariatric surgery:</span></strong><span style=\"font-size:12.0pt\"> Bariatric surgery is reserved for patients with severe obesity (BMI &ge; 40 kg/m&sup2;) or those with BMI &ge; 35 kg/m&sup2; and significant comorbidities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. No intervention needed:</span></strong><span style=\"font-size:12.0pt\"> Although the patient does not have any current comorbidities, a BMI of 31 kg/m&sup2; puts her at risk for developing obesity-related health problems in the future. Therefore, intervention is recommended to prevent these complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-104442.png\" style=\"height:269px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The initial intervention for patients with class I obesity without comorbidities should be diet, exercise, and behavioral therapy.</span></span></span></p>",
    "correct_choice_id": 215107,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19961,
    "choices": [
      {
        "id": 79805,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GLP1 and GIP reduce insulin secretion. </span></span></span></p>"
      },
      {
        "id": 79806,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Portal to peripheral insulin ratio is 1:1 </span></span></span></p>"
      },
      {
        "id": 79807,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucose &lt; 70 mg/dL shuts off insulin secretion. </span></span></span></p>"
      },
      {
        "id": 79808,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin release from beta cells is glucose independent.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following regarding insulin is correct?</span></span></p>",
    "unique_key": "Q1185668",
    "question_audio": null,
    "question_video": null,
    "map_id": 19935,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Glucose &lt; 70 mg/dL shuts off insulin secretion.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin secretion is tightly regulated by blood glucose levels. When blood glucose levels fall below a threshold (typically around 70 mg/dL), insulin secretion is suppressed to prevent hypoglycemia. This is a crucial mechanism for maintaining glucose homeostasis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. GLP1 and GIP reduce insulin secretion:&nbsp;</span></strong><span style=\"font-size:12.0pt\">GLP1 (Glucagon-like peptide-1) and GIP (Glucose-dependent insulinotropic polypeptide) are incretin hormones that actually <em>increase</em> insulin secretion in response to oral glucose intake.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Portal to peripheral insulin ratio is 1:1:</span></strong><span style=\"font-size:12.0pt\"> The portal to peripheral insulin ratio is approximately 2:1, as a significant portion (50%) of insulin is cleared by the liver in the first pass.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Insulin release from beta cells is glucose independent:</span></strong><span style=\"font-size:12.0pt\"> This is incorrect. Glucose is the primary stimulator of insulin secretion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucose levels below 70 mg/dL shut off insulin secretion to prevent hypoglycemia.</span></span></span></p>",
    "correct_choice_id": 79807,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19980,
    "choices": [
      {
        "id": 79881,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal glucose tolerance </span></span></span></p>"
      },
      {
        "id": 79882,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Impaired glucose tolerance </span></span></span></p>"
      },
      {
        "id": 79883,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetes Mellitus </span></span></span></p>"
      },
      {
        "id": 79884,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">None of the above</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old patient came with the following reports. What is the likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-093727.png\" style=\"height:212px; width:500px\" /></span></span></p>",
    "unique_key": "Q3630101",
    "question_audio": null,
    "question_video": null,
    "map_id": 19953,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Diabetes Mellitus</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s blood glucose values meet the criteria for diabetes mellitus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">FBS (Fasting Blood Sugar):</span></strong><span style=\"font-size:12.0pt\"> 138 mg/dL is above the normal range (&lt;100 mg/dL) and within the range for diabetes (&ge;126 mg/dL).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">2-hour PG (2-hour Postprandial Glucose):</span></strong><span style=\"font-size:12.0pt\"> 260 mg/dL is well above the normal range (&lt;140 mg/dL) and the range for impaired glucose tolerance (140-199 mg/dL), indicating diabetes (&ge;200 mg/dL).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">HbA1c (Glycated Hemoglobin):</span></strong><span style=\"font-size:12.0pt\"> 7.9% is above the normal range (&lt;5.7%) and the range for prediabetes (5.7-6.4%), confirming the diagnosis of diabetes (&ge;6.5%).</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Normal glucose tolerance:</span></strong><span style=\"font-size:12.0pt\"> All values should be within the normal range for this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Impaired glucose tolerance:</span></strong><span style=\"font-size:12.0pt\"> The 2-hour PG value is too high for this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. None of the above:</span></strong><span style=\"font-size:12.0pt\"> The correct answer is listed in the options.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetes Mellitus is diagnosed with fasting blood sugar &ge;126 mg/dL, 2-hour postprandial glucose &ge;200 mg/dL, or HbA1c &ge;6.5%.</span></span></span></p>",
    "correct_choice_id": 79883,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 19989,
    "choices": [
      {
        "id": 79917,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Preprandial 80-130 mg/dL </span></span></span></p>"
      },
      {
        "id": 79918,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Postprandial &lt; 180 mg/dL </span></span></span></p>"
      },
      {
        "id": 79919,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbA1C &lt; 7% </span></span></span></p>"
      },
      {
        "id": 79920,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Goals should be more stringent in older adults</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is incorrect regarding glycemic targets in non-pregnant diabetics?</span></span></p>",
    "unique_key": "Q9411414",
    "question_audio": null,
    "question_video": null,
    "map_id": 19962,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Goals should be more stringent in older adults</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The American Diabetes Association (ADA) recommends that glycemic targets should be individualized for each patient, taking into account their age, overall health, and risk of hypoglycemia. While a HbA1c goal of &lt;7.0% is appropriate for many non-pregnant adults with diabetes, <strong>less stringent goals</strong> may be appropriate for older adults, especially those with a history of severe hypoglycemia, limited life expectancy, or advanced microvascular or macrovascular complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Preprandial 80-130 mg/dL:</span></strong><span style=\"font-size:12.0pt\"> This is the correct target range for preprandial capillary plasma glucose according to the ADA guidelines.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Postprandial &lt; 180 mg/dL:</span></strong><span style=\"font-size:12.0pt\"> This is the correct target range for peak postprandial capillary plasma glucose according to the ADA guidelines.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. HbA1C &lt; 7%:</span></strong><span style=\"font-size:12.0pt\"> This is the general target for HbA1c in most non-pregnant adults with diabetes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Summary:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-095420.png\" style=\"height:507px; width:1000px\" /></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glycemic targets in older adults should be less stringent due to increased risk of hypoglycemia.</span></span></span></p>",
    "correct_choice_id": 79920,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53901,
    "choices": [
      {
        "id": 215077,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Leptin </span></span></span></p>"
      },
      {
        "id": 215078,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adiponectin </span></span></span></p>"
      },
      {
        "id": 215079,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin</span></span></span></p>"
      },
      {
        "id": 215080,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TNF-&alpha;</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is reduced in obese patients?</span></span></span></p>",
    "unique_key": "Q3879598",
    "question_audio": null,
    "question_video": null,
    "map_id": 25496,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Adiponectin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adiponectin is a hormone produced by adipocytes (fat cells) that plays a role in regulating glucose and lipid metabolism. It has anti-inflammatory and insulin-sensitizing effects. In obese patients, adiponectin levels are often <strong>reduced</strong>, contributing to insulin resistance and the development of metabolic syndrome. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Leptin:</span></strong><span style=\"font-size:12.0pt\"> Leptin levels are typically elevated in obese patients, but its signaling is often impaired (leptin resistance). Elevated leptin is associated with endothelial damage resulting in CV risk. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Insulin:</span></strong><span style=\"font-size:12.0pt\"> Insulin levels are often elevated in obese patients due to insulin resistance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. TNF-&alpha;:</span></strong><span style=\"font-size:12.0pt\"> TNF-&alpha; (and IL-6) is increased in obesity, contributing to the chronic low-grade inflammation, which can cause endothelial injury and increase CV risk. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adiponectin levels are reduced in obese patients, contributing to insulin resistance and metabolic syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Adipokines in Obesity:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><u><span style=\"font-size:12.0pt\">Increased:</span></u><span style=\"font-size:12.0pt\"> Leptin, Insulin, Resistin, Proinflammatory cytokines (IL6/ TNF &alpha;)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><u><span style=\"font-size:12.0pt\">Decreased<em>:</em></span></u><span style=\"font-size:12.0pt\"> Adiponectin, Ghrelin</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 215078,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19963,
    "choices": [
      {
        "id": 79813,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antibodies </span></span></span></p>"
      },
      {
        "id": 79814,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CD4 T cells </span></span></span></p>"
      },
      {
        "id": 79815,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CD8 T cells </span></span></span></p>"
      },
      {
        "id": 79816,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inflammatory cytokines</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In type 1 diabetes, &beta; cell destruction is primarily mediated by:</span></span></span></p>",
    "unique_key": "Q6711529",
    "question_audio": null,
    "question_video": null,
    "map_id": 19937,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) CD8 T cells</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While all of the listed options play a role in the pathogenesis of type 1 diabetes, the direct destruction of beta cells is primarily mediated by cytotoxic CD8+ T cells. These cells recognize specific antigens presented on the surface of beta cells and induce apoptosis, leading to their destruction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Antibodies:</span></strong><span style=\"font-size:12.0pt\"> Autoantibodies against beta cell antigens are present in type 1 diabetes and serve as markers of the disease, but they do not directly cause beta cell death.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CD4 T cells:</span></strong><span style=\"font-size:12.0pt\"> CD4 T cells play a role in activating and coordinating the immune response, but they are not the primary mediators of beta cell destruction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Inflammatory cytokines:</span></strong><span style=\"font-size:12.0pt\"> Cytokines released by immune cells contribute to the inflammatory environment and can indirectly damage beta cells, but the direct killing is primarily mediated by CD8+ T cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><u>Educational Objective</u>: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CD8 T cells are the primary mediators of &beta; cell destruction in type 1 diabetes.</span></span></span></p>",
    "correct_choice_id": 79815,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19988,
    "choices": [
      {
        "id": 79913,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CV (Coefficient of Variation) is an equivalent of HbA1c </span></span></span></p>"
      },
      {
        "id": 79914,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CGM measures interstitial glucose </span></span></span></p>"
      },
      {
        "id": 79915,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low rates of hypo and hyperglycemia if used with insulin infusion device </span></span></span></p>"
      },
      {
        "id": 79916,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CGM can detect hypoglycemic unawareness</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is false regarding Continuous Glucose Monitoring (CGM) in diabetes?</span></span></p>",
    "unique_key": "Q8316543",
    "question_audio": null,
    "question_video": null,
    "map_id": 19961,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) CV (Coefficient of Variation) is an equivalent of HbA1c</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">CV and HbA1c are not equivalent:</span></strong><span style=\"font-size:12.0pt\"> The coefficient of variation (CV) measures glucose variability, or how much glucose levels fluctuate. GMI (Glucose Management Indicator) is a vague equivalent of HbA1C since both indicate MBG (Mean Blood Glucose).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CGM measures interstitial glucose:</span></strong><span style=\"font-size:12.0pt\"> CGM does not directly measure blood glucose. It measures glucose levels in the interstitial fluid, which closely reflects blood glucose but with a slight time lag.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Low rates of hypo and hyperglycemia if used with insulin infusion device:</span></strong><span style=\"font-size:12.0pt\"> CGM, especially when integrated with insulin pumps (forming a hybrid closed-loop system), can significantly reduce the risk of hypoglycemia and hyperglycemia by providing real-time data and automated insulin adjustments.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CGM can detect hypoglycemic unawareness:</span></strong><span style=\"font-size:12.0pt\"> CGM can alert patients to impending hypoglycemia, even if they are not experiencing typical symptoms, thus helping to prevent severe hypoglycemic events.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coefficient of Variation (CV) measures glucose variability and is not equivalent to HbA1c.</span></span></span></p>",
    "correct_choice_id": 79913,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53898,
    "choices": [
      {
        "id": 215065,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HDL cholesterol level of 58 mg/dL </span></span></span></p>"
      },
      {
        "id": 215066,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Triglyceride level of 160 mg/dL</span></span></span></p>"
      },
      {
        "id": 215067,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Taking a statin for hypercholesterolemia </span></span></span></p>"
      },
      {
        "id": 215068,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BMI of 28 kg/m&sup2;</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman from Chennai presents with a waist circumference of 92 cm, a blood pressure of 120/80 mmHg, and a fasting blood glucose of 110 mg/dL. Which of the following additional findings would be needed to diagnose metabolic syndrome?</span></span></p>",
    "unique_key": "Q6748120",
    "question_audio": null,
    "question_video": null,
    "map_id": 25493,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Triglyceride level of 160 mg/dL</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">According to the harmonizing definition of metabolic syndrome, at least 3 of the following five criteria are needed for diagnosis:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Abdominal obesity:</span></strong><span style=\"font-size:12.0pt\"> Waist circumference &gt;90cm for South Asian women (which the patient meets with 92 cm)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Triglycerides:</span></strong><span style=\"font-size:12.0pt\"> &ge;150 mg/dL (1.7 mmol/L) (which the patient would meet with 160 mg/dL)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">HDL cholesterol:</span></strong><span style=\"font-size:12.0pt\"> &lt;50 mg/dL (1.29 mmol/L) in women</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Blood pressure:</span></strong><span style=\"font-size:12.0pt\"> &ge;130/85 mmHg or on antihypertensive medication</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Fasting glucose:</span></strong><span style=\"font-size:12.0pt\"> &ge;100 mg/dL (5.6 mmol/L) or diagnosed type 2 diabetes (which the patient meets with 110 mg/dL)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient already meets the criteria for abdominal obesity and impaired fasting glucose. With the additional finding of elevated triglycerides (&ge;150 mg/dL), she would meet three criteria and thus be diagnosed with metabolic syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-100019.png\" style=\"height:653px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. HDL cholesterol level of 58 mg/dL:</span></strong><span style=\"font-size:12.0pt\"> This is within normal limits (&gt;50 mg/dL) and does not contribute to the diagnosis of metabolic syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Taking a statin for hypercholesterolemia:</span></strong><span style=\"font-size:12.0pt\"> This is a treatment for high cholesterol but is not a diagnostic criterion for metabolic syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. BMI of 28 kg/m&sup2;:</span></strong><span style=\"font-size:12.0pt\"> This is considered overweight but not obese, and while it can be associated with metabolic syndrome, it is not a direct diagnostic criterion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metabolic syndrome diagnosis requires at least three criteria, including central obesity, elevated triglycerides, low HDL cholesterol, high blood pressure, or high fasting glucose.</span></span></span></p>",
    "correct_choice_id": 215066,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "CriteriaBased"
    ]
  },
  {
    "id": 19955,
    "choices": [
      {
        "id": 79781,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ketogenic diet </span></span></span></p>"
      },
      {
        "id": 79782,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prednisolone </span></span></span></p>"
      },
      {
        "id": 79783,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Valproate d</span></span></span></p>"
      },
      {
        "id": 79784,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lamotrigine</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A neonate presents with seizures, microcephaly, and developmental delay. Brain imaging reveals abnormalities in the white matter. Genetic testing confirms a mutation in the SLC2A1 gene. What is the treatment of choice?</span></span></p>",
    "unique_key": "Q5683558",
    "question_audio": null,
    "question_video": null,
    "map_id": 19929,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Ketogenic diet</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The mutation in the SLC2A1 gene indicates GLUT1 deficiency syndrome, a rare metabolic disorder characterized by impaired glucose transport across the blood-brain barrier. This leads to neuroglycopenia (low glucose in the brain), causing seizures, developmental delay, and movement disorders.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The ketogenic diet is the treatment of choice for GLUT1 deficiency syndrome, bypassing the need for glucose transport via GLUT1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Prednisolone:</span></strong><span style=\"font-size:12.0pt\"> This is a corticosteroid used to treat inflammation and autoimmune conditions. It is not effective in GLUT1 deficiency syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Valproate&nbsp;</span></strong><span style=\"font-size:12.0pt\">and </span><strong><span style=\"font-size:12.0pt\">Option D. Lamotrigine:</span></strong><span style=\"font-size:12.0pt\"> These are anti-seizure medications that are generally ineffective in controlling seizures associated with GLUT1 deficiency syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-091146.png\" style=\"height:416px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GLUT1 deficiency syndrome, caused by SLC2A1 gene mutation, is best treated with a ketogenic diet to bypass glucose transport issues.</span></span></span></p>",
    "correct_choice_id": 79781,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 53906,
    "choices": [
      {
        "id": 215093,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Semaglutide </span></span></span></p>"
      },
      {
        "id": 215094,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Setmelanotide </span></span></span></p>"
      },
      {
        "id": 215095,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Orlistat </span></span></span></p>"
      },
      {
        "id": 215096,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Phentermine</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs is not approved for general obesity?</span></span></p>",
    "unique_key": "Q7851437",
    "question_audio": null,
    "question_video": null,
    "map_id": 25500,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Setmelanotide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Setmelanotide is not approved for general obesity. It is specifically approved for the treatment of obesity in patients with certain rare genetic conditions, such as proopiomelanocortin (POMC) deficiency, leptin receptor (LEPR) deficiency, or Bardet-Biedl syndrome (BBS).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Semaglutide:</span></strong><span style=\"font-size:12.0pt\"> This GLP-1 receptor agonist is approved for chronic weight management in adults with general obesity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Orlistat:</span></strong><span style=\"font-size:12.0pt\"> This lipase inhibitor is approved for weight loss in adults and adolescents with obesity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Phentermine:</span></strong><span style=\"font-size:12.0pt\"> This appetite suppressant is approved for short-term use in adults with obesity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Setmelanotide is not approved for general obesity but for specific genetic conditions like POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome.</span></span></span></p>",
    "correct_choice_id": 215094,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 53904,
    "choices": [
      {
        "id": 215085,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Most common mechanism of imprinting center mutations </span></span></span></p>"
      },
      {
        "id": 215086,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Loss of SNRPN gene </span></span></span></p>"
      },
      {
        "id": 215087,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inherited in autosomal dominant pattern </span></span></span></p>"
      },
      {
        "id": 215088,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduced Ghrelin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is true regarding Prader Willi Syndrome (PWS)?</span></span></p>",
    "unique_key": "Q5102124",
    "question_audio": null,
    "question_video": null,
    "map_id": 25498,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Loss of SNRPN gene</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prader-Willi Syndrome (PWS) is caused by the lack of expression of paternal genes in the 15q11-q13 region on chromosome 15. The SNRPN gene is a key imprinted gene in this region and its loss of expression contributes to the features of PWS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Most common mechanism of imprinting center mutations:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While imprinting center mutations can cause PWS, the <em><u>most common mechanism is a deletion</u></em> of the paternal 15q11-q13 region (about 70% of cases). 25% cases are due to maternal uniparental disomy and &lt; 1% cases are due to imprinting center mutations. <em><u>FISH is the 1<sup>st</sup> line diagnostic test</u></em> in PWS. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Inherited in autosomal dominant pattern:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Most cases of PWS are <em><u>sporadic</u></em> and do not show Mendelian inheritance. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Reduced Ghrelin:&nbsp;</span></strong><span style=\"font-size:12.0pt\"><em><u>Ghrelin levels are actually elevated</u></em> in individuals with PWS, contributing to their hyperphagia and obesity. Patients with PWS also show <em><u>reduced BDNF</u></em> expression, contributing to hyperphagia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prader-Willi syndrome is primarily caused by the loss of the SNRPN gene, leading to hyperphagia and obesity.</span></span></span></p>",
    "correct_choice_id": 215086,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "Factual"
    ]
  },
  {
    "id": 19982,
    "choices": [
      {
        "id": 79889,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbA1c </span></span></span></p>"
      },
      {
        "id": 79890,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral glucose tolerance test </span></span></span></p>"
      },
      {
        "id": 79891,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Plasma C-peptide level</span></span></span></p>"
      },
      {
        "id": 79892,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Random plasma glucose level</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 37-year-old obese woman presents to the clinic for a routine health evaluation. She frequently feels thirsty and wakes up at night to urinate. Which of the following studies is the most appropriate first test in evaluating this patient for diabetes mellitus?</span></span></p>",
    "unique_key": "Q8462291",
    "question_audio": null,
    "question_video": null,
    "map_id": 19955,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Random plasma glucose level</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s symptoms of thirst, polyuria, and recurrent yeast infections raise strong suspicion for diabetes mellitus. Given these symptoms, a random plasma glucose test is the most appropriate initial test. A random plasma glucose level of &gt;200 mg/dL, along with her symptoms, would be diagnostic of diabetes mellitus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Hemoglobin A1c:</span></strong><span style=\"font-size:12.0pt\"> While HbA1c is a valuable test for assessing long-term glycemic control, it is not the initial test of choice in a symptomatic patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Oral glucose tolerance test (OGTT):</span></strong><span style=\"font-size:12.0pt\"> OGTT is another diagnostic test for diabetes, but it is more time-consuming and not necessary if the random plasma glucose is diagnostic.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Plasma C-peptide level:</span></strong><span style=\"font-size:12.0pt\"> C-peptide is a marker of endogenous insulin production and is useful in distinguishing between type 1 and type 2 diabetes or evaluating hypoglycemia. It is not the first-line test for diagnosing diabetes in a symptomatic patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Random plasma glucose level is the most appropriate first test for evaluating a symptomatic patient for diabetes mellitus.</span></span></span></p>",
    "correct_choice_id": 79892,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 19959,
    "choices": [
      {
        "id": 79797,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibition of lipolysis </span></span></span></p>"
      },
      {
        "id": 79798,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Suppression of ketosis </span></span></span></p>"
      },
      {
        "id": 79799,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased glucose and potassium uptake by cells </span></span></span></p>"
      },
      {
        "id": 79800,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Induces vasoconstriction</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT insulin-mediated?</span></span></p>",
    "unique_key": "Q8316450",
    "question_audio": null,
    "question_video": null,
    "map_id": 19933,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Induces vasoconstriction</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin does not directly cause vasoconstriction. In fact, it has some vasodilatory effects through the production of nitric oxide. Vasoconstriction is typically mediated by other hormones like angiotensin II and catecholamines.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Inhibition of lipolysis:</span></strong><span style=\"font-size:12.0pt\"> Insulin suppresses the breakdown of stored fats, preventing the release of free fatty acids into the bloodstream.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Suppression of ketosis:</span></strong><span style=\"font-size:12.0pt\"> By promoting glucose utilization, insulin reduces the need for ketone body production, which occurs when the body relies on fats for energy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increased glucose and potassium uptake by cells:</span></strong><span style=\"font-size:12.0pt\"> Insulin stimulates glucose transporters (GLUT4) to move to the cell surface, facilitating glucose uptake. It also activates the sodium-potassium pump, promoting potassium uptake.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Summary of insulin action:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Increased:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Glycogenesis, protein synthesis, lipogenesis, NO production (vasodilation).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Decreased:</span></strong><span style=\"font-size:12.0pt\"> Glycogenolysis, lipolysis, ketosis.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Pathway:</span></strong><span style=\"font-size:12.0pt\"> RTK </span><span style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&rarr;</span></span><span style=\"font-size:12.0pt\"> IRS </span><span style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&rarr;</span></span><span style=\"font-size:12.0pt\"> Pi3k/Akt </span><span style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&rarr;</span></span><span style=\"font-size:12.0pt\"> &uarr; GLUT-4 translocation + &darr; GSK3 (activates glycogen synthase)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin inhibits lipolysis, suppresses ketosis, and increases glucose and potassium uptake but does not induce vasoconstriction.</span></span></span></p>",
    "correct_choice_id": 79800,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19975,
    "choices": [
      {
        "id": 79861,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage 0 </span></span></span></p>"
      },
      {
        "id": 79862,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage 1 </span></span></span></p>"
      },
      {
        "id": 79863,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage 2 </span></span></span></p>"
      },
      {
        "id": 79864,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage 3</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 5-year-old child comes for a routine check-up, and you notice that the child is positive for GAD and ZnT8 antibodies. The blood sugar levels are normal. What stage of type 1 diabetes is the patient in?</span></span></p>",
    "unique_key": "Q4571935",
    "question_audio": null,
    "question_video": null,
    "map_id": 19949,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Stage 1</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of two or more autoantibodies (in this case, GAD and ZnT8), even with normal blood sugar levels, indicates Stage 1 of type 1 diabetes. In this stage, the immune system has begun attacking the insulin-producing beta cells in the pancreas, but there are no symptoms and blood sugar levels remain normal.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Stage 0:</span></strong><span style=\"font-size:12.0pt\"> This stage represents a pre-clinical period where no autoantibodies have been detected. Patients may have genetic predisposition alone. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Stage 2:&nbsp;</span></strong><span style=\"font-size:12.0pt\">In this stage, individuals have multiple autoantibodies and dysglycemia (abnormal blood sugar levels). <em><u>Teplizumab</u></em> (anti CD3 mAb) has been approved for &ge; 8 years + stage 2 type 1 Diabetes (for delaying the progression to stage 3).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Stage 3:</span></strong><span style=\"font-size:12.0pt\"> This is the stage of overt diabetes, where the beta cells are destroyed and insulin production is insufficient, leading to hyperglycemia and symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-092103.png\" style=\"height:414px; width:500px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage 1 type 1 diabetes is characterized by the presence of multiple autoantibodies with normal blood glucose levels.</span></span></span></p>",
    "correct_choice_id": 79862,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 19976,
    "choices": [
      {
        "id": 79865,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduced Insulin receptor levels </span></span></span></p>"
      },
      {
        "id": 79866,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduced Tyrosine kinase activity </span></span></span></p>"
      },
      {
        "id": 79867,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased insulin levels </span></span></span></p>"
      },
      {
        "id": 79868,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduced IRS phosphorylation</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is a primary defect responsible for insulin resistance in type 2 diabetes?</span></span></p>",
    "unique_key": "Q7377698",
    "question_audio": null,
    "question_video": null,
    "map_id": 19950,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Reduced IRS phosphorylation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While all the options can contribute to insulin resistance, the primary defect in type 2 diabetes is a <strong>post-receptor defect,</strong> namely reduced tyrosine phosphorylation of insulin receptor substrates (IRS). This impairment in the intracellular signaling cascade disrupts insulin&#39;s ability to promote glucose uptake and utilization in target tissues.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Reduced Insulin receptor levels:</span></strong><span style=\"font-size:12.0pt\"> Although receptor levels can be reduced in insulin resistance, this is often a secondary effect due to chronic hyperinsulinemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Reduced Tyrosine kinase activity:</span></strong><span style=\"font-size:12.0pt\"> This can also be a consequence of chronic hyperinsulinemia rather than the primary cause of insulin resistance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increased insulin levels:</span></strong><span style=\"font-size:12.0pt\"> Increased insulin levels (hyperinsulinemia) are a compensatory response to insulin resistance, not the primary cause.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduced IRS phosphorylation is a primary defect responsible for insulin resistance in type 2 diabetes.</span></span></span></p>",
    "correct_choice_id": 79868,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19977,
    "choices": [
      {
        "id": 79869,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal glucose tolerance </span></span></span></p>"
      },
      {
        "id": 79870,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Impaired glucose tolerance </span></span></span></p>"
      },
      {
        "id": 79871,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetes Mellitus </span></span></span></p>"
      },
      {
        "id": 79872,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">None of the above</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old patient presents with the following blood sugar values. Which of the following is the most likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-092501.png\" style=\"height:121px; width:300px\" /></span></span></p>",
    "unique_key": "Q6079472",
    "question_audio": null,
    "question_video": null,
    "map_id": 19951,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Normal glucose tolerance</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s blood glucose values fall within the normal range for all three tests:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">FBS (Fasting Blood Sugar):</span></strong><span style=\"font-size:12.0pt\"> 98 mg/dL (normal range: &lt;100 mg/dL)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">2-hour PG (2-hour Postprandial Glucose):</span></strong><span style=\"font-size:12.0pt\"> 130 mg/dL (normal range: &lt;140 mg/dL)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">HbA1c (Glycated Hemoglobin):</span></strong><span style=\"font-size:12.0pt\"> 5.0% (normal range: &lt;5.7%)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Impaired glucose tolerance:</span></strong><span style=\"font-size:12.0pt\"> This would be the diagnosis if the 2-hour PG was between 140-199 mg/dL, but the patient&#39;s value is below this range.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Diabetes Mellitus:</span></strong><span style=\"font-size:12.0pt\"> This diagnosis requires either a fasting blood sugar of &ge;126 mg/dL, a 2-hour PG of &ge;200 mg/dL, or an HbA1c of &ge;6.5%.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. None of the above:</span></strong><span style=\"font-size:12.0pt\"> The correct answer is listed in the options.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal glucose tolerance is indicated by fasting blood sugar &lt;100 mg/dL, 2-hour postprandial glucose &lt;140 mg/dL, and HbA1c &lt;5.7%.</span></span></span></p>",
    "correct_choice_id": 79869,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 19978,
    "choices": [
      {
        "id": 79873,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal glucose tolerance </span></span></span></p>"
      },
      {
        "id": 79874,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Impaired glucose tolerance </span></span></span></p>"
      },
      {
        "id": 79875,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetes Mellitus </span></span></span></p>"
      },
      {
        "id": 79876,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">None of the above</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old patient came with the following reports. What is the diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-092709.png\" style=\"height:208px; width:400px\" /></span></span></p>",
    "unique_key": "Q6442224",
    "question_audio": null,
    "question_video": null,
    "map_id": 19952,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Impaired glucose tolerance</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s blood glucose values indicate impaired glucose tolerance (IGT).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">FBS (Fasting Blood Sugar):</span></strong><span style=\"font-size:12.0pt\"> 118 mg/dL falls within the range for prediabetes or impaired fasting glucose (100-125 mg/dL).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">2-hour PG (2-hour Postprandial Glucose):</span></strong><span style=\"font-size:12.0pt\"> 160 mg/dL falls in the range for impaired glucose tolerance (140-199 mg/dL).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">HbA1c (Glycated Hemoglobin):</span></strong><span style=\"font-size:12.0pt\"> 5.9% falls within the range for prediabetes (5.7-6.4%).</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGT is a pre-diabetic condition where the body does not process glucose as efficiently as it should, leading to higher-than-normal blood sugar levels after eating. It is a risk factor for developing type 2 diabetes mellitus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Normal glucose tolerance:</span></strong><span style=\"font-size:12.0pt\"> All values should be within the normal range for this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Diabetes Mellitus:</span></strong><span style=\"font-size:12.0pt\"> To diagnose diabetes, either the FBS needs to be &ge;126 mg/dL, the 2-hour PG needs to be &ge;200 mg/dL, or the HbA1c needs to be &ge;6.5%.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. None of the above:</span></strong><span style=\"font-size:12.0pt\"> The correct answer is listed in the options.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Impaired glucose tolerance is indicated by fasting blood sugar between 100-125 mg/dL, 2-hour postprandial glucose between 140-199 mg/dL, and HbA1c between 5.7-6.4%.</span></span></span></p>",
    "correct_choice_id": 79874,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19981,
    "choices": [
      {
        "id": 79885,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">10%</span></span></span></p>"
      },
      {
        "id": 79886,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">50%</span></span></span></p>"
      },
      {
        "id": 79887,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">85%</span></span></span></p>"
      },
      {
        "id": 79888,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">100%</span></span></span></p>"
      }
    ],
    "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">How commonly are islet cell antibodies found in patients with new-onset type 1 diabetes?</span></span></p>",
    "unique_key": "Q1837994",
    "question_audio": null,
    "question_video": null,
    "map_id": 19954,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) 85%</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">ICAs are present in the majority of individuals (&gt;85%) diagnosed with new-onset type 1 DM,</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Present in minority of individuals with newly diagnosed young type 2 DM (5&ndash;10%), and occasionally in individuals with gestational diabetes mellitus (&lt;5%). </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">ICAs are present in 3&ndash;4% of first-degree relatives of individuals with type 1 DM. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In combination with impaired insulin secretion after IV glucose tolerance testing, they predict a &gt;50% risk of developing type 1 DM within 5 years. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Increasing numbers of autoantibodies are associated with an increased risk of diabetes development. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In children with multiple autoantibodies, ~70% developed type 1 DM after 10 years of follow-up, with 80% developing diabetes after 15-year of follow-up. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><strong> </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Islet cell antibodies are found in approximately 85% of patients with new-onset type 1 diabetes.</span></span></span></p>",
    "correct_choice_id": 79887,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19983,
    "choices": [
      {
        "id": 79893,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She will likely require insulin therapy. </span></span></span></p>"
      },
      {
        "id": 79894,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She will have a progressive decline in glycemic control. </span></span></span></p>"
      },
      {
        "id": 79895,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">She has a high risk of developing microvascular complications. </span></span></span></p>"
      },
      {
        "id": 79896,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Her condition is typically managed with diet and exercise.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 15-year-old girl with a family history of diabetes presents with mild fasting hyperglycemia. She is not obese and has no autoantibodies. Genetic testing reveals a heterozygous mutation in the glucokinase (GCK) gene. Which of the following statements is true regarding her condition?</span></span></p>",
    "unique_key": "Q6587212",
    "question_audio": null,
    "question_video": null,
    "map_id": 19956,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Her condition is typically managed with diet and exercise.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A heterozygous mutation in the glucokinase (GCK) gene leads to a form of maturity-onset diabetes of the young (MODY) known as MODY 2 or GCK-MODY. This condition is characterized by mild, stable fasting hyperglycemia that is usually present from birth. Individuals with MODY 2 typically do not require medication and have a low risk of developing diabetes-related complications. Lifestyle modifications such as diet and exercise are usually sufficient for managing their condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. She will likely require insulin therapy:</span></strong><span style=\"font-size:12.0pt\"> Insulin therapy is generally not required for individuals with MODY 2.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. She will have a progressive decline in glycemic control:</span></strong><span style=\"font-size:12.0pt\"> Glycemic control in MODY 2 tends to be stable over time.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. She has a high risk of developing microvascular complications:</span></strong><span style=\"font-size:12.0pt\"> MODY 2 is associated with a very low risk of microvascular complications like retinopathy, nephropathy, and neuropathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MODY 2 due to GCK mutation is typically managed with diet and exercise, with low risk for complications.</span></span></span></p>",
    "correct_choice_id": 79896,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 19985,
    "choices": [
      {
        "id": 79901,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HNF1&alpha; </span></span></span></p>"
      },
      {
        "id": 79902,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HNF1&beta; </span></span></span></p>"
      },
      {
        "id": 79903,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NeuroD1 </span></span></span></p>"
      },
      {
        "id": 79904,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PDX1</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following mutations causing diabetes will likely respond to sulfonylureas?</span></span></p>",
    "unique_key": "Q4400112",
    "question_audio": null,
    "question_video": null,
    "map_id": 19958,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) HNF1&alpha;</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HNF1&alpha; mutations cause MODY 3. Individuals with MODY 3 typically have some degree of residual beta-cell function, meaning their pancreas can still produce insulin, although not as effectively as in people without diabetes. Sulfonylureas work by stimulating the release of insulin from beta cells. Therefore, patients with MODY 3 often respond well to sulfonylureas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with MODY3 tend to have lower urinary threshold for glucose (can have glycosuria even with normal blood glucose). </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. HNF1&beta;:</span></strong><span style=\"font-size:12.0pt\"> Mutations in this gene cause MODY 5, which is associated with progressive beta-cell dysfunction and may require insulin therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. NeuroD1:</span></strong><span style=\"font-size:12.0pt\"> Mutations in this gene cause a rare form of MODY that typically does not respond to sulfonylureas and may require insulin therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. PDX1:</span></strong><span style=\"font-size:12.0pt\"> Mutations in this gene cause MODY 4, which is also associated with progressive beta-cell dysfunction and may require insulin therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Summary:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Good response to SU: HNF1&alpha; (MODY 3), HNF4&alpha; (MODY 1), ABCC8, PAX4, KCNJ11.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No response to SU: HNF1&beta; (MODY 4), NeuroD1 (MODY 6), KLF11, CEL.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Response uncertain: PDX1 (MODY 5), INS, BLK.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rx not required: Heterozygous GCK mutations (MODY 2).</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HNF1&alpha; mutations in MODY respond well to sulfonylureas.</span></span></span></p>",
    "correct_choice_id": 79901,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19986,
    "choices": [
      {
        "id": 79905,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ketosis-prone type 2 diabetes </span></span></span></p>"
      },
      {
        "id": 79906,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MODY (Maturity-Onset Diabetes of the Young) </span></span></span></p>"
      },
      {
        "id": 79907,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Lean type 2 diabetes </span></span></span></p>"
      },
      {
        "id": 79908,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Prepubertal type 2 diabetes</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are atypical forms of diabetes except?</span></span></p>",
    "unique_key": "Q9013813",
    "question_audio": null,
    "question_video": null,
    "map_id": 19959,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) MODY (Maturity-Onset Diabetes of the Young)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MODY (Maturity-Onset Diabetes of the Young) is a monogenic form of diabetes caused by a single gene mutation. While it is less common than type 1 or type 2 diabetes, it is not considered an atypical form of diabetes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ketosis-prone type 2 diabetes:</span></strong><span style=\"font-size:12.0pt\"> This is considered atypical as it combines features of both type 1 and type 2 diabetes, with patients experiencing ketosis despite having insulin resistance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Lean type 2 diabetes:</span></strong><span style=\"font-size:12.0pt\"> This is atypical because type 2 diabetes is usually associated with obesity. 80% of type 2 diabetes patients are obese (elderly patients can be thin)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Prepubertal type 2 diabetes:</span></strong><span style=\"font-size:12.0pt\"> This is atypical because type 2 diabetes is typically diagnosed in adults. The increasing prevalence of childhood obesity has led to a rise in prepubertal type 2 diabetes cases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MODY is not considered an atypical form of diabetes.</span></span></span></p>",
    "correct_choice_id": 79906,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19987,
    "choices": [
      {
        "id": 79909,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Time in Range (TIR) &gt; 70% </span></span></span></p>"
      },
      {
        "id": 79910,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coefficient of Variation (CV) &gt; 36% </span></span></span></p>"
      },
      {
        "id": 79911,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Time Above Range (TAR) &lt; 25% </span></span></span></p>"
      },
      {
        "id": 79912,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Time Below Range (TBR) &lt; 4%</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All of the following are standard Continuous Glucose Monitoring (CGM) targets except?</span></span></span></p>",
    "unique_key": "Q5194387",
    "question_audio": null,
    "question_video": null,
    "map_id": 19960,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Coefficient of Variation (CV) &gt; 36%</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coefficient of Variation (CV) is a measure of glucose variability, but the standard target is to maintain CV below 36% (not above), indicating less fluctuation in glucose levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. Time in Range (TIR):</span></strong><span style=\"font-size:12.0pt\"> Represents the percentage of time spent within the target glucose range (70-180 mg/dL for most individuals). A higher TIR (&gt; 70%) is desirable. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Time Above Range (TAR):</span></strong><span style=\"font-size:12.0pt\"> Represents the percentage of time spent above the target glucose range, indicating hyperglycemia. A lower TAR (&lt; 25%) is desirable.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Time Below Range (TBR):</span></strong><span style=\"font-size:12.0pt\"> Represents the percentage of time spent below the target glucose range, indicating hypoglycemia. A lower TBR (&lt;4%) is desirable. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-094945.png\" style=\"height:501px; width:400px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Standard CGM targets include Time in Range &gt;70%, Time Above Range &lt;25%, Time Below Range &lt;4%, and CV &le;36%.</span></span></span></p>",
    "correct_choice_id": 79910,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19990,
    "choices": [
      {
        "id": 79921,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron deficiency </span></span></span></p>"
      },
      {
        "id": 79922,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">B12 deficiency </span></span></span></p>"
      },
      {
        "id": 79923,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hemolysis </span></span></span></p>"
      },
      {
        "id": 79924,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Splenectomy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Falsely high HbA1c is seen in all except?</span></span></p>",
    "unique_key": "Q4119670",
    "question_audio": null,
    "question_video": null,
    "map_id": 19963,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Hemolysis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbA1c (glycated hemoglobin) reflects the average blood glucose levels over the past 2-3 months. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Conditions that cause falsely elevated HbA1C:</span></strong></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">&uarr; RBC life span or &darr; turnover:&nbsp;</span></strong><span style=\"font-size:12.0pt\"><em><u>Fe, B12 or folate deficiency, Asplenia</u></em></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Glycation abnormality:</span></strong><span style=\"font-size:12.0pt\"> Uremia/acidosis</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Assay interference:</span></strong><span style=\"font-size:12.0pt\"> Hyperbilirubinemia, alcoholism</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Conditions that cause falsely low HbA1C:</span></strong></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">&darr; RBC life span or &uarr; turnover:&nbsp;</span></strong><span style=\"font-size:12.0pt\"><em><u>Hemolysis</u></em>, reticulocytosis, recent blood loss or recent PRBC transfusion, EPO therapy, hypersplenism (splenomegaly), Pregnancy</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Glycation abnormality:</span></strong><span style=\"font-size:12.0pt\"> Vitamin C/E (high dose ingestions)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Assay interference:</span></strong><span style=\"font-size:12.0pt\"> Hypertriglyceridemia</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbA1C is variable in hemoglobinopathies (but in HbC/ HbS &ndash; usually HbA1C is falsely low)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Iron deficiency:</span></strong><span style=\"font-size:12.0pt\"> Causes falsely high HbA1C (due to &darr; turnover)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. B12 deficiency:</span></strong><span style=\"font-size:12.0pt\"> Causes falsely high HbA1C (due to &darr; turnover)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Splenectomy:</span></strong><span style=\"font-size:12.0pt\"> Causes falsely high HbA1C (due to &uarr; RBC life span)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hemolysis causes falsely low HbA1c, while iron and B12 deficiency and splenectomy cause falsely high HbA1c.</span></span></span></p>",
    "correct_choice_id": 79923,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 19991,
    "choices": [
      {
        "id": 79925,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glycated Hb (HbA1c) </span></span></span></p>"
      },
      {
        "id": 79926,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glycated albumin </span></span></span></p>"
      },
      {
        "id": 79927,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fructosamine </span></span></span></p>"
      },
      {
        "id": 79928,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1,5-anhydroglucitol</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are markers of short-term glycemic control except?</span></span></p>",
    "unique_key": "Q2828001",
    "question_audio": null,
    "question_video": null,
    "map_id": 19964,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Glycated Hb (HbA1c)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbA1c reflects the average blood glucose levels over the past 2-3 months and is therefore a marker of <strong>long-term</strong> glycemic control.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Glycated albumin:</span></strong><span style=\"font-size:12.0pt\"> Measures glycated form of albumin weeks and is a marker of short-term glycemic control (over 2 weeks). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Fructosamine:</span></strong><span style=\"font-size:12.0pt\"> Measures glycated serum proteins (primarily albumin) and is another marker of short-term glycemic control (over 2 weeks).&nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 1,5-anhydroglucitol:</span></strong><span style=\"font-size:12.0pt\"> This is a monosaccharide that decreases with recent hyperglycemic spikes and is considered a marker of short-term glycemic control (1-2 weeks).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbA1c is a marker of long-term glycemic control, while glycated albumin, fructosamine, and 1,5-anhydroglucitol are markers of short-term glycemic control.</span></span></span></p>",
    "correct_choice_id": 79925,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 53900,
    "choices": [
      {
        "id": 215073,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Colon cancer </span></span></span></p>"
      },
      {
        "id": 215074,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hidradenitis suppurativa</span></span></span></p>"
      },
      {
        "id": 215075,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Knee osteoarthritis </span></span></span></p>"
      },
      {
        "id": 215076,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ovarian cancer</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following health conditions are associated with obesity EXCEPT:</span></span></p>",
    "unique_key": "Q3742233",
    "question_audio": null,
    "question_video": null,
    "map_id": 25495,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Ovarian cancer</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Obesity is a major risk factor for several types of cancer, including colon cancer. It is also linked to hidradenitis suppurativa and knee osteoarthritis (due to increased stress on knee joints). However, ovarian cancer is not directly associated with obesity (but there is some association with breast and uterine cancers). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Colon cancer:</span></strong><span style=\"font-size:12.0pt\"> Obesity is a known risk factor for colon cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hidradenitis suppurativa:</span></strong><span style=\"font-size:12.0pt\"> Obesity is a major risk factor for this inflammatory skin condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Knee osteoarthritis:</span></strong><span style=\"font-size:12.0pt\"> Excess weight puts stress on joints, increasing the risk of osteoarthritis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Health risks in obesity:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Cardiovascular:&nbsp;</span></strong><span style=\"font-size:12.0pt\">HTN, CHF, Cor pulmonale, Varicose veins, Pulmonary embolism, CAD, AF (<u>most common arrhythmia in obese individuals</u>).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Endocrine:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Metabolic syndrome<strong>, </strong>Type 2 diabetes (<u>most common complication of<em> </em>obesity</u>)<strong>, </strong>Dyslipidemia, PCOS</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Musculoskeletal:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Hyperuricemia/gout<strong>, </strong>Immobility<strong>, </strong>OA (knees and hips &ndash; <u>most common<em> </em>rheumatologic complication</u>)<strong>, </strong>Low back pain<strong>, </strong>CTS</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Psychological:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Depression/low self-esteem<strong>, </strong>Body image disturbance<strong>, </strong>Social stigmatization</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Integument:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Striae distensae<strong>, </strong>Stasis pigmentation of legs<strong>, </strong>Lymphedema<strong>, </strong>Cellulitis<strong>, </strong>Intertrigo, carbuncles<strong>, </strong>Acanthosis nigricans<strong>, </strong>Acrochordons (skin tags)<strong>, </strong>Hidradenitis suppurativa</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Respiratory:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Exertional<strong> </strong>Dyspnea (<em><u>most common pulmonary complication</u></em>), OSA, Pickwickian syndrome<strong>,</strong>Asthma</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Gastrointestinal:&nbsp;</span></strong><span style=\"font-size:12.0pt\">GERD (<em><u>most common GI complication</u></em>), NAFLD, Cholelithiasis, Hernias, CRC</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Genitourinary:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Urinary stress incontinence<strong>, </strong>Obesity-related glomerulopathy<strong>, </strong>Hypogonadism (male)<strong>, </strong>Breast and uterine cancer</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Pregnancy complications</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Neurologic:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Stroke, Idiopathic intracranial hypertension, Meralgia paresthetica, Dementia</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Obesity is associated with increased risks of colon cancer, hidradenitis suppurativa, and knee osteoarthritis but not specifically ovarian cancer.</span></span></span></p>",
    "correct_choice_id": 215076,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53902,
    "choices": [
      {
        "id": 215081,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stimulates POMC neurons </span></span></span></p>"
      },
      {
        "id": 215082,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibits NPY/AGRP neurons </span></span></span></p>"
      },
      {
        "id": 215083,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-inflammatory </span></span></span></p>"
      },
      {
        "id": 215084,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Resistance common in obese individuals</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is incorrect with regards to Leptin in humans?</span></span></p>",
    "unique_key": "Q7301546",
    "question_audio": null,
    "question_video": null,
    "map_id": 25497,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Anti-inflammatory</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Leptin is a hormone produced by adipose tissue that plays a key role in regulating energy balance by decreasing appetite and increasing energy expenditure. However, it is not considered to be anti-inflammatory. In fact, some studies suggest that leptin may even have pro-inflammatory effects in certain contexts.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-101508.png\" style=\"height:542px; width:500px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Stimulates POMC neurons:</span></strong><span style=\"font-size:12.0pt\"> Leptin does stimulate proopiomelanocortin (POMC) neurons in the hypothalamus, which leads to decreased appetite (via &alpha; &amp; &beta; MSH). MSH can stimulate BDNF neurons, which can also result in appetite suppression. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Inhibits NPY/AGRP neurons:</span></strong><span style=\"font-size:12.0pt\"> Leptin also inhibits neuropeptide Y (NPY) and agouti-related peptide (AGRP) neurons, further contributing to appetite suppression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Resistance common in obese individuals:</span></strong><span style=\"font-size:12.0pt\"> Leptin resistance, where the body becomes less responsive to leptin&#39;s signals, is a common feature of obesity. This can lead to increased appetite and difficulty losing weight.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Leptin, which is elevated in obesity, stimulates POMC neurons and inhibits NPY/AGRP neurons but is not anti-inflammatory.</span></span></span></p>",
    "correct_choice_id": 215083,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53905,
    "choices": [
      {
        "id": 215089,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bardet-Biedl syndrome</span></span></span></p>"
      },
      {
        "id": 215090,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Albright&#39;s hereditary osteodystrophy</span></span></span></p>"
      },
      {
        "id": 215091,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alstr&ouml;m syndrome</span></span></span></p>"
      },
      {
        "id": 215092,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prader-Willi syndrome</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 22-year-old man presents to the clinic with his mother for evaluation of obesity. He has been obese since childhood and has an intellectual disability. He also has short stature and small hands and feet. Testosterone levels are low on laboratory testing. Which of the following is the most likely underlying syndrome?</span></span></p>",
    "unique_key": "Q3976715",
    "question_audio": null,
    "question_video": null,
    "map_id": 25499,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Prader-Willi syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient&#39;s presentation aligns well with the classic features of Prader-Willi syndrome (PWS). It is a genetic disorder characterized by:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Childhood-onset obesity:</span></strong><span style=\"font-size:12.0pt\"> Due to hyperphagia (excessive eating).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Intellectual disability </span></strong><span style=\"font-size:12.0pt\">(Mild to moderate) with almond shaped eyes.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Psychiatric:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Obsession, rage.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Short stature &amp; acromicra (Small hands and feet).</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Hypogonadotropic hypogonadism, micropenis &amp; cryptorchidism.</span></strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Bardet-Biedl syndrome:</span></strong><span style=\"font-size:12.0pt\"> Characterized by retinitis pigmentosa, polydactyly, and renal abnormalities, which are not mentioned in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Albright&#39;s hereditary osteodystrophy:</span></strong><span style=\"font-size:12.0pt\"> This syndrome is characterized by short stature &amp; characteristic skeletal abnormalities (brachydactyly). Seen with PHP (type 1) &amp; PPHP. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Alstr&ouml;m syndrome:</span></strong><span style=\"font-size:12.0pt\"> Characterized by retinal (cone-rod) dystrophy &amp; sensorineural hearing loss, which are not mentioned in this patient. Diagnosed by Marshall criteria. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prader-Willi syndrome is characterized by childhood-onset obesity, intellectual disability, short stature, and hypogonadism.</span></span></span></p>",
    "correct_choice_id": 215092,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53907,
    "choices": [
      {
        "id": 215097,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">MC4R </span></span></span></p>"
      },
      {
        "id": 215098,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">POMC </span></span></span></p>"
      },
      {
        "id": 215099,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">PCSK1 </span></span></span></p>"
      },
      {
        "id": 215100,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">LEPR</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most common gene contributing to obesity in the general population is:</span></span></p>",
    "unique_key": "Q4374687",
    "question_audio": null,
    "question_video": null,
    "map_id": 25501,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) MC4R</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mutations in the melanocortin 4 receptor (MC4R) gene are the most common monogenic cause of obesity in the general population. Pathogenic variants in MC4R are found in up to 5-6% of cases of severe childhood obesity and up to 0.3% of the general population. These mutations disrupt the melanocortin signaling pathway, which plays a crucial role in appetite regulation and energy homeostasis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. POMC:</span></strong><span style=\"font-size:12.0pt\"> Mutations in the proopiomelanocortin (POMC) gene are less common than MC4R mutations and are associated with severe early-onset obesity, adrenal insufficiency, and red hair pigmentation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. PCSK1:</span></strong><span style=\"font-size:12.0pt\"> Mutations in the prohormone convertase 1 (PCSK1) gene are also rare and lead to a complex syndrome with obesity, hypoglycemia, and various endocrine deficiencies.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. LEPR:</span></strong><span style=\"font-size:12.0pt\"> Mutations in the leptin receptor (LEPR) gene are rare and result in severe early-onset obesity, hyperphagia, and hypogonadotropic hypogonadism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MC4R gene mutations are the most common genetic cause of obesity in the general population.</span></span></span></p>",
    "correct_choice_id": 215097,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53908,
    "choices": [
      {
        "id": 215101,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Laparoscopic adjustable gastric banding </span></span></span></p>"
      },
      {
        "id": 215102,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Roux-en-Y gastric bypass </span></span></span></p>"
      },
      {
        "id": 215103,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sleeve gastrectomy </span></span></span></p>"
      },
      {
        "id": 215104,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intragastric balloon placement</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman with a BMI of 42 kg/m&sup2; and type 2 diabetes mellitus presents with uncontrolled glycemic levels despite optimal medical management. She has no contraindications to surgery. Which of the following procedures is MOST likely to result in long-term remission of her diabetes?</span></span></p>",
    "unique_key": "Q9078555",
    "question_audio": null,
    "question_video": null,
    "map_id": 25502,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Roux-en-Y gastric bypass</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Roux-en-Y gastric bypass (RYGB) has been shown to have the highest rates of long-term remission of type 2 diabetes compared to other bariatric procedures. This is likely due to a combination of factors including restriction, malabsorption, and changes in gut hormones that improve glucose metabolism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Laparoscopic adjustable gastric banding (LAGB):</span></strong><span style=\"font-size:12.0pt\"> LAGB is primarily a restrictive procedure and has a lower rate of diabetes remission compared to RYGB.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Sleeve gastrectomy:</span></strong><span style=\"font-size:12.0pt\"> While sleeve gastrectomy can also induce diabetes remission, the rates are not as high as RYGB, particularly in the long term.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Intragastric balloon placement:</span></strong><span style=\"font-size:12.0pt\"> This is a temporary, non-surgical option for weight loss and is not as effective as bariatric surgery in achieving long-term diabetes remission.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Roux-en-Y gastric bypass is the most effective bariatric procedure for long-term remission of type 2 diabetes.</span></span></span></p>",
    "correct_choice_id": 215102,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 53910,
    "choices": [
      {
        "id": 215109,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lorcaserin </span></span></span></p>"
      },
      {
        "id": 215110,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Setmelanotide </span></span></span></p>"
      },
      {
        "id": 215111,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Liraglutide </span></span></span></p>"
      },
      {
        "id": 215112,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bupropion</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following weight loss drugs has been withdrawn recently due to an increased risk of cancers?</span></span></p>",
    "unique_key": "Q2848731",
    "question_audio": null,
    "question_video": null,
    "map_id": 25504,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Lorcaserin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lorcaserin, sold under the brand name Belviq, was withdrawn from the market in 2020 due to an increased risk of cancer identified in a clinical trial. The U.S. Food and Drug Administration (FDA) requested the manufacturer to voluntarily withdraw the drug after the trial data showed a higher occurrence of various types of cancer in patients taking lorcaserin compared to those taking a placebo.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Setmelanotide:</span></strong><span style=\"font-size:12.0pt\"> This drug is approved for specific genetic causes of obesity and is not associated with an increased risk of cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Liraglutide:</span></strong><span style=\"font-size:12.0pt\"> This GLP-1 receptor agonist is used for weight management and diabetes treatment and has not been shown to increase cancer risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Bupropion:</span></strong><span style=\"font-size:12.0pt\"> This antidepressant is sometimes used off-label for weight loss and is not associated with an increased risk of cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lorcaserin was withdrawn from the market due to an increased risk of cancer.</span></span></span></p>",
    "correct_choice_id": 215109,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 20096,
    "choices": [
      {
        "id": 80345,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Repeat fasting blood sugar (FBS) for 3 days </span></span></span></p>"
      },
      {
        "id": 80346,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Do a 3 AM blood glucose check </span></span></span></p>"
      },
      {
        "id": 80347,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase evening/night time insulin dose </span></span></span></p>"
      },
      {
        "id": 80348,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduce carbohydrate intake in meals</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old man with type 1 diabetes on insulin therapy reports waking up with high blood glucose levels despite going to bed with normal readings. Which of the following would be most helpful in determining the cause of the morning hyperglycemia?</span></span></span></p>",
    "unique_key": "Q5290658",
    "question_audio": null,
    "question_video": null,
    "map_id": 20049,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Do a 3 AM blood glucose check</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s symptoms could be due to either the Somogyi effect or the dawn phenomenon:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Somogyi effect:</span></strong><span style=\"font-size:12.0pt\"> Nocturnal hypoglycemia triggers a counter-regulatory hormone release, leading to rebound hyperglycemia in the morning.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Dawn phenomenon:</span></strong><span style=\"font-size:12.0pt\"> Normal hormonal changes in the early morning hours lead to increased insulin resistance and elevated blood glucose.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 3 AM blood glucose check can help differentiate between these two conditions:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Hypoglycemia at 3 AM:</span></strong><span style=\"font-size:12.0pt\"> Suggests the Somogyi effect.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Normal or elevated glucose at 3 AM:</span></strong><span style=\"font-size:12.0pt\"> Suggests the dawn phenomenon.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Identifying the underlying cause is crucial for appropriate treatment adjustments.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Repeat FBS for 3 days:</span></strong><span style=\"font-size:12.0pt\"> While useful for assessing overall glycemic control, it won&#39;t pinpoint the cause of the morning hyperglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increase evening/night time insulin dose:</span></strong><span style=\"font-size:12.0pt\"> This might be appropriate if the dawn phenomenon is confirmed, but it could worsen hypoglycemia if the Somogyi effect is the cause.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Reduce carbohydrate intake in meals:</span></strong><span style=\"font-size:12.0pt\"> This could help manage overall blood sugar levels but may not address the specific issue of morning hyperglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 3 AM blood glucose check helps differentiate between the Somogyi effect (nocturnal hypoglycemia) and the dawn phenomenon (early morning insulin resistance).</span></span></span></p>",
    "correct_choice_id": 80346,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 53931,
    "choices": [
      {
        "id": 215193,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glycemic index </span></span></span></p>"
      },
      {
        "id": 215194,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glycemic load </span></span></span></p>"
      },
      {
        "id": 215195,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin to carbohydrate ratio </span></span></span></p>"
      },
      {
        "id": 215196,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Preprandial blood glucose values</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is essential for calculating insulin dose prior to a meal in type 1 diabetics?</span></span></p>",
    "unique_key": "Q6633971",
    "question_audio": null,
    "question_video": null,
    "map_id": 25525,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Insulin to carbohydrate ratio</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The insulin to carbohydrate ratio (I:C ratio) is the most essential factor for calculating the insulin dose for a meal in type 1 diabetes. It represents the number of grams of carbohydrates covered by one unit of insulin. By knowing the I:C ratio and the amount of carbohydrates in a meal, the patient can calculate the appropriate insulin dose.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Glycemic index:</span></strong><span style=\"font-size:12.0pt\"> While the glycemic index provides information about how quickly a food raises blood sugar, it is not directly used in calculating the insulin dose.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Glycemic load:</span></strong><span style=\"font-size:12.0pt\"> Glycemic load combines the glycemic index with the amount of carbohydrate in a food. It can be helpful in meal planning, but the I:C ratio is the primary tool for calculating the insulin dose.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Preprandial blood glucose values:</span></strong><span style=\"font-size:12.0pt\"> While important for determining the need for a correction dose of insulin, preprandial blood glucose values alone are not sufficient to calculate the mealtime insulin dose.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The insulin to carbohydrate ratio is essential for calculating the insulin dose for a meal in type 1 diabetes.</span></span></span></p>",
    "correct_choice_id": 215195,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 20081,
    "choices": [
      {
        "id": 80285,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Check ketones </span></span></span></p>"
      },
      {
        "id": 80286,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inject insulin and exercise </span></span></span></p>"
      },
      {
        "id": 80287,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Avoid carbohydrates for the day </span></span></span></p>"
      },
      {
        "id": 80288,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recheck CBG the next day</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 21-year-old professional gym trainer who is a known type 1 diabetic is about to start a training session. Just before the session, he notices his capillary blood glucose (CBG) to be 280 mg/dL. What should he do?</span></span></p>",
    "unique_key": "Q8787013",
    "question_audio": null,
    "question_video": null,
    "map_id": 20034,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Check ketones</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A CBG of 280 mg/dL indicates significant hyperglycemia, which can be dangerous for people with type 1 diabetes. Before exercising, it is essential to check for ketones. The presence of ketones indicates that the body is breaking down fat for energy due to insufficient insulin, and this can lead to diabetic ketoacidosis (DKA), a serious condition. If ketones are present, the individual should not exercise and seek medical attention immediately.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Glycemic management during exercise:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">CBG &lt; 90 mg/dL:</span></strong><span style=\"font-size:12.0pt\"> Ingest 15 to 30&thinsp;g of glucose before starting exercise. Delay exercise until blood glucose is&nbsp;90&thinsp;mg/dL and monitor closely for hypoglycaemia.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">CBG 90 to 125 mg/dL:</span></strong><span style=\"font-size:12.0pt\"> Ingest 10&thinsp;g of glucose before starting aerobic exercise. Anaerobic exercise and high intensity interval training sessions can be started.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">CBG 126 to 250 mg/dL:</span></strong><span style=\"font-size:12.0pt\"> Aerobic exercise can be started. </span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anaerobic exercise can be started, but glucose concentrations could rise.</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">CBG &gt; 250 mg/dL</span></strong><span style=\"font-size:12.0pt\">: Check ketones. </span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ketones &lt; 0&middot;6&thinsp;mmol/L: Mild-to-moderate aerobic exercise can be started</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ketones 0.6- 1&middot;4&thinsp;mmol/L: Exercise should be restricted to a light intensity for only a brief duration (&lt;30&thinsp;min) and a small corrective insulin dose might be needed. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ketones &ge;1.5&thinsp;mmol/L: Exercise is contraindicated and glucose management should be initiated rapidly as per the advice of the healthcare professional team.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Inject insulin and exercise:</span></strong><span style=\"font-size:12.0pt\"> Injecting insulin before exercise could lead to hypoglycemia during the workout, which can be dangerous.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Avoid carbohydrates for the day:</span></strong><span style=\"font-size:12.0pt\"> This could also lead to hypoglycemia as carbohydrates are the primary source of energy for the body.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Recheck CBG the next day:</span></strong><span style=\"font-size:12.0pt\"> Delaying action on elevated blood sugar levels is not recommended and could lead to complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Check for ketones before exercising if blood glucose levels are above 250 mg/dL to prevent the risk of diabetic ketoacidosis.</span></span></span></p>",
    "correct_choice_id": 80285,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20098,
    "choices": [
      {
        "id": 80353,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Empagliflozin </span></span></span></p>"
      },
      {
        "id": 80354,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dulaglutide </span></span></span></p>"
      },
      {
        "id": 80355,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pioglitazone </span></span></span></p>"
      },
      {
        "id": 80356,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sitagliptin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 54-year-old diabetic patient presents with breathlessness to the emergency department. On evaluation, the patient&#39;s ejection fraction (EF) is 35%. Which of the following medications should be avoided for the treatment of diabetes in this patient?</span></span></p>",
    "unique_key": "Q9605039",
    "question_audio": null,
    "question_video": null,
    "map_id": 20051,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Pioglitazone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pioglitazone, a thiazolidinedione (TZD), is contraindicated in patients with symptomatic heart failure due to its potential to worsen fluid retention and exacerbate heart failure. A reduced ejection fraction (EF) of 35% indicates systolic heart failure, making pioglitazone an inappropriate choice for this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Empagliflozin (SGLT2 inhibitor):</span></strong><span style=\"font-size:12.0pt\"> Empagliflozin has been shown to have cardioprotective effects and can be beneficial in patients with heart failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Dulaglutide (GLP-1 receptor agonist):</span></strong><span style=\"font-size:12.0pt\"> GLP-1 receptor agonists like dulaglutide have shown cardiovascular benefits and may be considered in patients with heart failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Sitagliptin (DPP-4 inhibitor):</span></strong><span style=\"font-size:12.0pt\"> DPP-4 inhibitors are generally safe in patients with heart failure and do not have significant negative effects on cardiac function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Avoid pioglitazone in patients with symptomatic heart failure due to the risk of fluid retention and exacerbation of heart failure.</span></span></span></p>",
    "correct_choice_id": 80355,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20089,
    "choices": [
      {
        "id": 80317,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metformin </span></span></span></p>"
      },
      {
        "id": 80318,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Canagliflozin </span></span></span></p>"
      },
      {
        "id": 80319,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Semaglutide </span></span></span></p>"
      },
      {
        "id": 80320,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pioglitazone</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman with type 2 diabetes on insulin was recently started on a new drug. After a week, she presents with nausea, vomiting, abdominal pain, near-normal blood glucose, elevated anion gap metabolic acidosis, and elevated plasma ketones. Which of the following medications is the most likely cause?</span></span></p>",
    "unique_key": "Q7706261",
    "question_audio": null,
    "question_video": null,
    "map_id": 20042,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Canagliflozin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation is consistent with euglycemic diabetic ketoacidosis (euDKA), a rare but serious complication of diabetes. While DKA is typically associated with high blood glucose levels, euDKA occurs with near-normal or even low blood glucose.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Canagliflozin, an SGLT2 inhibitor, is known to increase the risk of euDKA. It works by increasing urinary glucose excretion, which can lead to a relative deficit of glucose available for energy. This can trigger the body to break down fat for fuel, producing ketones and leading to acidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Metformin:</span></strong><span style=\"font-size:12.0pt\"> Metformin can rarely cause lactic acidosis but not associated with euDKA. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Semaglutide:</span></strong><span style=\"font-size:12.0pt\"> Semaglutide (a GLP-1 receptor agonist) is not associated with euDKA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pioglitazone:</span></strong><span style=\"font-size:12.0pt\"> Pioglitazone (a thiazolidinedione) is not known to cause euDKA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Canagliflozin, an SGLT2 inhibitor, can cause euglycemic diabetic ketoacidosis (euDKA).</span></span></span></p>",
    "correct_choice_id": 80318,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 20094,
    "choices": [
      {
        "id": 80337,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metformin </span></span></span></p>"
      },
      {
        "id": 80338,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Linagliptin </span></span></span></p>"
      },
      {
        "id": 80339,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Empagliflozin </span></span></span></p>"
      },
      {
        "id": 80340,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin Glargine</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 43-year-old lady presents with a 3-month history of 7 kg weight loss despite increased appetite and nocturia. Lab reports showed a fasting blood sugar (FBS) of 331 mg/dL and an HbA1c of 11.2%. Which of the following would be the most appropriate initial therapy?</span></span></p>",
    "unique_key": "Q8379737",
    "question_audio": null,
    "question_video": null,
    "map_id": 20047,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Insulin Glargine</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient presents with significant hyperglycemia (elevated FBS and HbA1c) along with classic symptoms of diabetes (weight loss, polyuria, polydipsia). This presentation, combined with the rapid weight loss, suggests a new-onset type 1 or ketosis-prone type 2 diabetes mellitus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Insulin&nbsp;</span></strong><span style=\"font-size:12.0pt\">is recommended as the first injectable in patients who are having severe hyperglycemia (FBS &gt; 300 or A1C &gt; 10%) and/or those who are symptomatic (like in this case).</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Metformin:</span></strong><span style=\"font-size:12.0pt\"> While metformin is a first-line agent for type 2 diabetes, it is not appropriate for initial therapy in patients with severe hyperglycemia or those suspected of having type 1 diabetes due to the risk of lactic acidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Linagliptin:</span></strong><span style=\"font-size:12.0pt\"> This is a DPP-4 inhibitor that increases incretin levels, promoting insulin release and decreasing glucagon secretion. It is not potent enough to manage the severe hyperglycemia in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Empagliflozin:</span></strong><span style=\"font-size:12.0pt\"> This is an SGLT2 inhibitor that increases urinary glucose excretion. While it can help lower blood sugar, it can also increase the risk of euglycemic DKA, especially in patients with significant hyperglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin is recommended for patients with severe hyperglycemia (FBS &gt; 300 or A1C &gt; 10%) and/or those who are symptomatic.</span></span></span></p>",
    "correct_choice_id": 80340,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20101,
    "choices": [
      {
        "id": 80365,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Proliferative retinopathy </span></span></span></p>"
      },
      {
        "id": 80366,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ESRD (End-Stage Renal Disease) </span></span></span></p>"
      },
      {
        "id": 80367,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neuropathy </span></span></span></p>"
      },
      {
        "id": 80368,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripheral arterial disease</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is a contraindication for vigorous exercise in individuals with diabetes?</span></span></p>",
    "unique_key": "Q7453131",
    "question_audio": null,
    "question_video": null,
    "map_id": 20054,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Proliferative retinopathy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Proliferative retinopathy is a severe form of diabetic eye disease characterized by the growth of new blood vessels in the retina. These vessels are fragile and prone to bleeding, which can lead to vision loss. Vigorous exercise can increase the risk of bleeding in the eye and potentially worsen retinopathy. Therefore, it is a contraindication for strenuous physical activity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. ESRD (End-Stage Renal Disease):</span></strong><span style=\"font-size:12.0pt\"> While exercise should be adjusted based on kidney function and individual tolerance, it is not an absolute contraindication.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Neuropathy:</span></strong><span style=\"font-size:12.0pt\"> Exercise is generally encouraged in patients with diabetic neuropathy, as it can help improve nerve function and reduce pain. However, certain types of exercise may need to be modified based on the severity of neuropathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Peripheral arterial disease (PAD):</span></strong><span style=\"font-size:12.0pt\"> Exercise can actually be beneficial for PAD as it improves circulation and reduces symptoms. However, the intensity and duration should be adjusted based on the severity of PAD and the individual&#39;s tolerance. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vigorous exercise is contraindicated in individuals with proliferative retinopathy due to the risk of retinal bleeding.</span></span></span></p>",
    "correct_choice_id": 80365,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 20091,
    "choices": [
      {
        "id": 80325,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Liraglutide </span></span></span></p>"
      },
      {
        "id": 80326,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Dulaglutide </span></span></span></p>"
      },
      {
        "id": 80327,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Semaglutide </span></span></span></p>"
      },
      {
        "id": 80328,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tirzepatide</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old woman with type 2 diabetes mellitus and obesity presents to the clinic. She is currently taking metformin 1000 mg twice daily, but her glycemic control remains suboptimal (HbA1c 8.5%). She is interested in a medication that can help with both weight loss and glucose control. Which of the following medications would be most appropriate for this patient?</span></span></p>",
    "unique_key": "Q1225117",
    "question_audio": null,
    "question_video": null,
    "map_id": 20044,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Tirzepatide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, making it a suitable option for patients with type 2 diabetes who need both improved glycemic control and weight loss. It has been shown to be more effective than other GLP-1 receptor agonists in achieving these goals.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Liraglutide, Option B. Dulaglutide&nbsp;</span></strong><span style=\"font-size:12.0pt\">and </span><strong><span style=\"font-size:12.0pt\">Option C. Semaglutide:</span></strong><span style=\"font-size:12.0pt\"> While these GLP-1 receptor agonists can promote weight loss and improve glycemic control, tirzepatide has shown superior efficacy in clinical trials compared to these options.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tirzepatide, a dual GIP and GLP-1 receptor agonist, is highly effective for both glycemic control and weight loss in type 2 diabetes.</span></span></span></p>",
    "correct_choice_id": 80328,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 53933,
    "choices": [
      {
        "id": 215201,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metformin </span></span></span></p>"
      },
      {
        "id": 215202,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pioglitazone </span></span></span></p>"
      },
      {
        "id": 215203,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tesamorelin </span></span></span></p>"
      },
      {
        "id": 215204,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metreleptin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is NOT used for the treatment of HIV-associated lipodystrophy?</span></span></span></p>",
    "unique_key": "Q4406246",
    "question_audio": null,
    "question_video": null,
    "map_id": 25527,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Metreleptin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metreleptin is a recombinant human leptin analog used to treat generalized lipodystrophy, not specifically HIV-associated lipodystrophy (HALS). HALS is a distinct form of lipodystrophy characterized by fat redistribution, often involving loss of subcutaneous fat in the face, limbs, and buttocks, and accumulation of visceral fat in the abdomen.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Metformin:</span></strong><span style=\"font-size:12.0pt\"> Can reduce abdominal fat in HALS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Pioglitazone:</span></strong><span style=\"font-size:12.0pt\"> Can be used to treat lipoatrophy and hepatic steatosis in HALS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Tesamorelin:</span></strong><span style=\"font-size:12.0pt\"> A growth hormone-releasing hormone analog that helps reduce excess abdominal fat in HALS (but IGF-1 should be monitored). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metreleptin is used to treat generalized lipodystrophy and is not specifically used for HIV-associated lipodystrophy.</span></span></span></p>",
    "correct_choice_id": 215204,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 20079,
    "choices": [
      {
        "id": 80277,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspart </span></span></span></p>"
      },
      {
        "id": 80278,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glargine </span></span></span></p>"
      },
      {
        "id": 80279,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NPH </span></span></span></p>"
      },
      {
        "id": 80280,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Regular</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following preparations of insulin has the longest time to onset and the longest duration of action?</span></span></p>",
    "unique_key": "Q8721513",
    "question_audio": null,
    "question_video": null,
    "map_id": 20032,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Glargine</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glargine is a long-acting insulin analog designed to provide a basal level of insulin over an extended period. It has a slow onset of action (1-2 hours) and a prolonged duration of action (20-24 hours), making it suitable for providing consistent background insulin levels throughout the day.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Aspart:</span></strong><span style=\"font-size:12.0pt\"> This is a rapid-acting insulin analog with a quick onset (15-30 minutes) and short duration (3-5 hours).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. NPH:</span></strong><span style=\"font-size:12.0pt\"> This is an intermediate-acting insulin with a slower onset (1-2 hours) and moderate duration (12-18 hours).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Regular:</span></strong><span style=\"font-size:12.0pt\"> This is a short-acting insulin with a relatively quick onset (30-60 minutes) and shorter duration (5-8 hours).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-123019.png\" style=\"height:265px; width:500px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-123213.png\" style=\"height:558px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glargine is a long-acting insulin analog with a slow onset (1-2 hours) and prolonged duration (20-24 hours).</span></span></span></p>",
    "correct_choice_id": 80278,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 20080,
    "choices": [
      {
        "id": 80281,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inject insulin at the same site every day. </span></span></span></p>"
      },
      {
        "id": 80282,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Evening NPH insulin is preferably injected in the abdomen. </span></span></span></p>"
      },
      {
        "id": 80283,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Regular insulin is preferably injected in the legs/arms. </span></span></span></p>"
      },
      {
        "id": 80284,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cleaning the injection site with an alcohol swab is not necessary.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following regarding insulin injection is true?</span></span></p>",
    "unique_key": "Q7751834",
    "question_audio": null,
    "question_video": null,
    "map_id": 20033,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Cleaning the injection site with an alcohol swab is not necessary.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While cleaning the injection site with an alcohol swab is a common practice, it is not necessary for routine insulin injections. If the skin is visibly clean and dry - disinfecting with alcohol does not reduce the risk of infection and may cause unnecessary discomfort. However, if the skin is dirty, it is recommended to clean it with soap and water before injection. Recommendations for insulin -</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin can be injected into the abdominal wall, leg, arm, or buttock.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Human insulins are absorbed fastest from the abdominal wall, slowest from the leg and buttock, and at an intermediate rate from the arm. These differences can be useful clinically:</span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pre-meal regular insulin should be rapidly absorbed, and injection into the abdominal wall may therefore be preferable.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pre-evening meal dosing of NPH should be slowly absorbed to ensure a duration of action that lasts through the night, and injection in the leg or buttock may be preferable.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The absorption of the long-acting basal insulin analogs, glargine and degludec, do not appear to be significantly influenced by injection site.</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Do not expose insulin to extremes of temperature.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Efficacy of some insulins (especially intermediate and long acting forms) may decrease &gt; 30 days. Refrigerate (DO NOT FREEZE) insulin vials between injections. </span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">If using pens &ndash; recommendations vary based on the manufacturer. Unopened pens can be stored in refrigerator and one opened pens can be kept at room temperature for 14-28 days. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Premix insulins lose potency more quickly than others. </span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Shallow injections result in pain whereas inadvertent deeper (IM) injections can result in erratic/rapid absorption. Most injections are given at 90<sup>0</sup> angle with skin pinched/lifted. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-123704.png\" style=\"height:303px; width:600px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Inject insulin at the same site every day:</span></strong><span style=\"font-size:12.0pt\"> This is incorrect. Rotating injection sites within a body area is important to prevent lipodystrophy, which can affect insulin absorption.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Evening NPH is preferably injected in the abdomen:</span></strong><span style=\"font-size:12.0pt\"> Pre-evening meal dosing of NPH should be slowly absorbed to ensure a duration of action that lasts through the night, and injection in the leg or buttock may be preferable. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Regular insulin is preferably injected in the legs/buttocks:</span></strong><span style=\"font-size:12.0pt\"> Pre-meal regular insulin should be rapidly absorbed, and injection into the abdominal wall may therefore be preferable.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Routine cleaning of the insulin injection site with an alcohol swab is not necessary if the skin is visibly clean and dry.</span></span></span></p>",
    "correct_choice_id": 80284,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "InstrumentsBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 20082,
    "choices": [
      {
        "id": 80289,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sitagliptin </span></span></span></p>"
      },
      {
        "id": 80290,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pioglitazone </span></span></span></p>"
      },
      {
        "id": 80291,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Canagliflozin </span></span></span></p>"
      },
      {
        "id": 80292,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Semaglutide</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A morbidly obese diabetic woman on metformin (MF) cannot achieve glycemic control. She has had a previous osteoporotic fracture and does not want injectable medications. Which of the following would be suitable to reduce her glucose levels?</span></span></p>",
    "unique_key": "Q4820355",
    "question_audio": null,
    "question_video": null,
    "map_id": 20035,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Semaglutide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While Semaglutide is primarily available as an injectable medication, it is now also available in oral form. It is a glucagon-like peptide-1 (GLP-1) receptor agonist that promotes weight loss and improves glycemic control. It is a suitable option for this patient as it addresses both her uncontrolled diabetes and obesity, and it&#39;s available in a non-injectable form.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Sitagliptin:</span></strong><span style=\"font-size:12.0pt\"> DPP-4 inhibitor, not associated with significant weight loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Pioglitazone:</span></strong><span style=\"font-size:12.0pt\"> Thiazolidinedione, associated with weight gain and increased fracture risk, contraindicated in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Canagliflozin:</span></strong><span style=\"font-size:12.0pt\"> SGLT2 inhibitor, while it promotes weight loss, it has been associated with increased fracture risk in some studies, making it less suitable for this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Semaglutide is available in oral form and is suitable for obese diabetic patients seeking non-injectable medications that promote weight loss and improve glycemic control.</span></span></span></p>",
    "correct_choice_id": 80292,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20083,
    "choices": [
      {
        "id": 80293,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pioglitazone </span></span></span></p>"
      },
      {
        "id": 80294,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Empagliflozin </span></span></span></p>"
      },
      {
        "id": 80295,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sitagliptin </span></span></span></p>"
      },
      {
        "id": 80296,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin glargine</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 68-year-old woman with type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) has an HbA1c of 8.2% despite metformin and glimepiride therapy. She has a history of recurrent hypoglycemia and is concerned about weight gain. Which of the following medications would be the most appropriate addition to her regimen?</span></span></p>",
    "unique_key": "Q7549897",
    "question_audio": null,
    "question_video": null,
    "map_id": 20036,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Empagliflozin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Empagliflozin is an SGLT2 inhibitor, a class of drugs that promotes urinary glucose excretion, leading to lower blood sugar levels. It has the following advantages in this patient&#39;s case:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Low risk of hypoglycemia:</span></strong><span style=\"font-size:12.0pt\"> SGLT2 inhibitors do not cause hypoglycemia, which is a significant concern for this patient.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Weight loss:</span></strong><span style=\"font-size:12.0pt\"> Empagliflozin can promote modest weight loss, addressing the patient&#39;s concern about weight gain.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Cardiovascular benefit:</span></strong><span style=\"font-size:12.0pt\"> SGLT2 inhibitors have been shown to reduce cardiovascular mortality and morbidity in patients with T2DM and established CVD.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pioglitazone:</span></strong><span style=\"font-size:12.0pt\"> This is a thiazolidinedione (TZD) associated with weight gain and fluid retention, which would be undesirable for this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Sitagliptin:</span></strong><span style=\"font-size:12.0pt\"> This is a DPP-4 inhibitor that may not provide sufficient glycemic control and does not have the cardiovascular benefits seen with SGLT2 inhibitors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Insulin glargine:</span></strong><span style=\"font-size:12.0pt\"> Insulin therapy is a potential option, but it carries a higher risk of hypoglycemia control and does not have the cardiovascular benefits seen with SGLT2 inhibitors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Empagliflozin is suitable for patients with T2DM and cardiovascular disease as it reduces CV mortality, causes weight loss, and has a low risk of hypoglycemia.</span></span></span></p>",
    "correct_choice_id": 80294,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20084,
    "choices": [
      {
        "id": 80297,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metformin </span></span></span></p>"
      },
      {
        "id": 80298,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pioglitazone </span></span></span></p>"
      },
      {
        "id": 80299,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Empagliflozin </span></span></span></p>"
      },
      {
        "id": 80300,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Liraglutide</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old woman with type 2 diabetes and a history of MEN2A is considering starting a new anti-diabetic medication. Which of the following should be avoided?</span></span></p>",
    "unique_key": "Q2638945",
    "question_audio": null,
    "question_video": null,
    "map_id": 20037,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Liraglutide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Liraglutide, a GLP-1 receptor agonist, has been associated with an increased risk of medullary thyroid carcinoma (MTC) and pancreatic cancer in preclinical and observational studies. While the clinical significance of these findings remains unclear, caution is warranted in patients with MEN2A, who already have an increased risk of MTC and other endocrine tumors. Therefore, it&#39;s generally recommended to avoid liraglutide and other GLP-1 receptor agonists in this population.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Metformin:</span></strong><span style=\"font-size:12.0pt\"> This is a first-line medication for type 2 diabetes and has not been associated with increased cancer risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Pioglitazone:</span></strong><span style=\"font-size:12.0pt\"> This is a thiazolidinedione that has been associated with a potential increased risk of bladder cancer and a possible increased risk of breast cancer in some studies. However, it is not specifically linked to the cancers associated with MEN2A.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Empagliflozin:</span></strong><span style=\"font-size:12.0pt\"> This is an SGLT2 inhibitor and has not been linked to increased cancer risk in MEN2A.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Avoid GLP-1 receptor agonists like liraglutide in patients with MEN2A due to the increased risk of medullary thyroid carcinoma.</span></span></span></p>",
    "correct_choice_id": 80300,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20085,
    "choices": [
      {
        "id": 80301,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Pioglitazone </span></span></span></p>"
      },
      {
        "id": 80302,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Dulaglutide </span></span></span></p>"
      },
      {
        "id": 80303,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Semaglutide </span></span></span></p>"
      },
      {
        "id": 80304,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exenatide</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 44-year-old man with a history of long-standing poorly controlled type 2 diabetes presents with blurred vision. On examination, there is severe non-proliferative diabetic retinopathy (NPDR) with macular edema. Which of the following drugs will be the best in this patient?</span></span></p>",
    "unique_key": "Q4556851",
    "question_audio": null,
    "question_video": null,
    "map_id": 20038,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Dulaglutide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dulaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA). GLP-1 RAs have been shown to improve glycemic control and reduce the risk of cardiovascular events in patients with type 2 diabetes. Additionally, they have been found to have a potential protective effect on diabetic retinopathy, including macular edema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pioglitazone:</span></strong><span style=\"font-size:12.0pt\"> Pioglitazone is a thiazolidinedione that can improve glycemic control but can worsen diabetic retinopathy and macular edema. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Semaglutide:</span></strong><span style=\"font-size:12.0pt\"> Another GLP-1 RA, that gives good glycemic control but studies indicate increased risk of worsening diabetic retinopathy. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Exenatide: </span></strong><span style=\"font-size:12.0pt\">Another GLP-1 RA, that gives good glycemic control but studies indicate increased risk of worsening diabetic retinopathy. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dulaglutide is the preferred GLP-1 receptor agonist for patients with severe NPDR and macular edema due to its potential protective effect on diabetic retinopathy.</span></span></span></p>",
    "correct_choice_id": 80302,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20086,
    "choices": [
      {
        "id": 80305,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pioglitazone </span></span></span></p>"
      },
      {
        "id": 80306,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Semaglutide </span></span></span></p>"
      },
      {
        "id": 80307,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Repaglinide </span></span></span></p>"
      },
      {
        "id": 80308,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Glibenclamide</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old man presents with long-standing type 2 diabetes and ESRD (end-stage renal disease). His eGFR is 8 mL/min/1.73 m&sup2;, and he is currently non-oliguric. Which of the following drugs should be avoided?</span></span></p>",
    "unique_key": "Q6257194",
    "question_audio": null,
    "question_video": null,
    "map_id": 20039,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Glibenclamide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glbenclamide (Glyburide) has a long half-life and is primarily excreted by the kidneys. It can accumulate in patients with ESRD, increasing the risk of prolonged and severe hypoglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pioglitazone (TZD):</span></strong><span style=\"font-size:12.0pt\"> Not excreted by kidneys, so can be safely used in CKD (at any stage). But cautious use is warranted in view of fluid retention and bone loss which can complicate volume overload state and renal osteodystrophy in ESRD patients. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Semaglutide:</span></strong><span style=\"font-size:12.0pt\"> This GLP-1 receptor agonist can be used safely in CKD (at any stage) without doe adjustment. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Repaglinide:</span></strong><span style=\"font-size:12.0pt\"> This meglitinide has a short half-life and is primarily metabolized by the liver, making it a safer option for patients with renal impairment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Drugs that can be used without dose adjustment in ESRD (eGFR &lt; 15) - Linagliptin, Liraglutide (but caution), dulaglutide, semaglutide, repaglinide, glipizide (start slowly and titrate) and Pioglitazone/Rosiglitazone. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-131422.png\" style=\"height:1004px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Avoid Glibenclamide in patients with ESRD due to the risk of prolonged and severe hypoglycemia.</span></span></span></p>",
    "correct_choice_id": 80308,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20087,
    "choices": [
      {
        "id": 80309,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fasting blood sugar </span></span></span></p>"
      },
      {
        "id": 80310,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Postprandial blood sugar </span></span></span></p>"
      },
      {
        "id": 80311,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Both a and c </span></span></span></p>"
      },
      {
        "id": 80312,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum albumin levels</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;A 40-year-old male with newly diagnosed diabetes has an HbA1c of 7%. What is the major contributor to his current HbA1c? </span></span></p>",
    "unique_key": "Q9927238",
    "question_audio": null,
    "question_video": null,
    "map_id": 20040,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Postprandial blood sugar</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbA1c reflects the average blood glucose levels over the past 2-3 months. While both fasting and postprandial blood sugar contribute to HbA1c, postprandial blood sugar (blood sugar levels after meals) typically has a greater impact on overall glycemic control and HbA1c levels in individuals with lower HbA1C (especially if HbA1C is &lt; 7.3%).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Fasting blood sugar:</span></strong><span style=\"font-size:12.0pt\"> Contribution to HbA1C becomes significant at higher HbA1C (especially if HbA1C is &gt; 9.2%)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Both A and C:&nbsp;</span></strong><span style=\"font-size:12.0pt\">At HbA1C of 7.3-9.2% the contribution by Fasting and Post prandial sugars are roughly equivalent. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Serum albumin levels:</span></strong><span style=\"font-size:12.0pt\"> Its levels do not influence HbA1c (rather it influences levels of fructosamine and glycated albumin). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In individuals with lower HbA1c levels (&lt;7.3%), postprandial blood sugar has a greater impact on overall glycemic control and HbA1c levels.</span></span></span></p>",
    "correct_choice_id": 80310,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 20088,
    "choices": [
      {
        "id": 80313,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glibenclamide </span></span></span></p>"
      },
      {
        "id": 80314,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dapagliflozin </span></span></span></p>"
      },
      {
        "id": 80315,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Liraglutide </span></span></span></p>"
      },
      {
        "id": 80316,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pramlintide</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 63-year-old man with type 2 diabetes presents with newly diagnosed bladder cancer. Which of the following drugs should be avoided?</span></span></p>",
    "unique_key": "Q1052253",
    "question_audio": null,
    "question_video": null,
    "map_id": 20041,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Dapagliflozin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recent studies have suggested a potential association between the use of SGLT2 inhibitors, such as dapagliflozin, and an increased risk of bladder cancer. While the evidence is not definitive, it is generally recommended to use caution or avoid these drugs in patients with a history of bladder cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Glibenclamide (a sulfonylurea):</span></strong><span style=\"font-size:12.0pt\"> There is no established link between sulfonylureas and bladder cancer risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Liraglutide (a GLP-1 receptor agonist):</span></strong><span style=\"font-size:12.0pt\"> GLP-1 receptor agonists have not been associated with an increased risk of bladder cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pramlintide (an amylin analog):</span></strong><span style=\"font-size:12.0pt\"> Pramlintide has not been linked to any increased cancer risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Avoid Dapagliflozin in patients with a history of bladder cancer due to the potential association with an increased risk of bladder cancer.</span></span></span></p>",
    "correct_choice_id": 80314,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20090,
    "choices": [
      {
        "id": 80321,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduction in CV mortality </span></span></span></p>"
      },
      {
        "id": 80322,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Can cause euglycemic ketoacidosis </span></span></span></p>"
      },
      {
        "id": 80323,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduces glucagon release </span></span></span></p>"
      },
      {
        "id": 80324,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Can cause hypotension</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following regarding the effects of SGLT2 inhibitors is incorrect?</span></span></p>",
    "unique_key": "Q9550542",
    "question_audio": null,
    "question_video": null,
    "map_id": 20043,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Reduces glucagon release</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SGLT2 inhibitors do not reduce glucagon release; in fact, they can <strong>increase</strong> glucagon levels (because of their glucose lowering effect). This increase in glucagon can contribute to euglycemic DKA, especially in conditions of stress or illness.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Reduction in CV mortality:</span></strong><span style=\"font-size:12.0pt\"> SGLT2 inhibitors have been shown to reduce cardiovascular mortality in patients with type 2 diabetes, especially those with established cardiovascular disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Can cause euglycemic ketoacidosis:</span></strong><span style=\"font-size:12.0pt\"> This is a known side effect of SGLT2 inhibitors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Can cause hypotension:</span></strong><span style=\"font-size:12.0pt\"> SGLT2 inhibitors can cause mild to moderate hypotension due to their diuretic effect. They can reduce SBP by </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 3-6 mm Hg on average. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SGLT2 inhibitors do not reduce glucagon release; they can actually increase glucagon levels.</span></span></span></p>",
    "correct_choice_id": 80323,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 20092,
    "choices": [
      {
        "id": 80329,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glargine </span></span></span></p>"
      },
      {
        "id": 80330,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Icodec </span></span></span></p>"
      },
      {
        "id": 80331,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Degludec </span></span></span></p>"
      },
      {
        "id": 80332,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Detemir</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is the longest-acting basal insulin analog?</span></span></span></p>",
    "unique_key": "Q2009779",
    "question_audio": null,
    "question_video": null,
    "map_id": 20045,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Icodec</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin icodec is an ultra-long-acting basal insulin analog with a duration of action exceeding 42 hours, allowing for flexible dosing regimens (once weekly or every other week).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Glargine:</span></strong><span style=\"font-size:12.0pt\"> While glargine is a long-acting insulin, its duration of action is around 24 hours.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Degludec:</span></strong><span style=\"font-size:12.0pt\"> This is another long-acting insulin with a duration of action exceeding 42 hours, but not as long as icodec.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Detemir:</span></strong><span style=\"font-size:12.0pt\"> Detemir is a long-acting insulin with a duration of action of around 20-24 hours.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin icodec is an ultra-long-acting basal insulin analog with a duration of action exceeding 42 hours.</span></span></span></p>",
    "correct_choice_id": 80330,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 20093,
    "choices": [
      {
        "id": 80333,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Liraglutide </span></span></span></p>"
      },
      {
        "id": 80334,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Empagliflozin </span></span></span></p>"
      },
      {
        "id": 80335,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pioglitazone </span></span></span></p>"
      },
      {
        "id": 80336,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metformin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 54-year-old obese female with type 2 diabetes for 10 years came for a master health check-up. Routine USG revealed gallstones, and her triglyceride levels are 1620 mg/dL. Which of the following drugs should be avoided?</span></span></span></p>",
    "unique_key": "Q7421770",
    "question_audio": null,
    "question_video": null,
    "map_id": 20046,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Liraglutide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Liraglutide, a GLP-1 receptor agonist, has been associated with an increased risk of gallstones and pancreatitis, especially in patients with pre-existing gallbladder disease or high triglyceride (TG) levels. Given the patient&#39;s gallstones and significantly elevated triglycerides (1620 mg/dL), liraglutide should be avoided.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Empagliflozin (SGLT2 inhibitor):</span></strong><span style=\"font-size:12.0pt\"> Not associated with an increased risk of gallstones or pancreatitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Pioglitazone (thiazolidinedione):</span></strong><span style=\"font-size:12.0pt\"> Not known to directly increase gallstone or pancreatitis risk. Pioglitazone can reduce TG and increase HDL (but it can slightly increase LDL as well). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Metformin (biguanide):</span></strong><span style=\"font-size:12.0pt\"> Not associated with an increased risk of gallstones or pancreatitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Avoid liraglutide in patients with gallstones and significantly elevated triglycerides due to the risk of gallstones and pancreatitis.</span></span></span></p>",
    "correct_choice_id": 80333,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20095,
    "choices": [
      {
        "id": 80341,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Semaglutide </span></span></span></p>"
      },
      {
        "id": 80342,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Glimepiride </span></span></span></p>"
      },
      {
        "id": 80343,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Pioglitazone </span></span></span></p>"
      },
      {
        "id": 80344,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin glargine</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old man with poorly controlled type 2 diabetes (HbA1c 9.1%) is already on metformin, empagliflozin (SGLT2 inhibitor), and sitagliptin (DPP-4 inhibitor). He has well-controlled dyslipidemia and hypertension with telmisartan and rosuvastatin. Which medication would be the most appropriate next step to improve glycemic control?</span></span></p>",
    "unique_key": "Q2342468",
    "question_audio": null,
    "question_video": null,
    "map_id": 20048,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Semaglutide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Given the patient&#39;s history of poorly controlled diabetes despite multiple oral agents and the presence of multiple cardiovascular risk factors, a GLP-1 receptor agonist like semaglutide is the most appropriate next step. GLP-1 RAs have been shown to improve glycemic control, promote weight loss, and, importantly, reduce cardiovascular risk in patients with type 2 diabetes and established cardiovascular disease. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In most patients, the first line injectable in current practice is GLP1RA (except for those who are having severe/symptomatic hyperglycemia where insulin can be preferred ahead of GLP1RA). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Glimepiride:</span></strong><span style=\"font-size:12.0pt\"> This is a sulfonylurea, which carries a risk of hypoglycemia and weight gain. It does not offer the same cardiovascular benefits as semaglutide.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Pioglitazone:</span></strong><span style=\"font-size:12.0pt\"> This is a thiazolidinedione associated with weight gain and fluid retention, which could be problematic for this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Insulin glargine:</span></strong><span style=\"font-size:12.0pt\"> While insulin can improve glycemic control, it does not address the cardiovascular risk factors and carries a risk of hypoglycemia. Additionally, the patient may prefer a non-injectable option.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Semaglutide is a GLP-1 receptor agonist that improves glycemic control, promotes weight loss, and reduces cardiovascular risk in patients with type 2 diabetes and established cardiovascular disease.</span></span></span></p>",
    "correct_choice_id": 80341,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 20097,
    "choices": [
      {
        "id": 80349,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Retinopathy </span></span></span></p>"
      },
      {
        "id": 80350,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripheral Artery Disease (PAD) </span></span></span></p>"
      },
      {
        "id": 80351,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neuropathy </span></span></span></p>"
      },
      {
        "id": 80352,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nephropathy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Strict glycemic control in Type 2 Diabetes can reduce all the complications except:</span></span></p>",
    "unique_key": "Q6616553",
    "question_audio": null,
    "question_video": null,
    "map_id": 20050,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Peripheral Artery Disease (PAD)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While strict glycemic control is crucial in managing type 2 diabetes and reducing the risk of microvascular complications like retinopathy, neuropathy, and nephropathy, its impact on macrovascular complications like peripheral artery disease (PAD) is less clear. PAD is primarily driven by atherosclerosis, which is influenced by multiple factors including hyperglycemia, dyslipidemia, hypertension, and smoking. While good glycemic control can help reduce the risk of PAD, it is not the sole determinant.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Retinopathy:</span></strong><span style=\"font-size:12.0pt\"> Strict glycemic control has been proven to significantly reduce the risk and progression of diabetic retinopathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Neuropathy:</span></strong><span style=\"font-size:12.0pt\"> Tight glucose control can slow the onset and progression of diabetic neuropathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Nephropathy:</span></strong><span style=\"font-size:12.0pt\"> Maintaining optimal blood glucose levels is crucial in preventing and delaying the progression of diabetic nephropathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Strict glycemic control reduces microvascular complications (retinopathy, neuropathy, nephropathy) but has less clear impact on macrovascular complications like PAD.</span></span></span></p>",
    "correct_choice_id": 80350,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 20099,
    "choices": [
      {
        "id": 80357,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metformin </span></span></span></p>"
      },
      {
        "id": 80358,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Linagliptin </span></span></span></p>"
      },
      {
        "id": 80359,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pioglitazone </span></span></span></p>"
      },
      {
        "id": 80360,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chlorthalidone</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 54-year-old woman who was a known diabetic and hypertensive presented with angioedema. Which of the following drugs could be responsible?</span></span></p>",
    "unique_key": "Q1444444",
    "question_audio": null,
    "question_video": null,
    "map_id": 20052,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Linagliptin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, a class of drugs used to treat type 2 diabetes. DPP-4 inhibitors have been associated with an increased risk of angioedema, particularly in patients also taking ACE inhibitors (a common class of blood pressure medication).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Metformin:</span></strong><span style=\"font-size:12.0pt\"> This is a biguanide used to treat type 2 diabetes and is not associated with angioedema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Pioglitazone:</span></strong><span style=\"font-size:12.0pt\"> This is a thiazolidinedione used to treat type 2 diabetes and is not associated with angioedema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Chlorthalidone:</span></strong><span style=\"font-size:12.0pt\"> This is a thiazide diuretic used to treat hypertension and is not known to cause angioedema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Linagliptin, a DPP-4 inhibitor, can cause angioedema, particularly in patients also taking ACE inhibitors.</span></span></span></p>",
    "correct_choice_id": 80358,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 20100,
    "choices": [
      {
        "id": 80361,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glimepiride </span></span></span></p>"
      },
      {
        "id": 80362,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Linagliptin </span></span></span></p>"
      },
      {
        "id": 80363,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Liraglutide </span></span></span></p>"
      },
      {
        "id": 80364,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acarbose</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old man presents with newly diagnosed diabetes and an HbA1c of 8%. He has a history of sulfa allergy since childhood. Which of the following drugs should be avoided?</span></span></span></p>",
    "unique_key": "Q9080023",
    "question_audio": null,
    "question_video": null,
    "map_id": 20053,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Glimepiride</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glimepiride is a sulfonylurea, a class of drugs that are chemically similar to sulfonamides (sulfa drugs). Patients with a known sulfa allergy may also be allergic to sulfonylureas and could experience a cross-reaction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Linagliptin:</span></strong><span style=\"font-size:12.0pt\"> This is a DPP-4 inhibitor and is not structurally related to sulfa drugs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Liraglutide:</span></strong><span style=\"font-size:12.0pt\"> This is a GLP-1 receptor agonist and is not structurally related to sulfa drugs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Acarbose:</span></strong><span style=\"font-size:12.0pt\"> This is an alpha-glucosidase inhibitor and is not structurally related to sulfa drugs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Avoid sulfonylureas like glimepiride in patients with a known sulfa allergy due to the risk of cross-reaction.</span></span></span></p>",
    "correct_choice_id": 80361,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 53932,
    "choices": [
      {
        "id": 215197,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">140-180 mg/dL </span></span></span></p>"
      },
      {
        "id": 215198,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">80-180 mg/dL </span></span></span></p>"
      },
      {
        "id": 215199,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">81-108 mg/dL </span></span></span></p>"
      },
      {
        "id": 215200,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">150-200 mg/dL</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is a recommended glycemic target in critically ill patients?</span></span></p>",
    "unique_key": "Q3348312",
    "question_audio": null,
    "question_video": null,
    "map_id": 25526,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) 140-180 mg/dL</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The American Diabetes Association (ADA) recommends a target blood glucose range of 140-180 mg/dL for most critically ill patients. This range is a balance between avoiding hypoglycemia (which can be dangerous in critically ill patients) and preventing the complications of hyperglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 80-180 mg/dL:</span></strong><span style=\"font-size:12.0pt\"> This range is too narrow and may be difficult to achieve without increasing the risk of hypoglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. 81-108 mg/dL:</span></strong><span style=\"font-size:12.0pt\"> NICE-SUGAR study found increased mortality in critically ill patients when this target is followed. Hence, it is not recommended.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 150-200 mg/dL:</span></strong><span style=\"font-size:12.0pt\"> This is not a recommended target in hospitalized patients. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The recommended glycemic target in critically ill patients is 140-180 mg/dL to balance the risk of hypoglycemia and hyperglycemia complications.</span></span></span></p>",
    "correct_choice_id": 215197,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased"
    ]
  },
  {
    "id": 53934,
    "choices": [
      {
        "id": 215205,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fetal hyperinsulinemia </span></span></span></p>"
      },
      {
        "id": 215206,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metformin is not FDA approved for GDM </span></span></span></p>"
      },
      {
        "id": 215207,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Strict control of glucose is required </span></span></span></p>"
      },
      {
        "id": 215208,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High risk of neonatal hyperglycemia</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT true regarding diabetes in gestational diabetes mellitus (GDM)?</span></span></p>",
    "unique_key": "Q3443598",
    "question_audio": null,
    "question_video": null,
    "map_id": 25528,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) High risk of neonatal hyperglycemia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gestational diabetes mellitus (GDM) is characterized by high blood glucose levels during pregnancy. It can lead to fetal hyperinsulinemia as the fetus is exposed to high maternal glucose levels, stimulating insulin production. This can result in neonatal hypoglycemia (low blood sugar) after birth, not hyperglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Fetal hyperinsulinemia:</span></strong><span style=\"font-size:12.0pt\"> This is true. High maternal glucose levels can lead to increased insulin production in the fetus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Metformin is not FDA approved for GDM:</span></strong><span style=\"font-size:12.0pt\"> This is true. While metformin is increasingly used off-label for GDM, it is not currently FDA-approved for this indication.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Strict control of glucose is required:</span></strong><span style=\"font-size:12.0pt\"> This is true. Maintaining tight glycemic control during pregnancy is crucial for preventing complications in both the mother and the fetus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GDM can lead to fetal hyperinsulinemia and neonatal hypoglycemia, not hyperglycemia.</span></span></span></p>",
    "correct_choice_id": 215208,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19945,
    "choices": [
      {
        "id": 79741,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In 3 months </span></span></span></p>"
      },
      {
        "id": 79742,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In 6 months </span></span></span></p>"
      },
      {
        "id": 79743,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In 1 year </span></span></span></p>"
      },
      {
        "id": 79744,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In 5 years</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old patient with newly diagnosed type 2 diabetes mellitus (T2DM) has a negative urine microalbumin test. When should the next urine microalbumin test be repeated?</span></span></p>",
    "unique_key": "Q6840122",
    "question_audio": null,
    "question_video": null,
    "map_id": 19919,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) In 1 year</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Annual screening for microalbuminuria is recommended for patients with type 2 diabetes to detect early signs of diabetic nephropathy (kidney disease). A negative test result indicates no current evidence of kidney damage, therefore, the next screening should be done in a year.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-094813.png\" style=\"height:477px; width:1000px\" /></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. In 3 months:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Too frequent for routine screening and not necessary with a negative initial test.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. In 6 months:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While more frequent screening may be indicated in some cases,&nbsp;annual testing is generally sufficient for initial monitoring.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. In 5 years:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Too infrequent for monitoring diabetic nephropathy,&nbsp;as significant damage could occur undetected in this time frame.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Annual screening for microalbuminuria is recommended in type 2 diabetes to detect early signs of diabetic nephropathy.</span></span></span></p>",
    "correct_choice_id": 79743,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "InvestigationBased"
    ]
  },
  {
    "id": 19937,
    "choices": [
      {
        "id": 79709,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Diabetic dermopathy </span></span></span></p>"
      },
      {
        "id": 79710,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Necrobiosis lipoidica diabeticorum </span></span></span></p>"
      },
      {
        "id": 79711,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lichen planus </span></span></span></p>"
      },
      {
        "id": 79712,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Scleredema</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 54-year-old man with long-standing diabetes presents with the lesion shown in the image. Identify the condition:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-093055.png\" style=\"height:217px; width:300px\" /></span></span></p>",
    "unique_key": "Q9121333",
    "question_audio": null,
    "question_video": null,
    "map_id": 19911,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Diabetic dermopathy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image shows multiple, well-defined, hyperpigmented atrophic macules over both shins, which is characteristic of diabetic dermopathy. Diabetic dermopathy, also known as shin spots, is the most common cutaneous manifestation of diabetes mellitus. It is caused by changes in the small blood vessels of the skin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Necrobiosis lipoidica diabeticorum:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This condition presents as larger,&nbsp;yellowish-brown patches with a raised,&nbsp;reddish border,&nbsp;often located on the shins.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Lichen planus:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This inflammatory skin condition presents as purple,&nbsp;itchy,&nbsp;flat-topped bumps.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Scleredema:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This condition is characterized by thickening and hardening of the skin,&nbsp;usually on the back or neck.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetic dermopathy, characterized by hyperpigmented atrophic macules over the shins, is the most common cutaneous manifestation of diabetes.</span></span></span></p>",
    "correct_choice_id": 79709,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 54043,
    "choices": [
      {
        "id": 215641,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulinoma </span></span></span></p>"
      },
      {
        "id": 215642,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Factitious hypoglycemia due to sulfonylurea</span></span></span></p>"
      },
      {
        "id": 215643,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-insulin-mediated hypoglycemia </span></span></span></p>"
      },
      {
        "id": 215644,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGF-2 related hypoglycemia</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old man presents with recurrent hypoglycemia, confirmed by Whipple&#39;s triad. Laboratory investigations reveal a beta-hydroxybutyrate (&beta;-OHB) level of 5 mmol/L and a poor blood glucose response to glucagon. The most likely diagnosis is:</span></span></p>",
    "unique_key": "Q3868642",
    "question_audio": null,
    "question_video": null,
    "map_id": 25636,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Non-insulin-mediated hypoglycemia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Elevated &beta;-OHB levels&nbsp;</span></strong><span style=\"font-size:12.0pt\">and&nbsp;<strong>Poor response to glucagon </strong>indicated that the hypoglycemia is not mediated by insulin or insulin like factors (IGF-2). Examples include critical illness, organ failure (liver, kidney), sepsis, counter-regulatory hormone deficiencies (GH/cortisol) etc. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Insulinoma:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This would typically present with suppressed ketone levels due to the inhibitory effect of excess insulin on lipolysis and ketogenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Factitious hypoglycemia due to sulfonylurea:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Sulfonylureas increase insulin secretion,&nbsp;and hypoglycemia due to these medications would and tend to have suppressed &beta;-OHB (&lt; 2.7 mmol/L) in view of hyperinsulinemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. IGF-2 related hypoglycemia:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is a rare cause of hypoglycemia and tend to have suppressed &beta;-OHB (&lt; 2.7 mmol/L) in view of insulin like action. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated &beta;-OHB levels and poor response to glucagon indicate non-insulin-mediated hypoglycemia, such as critical illness or organ failure.</span></span></span></p>",
    "correct_choice_id": 215643,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 19947,
    "choices": [
      {
        "id": 79749,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue the insulin infusion </span></span></span></p>"
      },
      {
        "id": 79750,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Switch to subcutaneous insulin </span></span></span></p>"
      },
      {
        "id": 79751,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add dextrose to the intravenous fluids </span></span></span></p>"
      },
      {
        "id": 79752,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase the rate of the insulin infusion</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old man with type 2 diabetes presents to the emergency department with DKA. His initial blood glucose level is 650 mg/dL. After 6 hours of treatment with intravenous fluids and insulin, his blood glucose drops to 200 mg/dL. Which of the following is the most appropriate next step in management?</span></span></p>",
    "unique_key": "Q8201858",
    "question_audio": null,
    "question_video": null,
    "map_id": 19921,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Add dextrose to the intravenous fluids</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When the blood glucose level drops to 200-250 mg/dL during DKA treatment, it is crucial to add dextrose to the intravenous fluids to prevent hypoglycemia and to maintain a target plasma glucose is 150-200 mg/dL. Insulin infusion can thus, be continued at a lower rate to ensure correction of ketoacidosis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Discontinue the insulin infusion:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Insulin should not be discontinued until the ketoacidosis is resolved,&nbsp;as indicated by a normal anion gap and beta-hydroxybutyrate level.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Switch to subcutaneous insulin:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Subcutaneous insulin is not appropriate in the acute management of DKA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Increase the rate of the insulin infusion:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Increasing the insulin infusion rate could lead to hypoglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When blood glucose drops to 200-250 mg/dL during DKA treatment, add dextrose to IV fluids to prevent hypoglycemia and continue insulin infusion.</span></span></span></p>",
    "correct_choice_id": 79751,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19932,
    "choices": [
      {
        "id": 79689,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">3% NaCl </span></span></span></p>"
      },
      {
        "id": 79690,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV fluids </span></span></span></p>"
      },
      {
        "id": 79691,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin infusion </span></span></span></p>"
      },
      {
        "id": 79692,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Potassium supplementation</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A young woman with type 1 diabetes presents to the emergency department with diabetic ketoacidosis (DKA) after stopping insulin. On examination, she is delirious and initial laboratory reports show:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">S. Na 128 mEq/L, S. K+ 4.3 mEq/L, BUN 76 mg/dL, S. Cr 2.2 mg/dL, S. HCO3- 10 mEq/L, Blood glucose 520 mg/dL. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is NOT an appropriate treatment?</span></span></span></p>",
    "unique_key": "Q4323650",
    "question_audio": null,
    "question_video": null,
    "map_id": 19906,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) 3% NaCl</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient presents with pseudohyponatremia, which is a falsely low sodium level due to the presence of hyperglycemia. The corrected sodium level can be calculated using the following formula:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Corrected Sodium = Measured Sodium + 1.6 mEq/L * (Serum Glucose [mg/dL] - 100 mg/dL) / 100</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In this case, the corrected sodium is:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Corrected Sodium = 128 mEq/L + 1.6 mEq/L * (520 mg/dL - 100 mg/dL) / 100 = 135 mEq/L</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Since the corrected sodium is within the normal range (135-145 mEq/L), administering hypertonic saline (3% NaCl) is not indicated. In fact, it could be harmful by worsening hyperosmolar state. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 0.9% sodium chloride (NaCl):</span></strong><span style=\"font-size:12.0pt\"> This isotonic fluid is appropriate for rehydration in DKA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Insulin infusion:</span></strong><span style=\"font-size:12.0pt\"> This is essential to lower blood glucose levels and correct ketoacidosis in DKA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Potassium supplementation:</span></strong><span style=\"font-size:12.0pt\"> While initial potassium levels are normal, they can drop rapidly with insulin therapy. Therefore, potassium supplementation is often necessary during DKA treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypertonic saline (3% NaCl) is not indicated in DKA with pseudohyponatremia; it could worsen the hyperosmolar state.</span></span></span></p>",
    "correct_choice_id": 79689,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19949,
    "choices": [
      {
        "id": 79757,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV Aspart </span></span></span></p>"
      },
      {
        "id": 79758,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV KCl </span></span></span></p>"
      },
      {
        "id": 79759,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV NaHCO3 </span></span></span></p>"
      },
      {
        "id": 79760,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CT head</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 17-year-old boy with type 1 diabetes presents with vomiting, abdominal pain, lethargy, and drowsiness. His blood glucose is 350 mg/dL, and ABG shows the following &ndash; pH 7.24, S. Na 130 mEq/L, S. K 3.0 mEq/L, S. HCO3- 14 mEq/L, and S. Cl 88 mEq/L. His BP is 90/60 mm Hg, and IV fluids were rushed. Which of the following is the most appropriate next step in management?</span></span></p>",
    "unique_key": "Q6280882",
    "question_audio": null,
    "question_video": null,
    "map_id": 19923,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) IV KCl</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient is presenting with diabetic ketoacidosis (DKA) based on the clinical presentation (vomiting, abdominal pain, lethargy, drowsiness), elevated blood glucose (350 mg/dL), and metabolic acidosis on ABG (pH 7.24, bicarbonate 14 mEq/L). The patient also has significant hypokalemia (K+ 3.0 mEq/L) which is a common electrolyte disturbance in DKA due to increased urinary potassium loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Hypokalemia and Insulin:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Insulin administration can further exacerbate hypokalemia by shifting potassium from the extracellular to the intracellular space.&nbsp;Therefore,&nbsp;potassium replacement should be initiated before starting insulin therapy in DKA.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. IV Aspart:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Insulin therapy is essential in DKA but should be started after correcting hypokalemia. Regular insulin is preferred for IV use in view of lesser cost but rapid acting analogs can also be used for IV use and are not contraindicated. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. IV NaHCO3:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Sodium bicarbonate is generally not recommended in DKA unless the pH is less than 6.9 or there are significant cardiac complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CT head:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Cerebral edema is a rare complication of DKA and usually occurs in children during treatment. It is not the immediate priority in this scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Administer IV potassium chloride to correct hypokalemia before initiating insulin therapy in DKA to prevent severe hypokalemia.</span></span></span></p>",
    "correct_choice_id": 79758,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19931,
    "choices": [
      {
        "id": 79685,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Arterial pH &gt;7.3 </span></span></span></p>"
      },
      {
        "id": 79686,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated plasma ketones </span></span></span></p>"
      },
      {
        "id": 79687,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Osmolality &lt;320 mOsm/mL </span></span></span></p>"
      },
      {
        "id": 79688,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sodium &lt;135 mEq/L</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following laboratory values is typically seen in hyperglycemic hyperosmolar state (HHS) and not in diabetic ketoacidosis (DKA)?</span></span></p>",
    "unique_key": "Q9495273",
    "question_audio": null,
    "question_video": null,
    "map_id": 19905,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Arterial pH &gt;7.3</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In hyperglycemic hyperosmolar state (HHS), the arterial pH is typically normal or near normal (&gt;7.3) due to the absence of significant ketoacidosis. This is in contrast to diabetic ketoacidosis (DKA), where the accumulation of ketone bodies leads to metabolic acidosis and a lower arterial pH (&lt;7.3).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Elevated plasma ketones:</span></strong><span style=\"font-size:12.0pt\"> This is a hallmark of DKA, not HHS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Osmolality &lt;320 mOsm/mL:</span></strong><span style=\"font-size:12.0pt\"> Hyperosmolarity can occur in both DKA and HHS but DKA patients tend to have a serum osmolality of &lt; 320 mOsm/L. HHS patients typically have a serum osmolality of &gt; 320 mOsm/L (due to extreme hyperglycemia). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Sodium &lt;135 mEq/L:</span></strong><span style=\"font-size:12.0pt\"> Hyponatremia (low sodium) can occur in both DKA and HHS but it is less pronounced and it is often normal in HHS (in view of severe dehydration and water loss). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In HHS, the arterial pH is typically normal or near normal (&gt;7.3) due to the absence of significant ketoacidosis.</span></span></span></p>",
    "correct_choice_id": 79685,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased"
    ]
  },
  {
    "id": 19933,
    "choices": [
      {
        "id": 79693,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cheiroarthropathy </span></span></span></p>"
      },
      {
        "id": 79694,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Macular edema </span></span></span></p>"
      },
      {
        "id": 79695,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Infections </span></span></span></p>"
      },
      {
        "id": 79696,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Feet Claudication</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following complications of diabetes mellitus is due to microvascular disease?</span></span></p>",
    "unique_key": "Q4327298",
    "question_audio": null,
    "question_video": null,
    "map_id": 19907,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Macular edema</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetic Macular edema is microvascular complication of diabetes mellitus. Macular edema is a complication of diabetic retinopathy, which is a microvascular disease affecting the small blood vessels in the retina. It occurs due to increased vascular permeability and leakage of fluid into the macula, leading to blurred vision. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cheiroarthropathy:</span></strong><span style=\"font-size:12.0pt\"> This refers to hand stiffness and joint changes, which are not primarily caused by microvascular disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Infections:</span></strong><span style=\"font-size:12.0pt\"> While diabetes can increase susceptibility to infections, it is not a direct consequence of microvascular disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Feet Claudication:</span></strong><span style=\"font-size:12.0pt\"> Claudication (pain with exertion) is a symptom of peripheral artery disease, which is a macrovascular complication of diabetes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Summary:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Microvascular complications (diabetes specific):</span></strong><span style=\"font-size:12.0pt\"> Retinopathy, macular edema, neuropathy, nephropathy (diabetic kidney disease). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Macrovascular complications:</span></strong><span style=\"font-size:12.0pt\"> CAD, PAD and cerebrovascular disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Nonvascular/multifactorial complications:</span></strong><span style=\"font-size:12.0pt\"> Infections, skin changes, cheiroarthropathy, cataract, glaucoma, periodontal disease, GI/GU complications and hearing loss. Some studies suggest that type 2 DM increases the risk of dementia and impaired cognitive function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetic macular edema is a microvascular complication of diabetes, caused by increased vascular permeability and fluid leakage into the macula</span></span></span></p>",
    "correct_choice_id": 79694,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19934,
    "choices": [
      {
        "id": 79697,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetic amyotrophy </span></span></span></p>"
      },
      {
        "id": 79698,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Distal symmetric polyneuropathy </span></span></span></p>"
      },
      {
        "id": 79699,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Herniation of a lumbar disk </span></span></span></p>"
      },
      {
        "id": 79700,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Meralgia paresthetica</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 74-year-old man with poorly controlled type 2 diabetes presents with sudden-onset, severe right thigh pain and weakness. His sensory examination is normal. MRI of the lower spine is unremarkable. What is the most likely cause of his symptoms?</span></span></p>",
    "unique_key": "Q2228263",
    "question_audio": null,
    "question_video": null,
    "map_id": 19908,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Diabetic amyotrophy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetic amyotrophy (also known as diabetic lumbosacral radiculoplexus neuropathy) is a microvascular complication of diabetes that affects the nerves supplying the proximal leg muscles, causing pain, weakness, and muscle wasting. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Distal symmetric polyneuropathy:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This typically affects the feet and hands first,&nbsp;causing sensory symptoms before motor weakness.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Herniation of a lumbar disk:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This would usually present with radicular pain and sensory changes,&nbsp;which are absent in this case. Also, MRI would have revealed the herniation. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Meralgia paresthetica:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This causes numbness and tingling in the outer thigh due to compression of the lateral femoral cutaneous nerve,&nbsp;but not severe pain or weakness.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetic amyotrophy is a microvascular complication affecting the nerves supplying proximal leg muscles, causing pain and weakness.</span></span></span></p>",
    "correct_choice_id": 79697,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19935,
    "choices": [
      {
        "id": 79701,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Suppression of Insulin release</span></span></span></p>"
      },
      {
        "id": 79702,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Release of Cortisol </span></span></span></p>"
      },
      {
        "id": 79703,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Release of Glucagon </span></span></span></p>"
      },
      {
        "id": 79704,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Release of Epinephrine</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following hormones has a delayed response in the defense against acute hypoglycemia?</span></span></p>",
    "unique_key": "Q6877377",
    "question_audio": null,
    "question_video": null,
    "map_id": 19909,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Release of Cortisol</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cortisol and growth hormone although involved in glucose counter-regulation, has a delayed response. It primarily supports glucose production during prolonged hypoglycemia (lasting more than 4 hours) and thus, cortisol and growth hormone play no role in defense against acute hypoglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Suppression of Insulin release:</span></strong><span style=\"font-size:12.0pt\">&nbsp;First line of defense in hypoglycemia. Insulin release is reduced at plasma glucose levels of &lt; 80-85 mg/dL and almost shuts off if levels are &lt; 70 mg/dL. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Release of Glucagon:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Second line of defense in acute hypoglycemia. Kicks off once glucose levels are &lt; 65-70 mg/dL. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Release of Epinephrine:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Import ant especially in glucagon deficient states. Kicks off once glucose levels are &lt; 65-70 mg/dL.&nbsp;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cortisol has a delayed response in hypoglycemia, primarily supporting glucose production during prolonged hypoglycemia.</span></span></span></p>",
    "correct_choice_id": 79702,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19936,
    "choices": [
      {
        "id": 79705,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Diabetic dermopathy </span></span></span></p>"
      },
      {
        "id": 79706,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Xerosis </span></span></span></p>"
      },
      {
        "id": 79707,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Necrobiosis lipoidica diabeticorum </span></span></span></p>"
      },
      {
        "id": 79708,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acanthosis nigricans</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">What is the most common cutaneous manifestation of diabetes mellitus?</span></span></span></p>",
    "unique_key": "Q5947994",
    "question_audio": null,
    "question_video": null,
    "map_id": 19910,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Xerosis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Xerosis and pruritis are the most common cutaneous manifestations of diabetes mellitus. They are usually relieved by skin moisturizers. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Diabetic dermopathy:</span></strong><span style=\"font-size:12.0pt\">&nbsp; Sometimes termed pigmented pretibial papules, or &ldquo;diabetic skin spots,&rdquo; begins as an erythematous macule or papule that evolves into an area of circular hyperpigmentation. These lesions result from minor mechanical trauma in the pretibial region and are more common in elderly men with DM.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Necrobiosis lipoidica diabeticorum:</span></strong><span style=\"font-size:12.0pt\">&nbsp;It is an uncommon disorder, accompanying diabetes in predominantly young women. This usually begins in the pretibial region as an erythematous plaque or papules that gradually enlarge, darken, and develop irregular margins, with atrophic centers and central ulceration. They are often painful. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Acanthosis nigricans:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is a velvety,&nbsp;hyperpigmented skin condition associated with insulin resistance.&nbsp;It is not the most common skin finding in diabetes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Xerosis (dry skin) and pruritis are the most common cutaneous manifestations of diabetes mellitus.</span></span></span></p>",
    "correct_choice_id": 79706,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19938,
    "choices": [
      {
        "id": 79713,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Microaneurysms </span></span></span></p>"
      },
      {
        "id": 79714,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neovascularization </span></span></span></p>"
      },
      {
        "id": 79715,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Papilledema </span></span></span></p>"
      },
      {
        "id": 79716,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Retinal detachment</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old man with long-standing type 2 diabetes mellitus undergoes an ophthalmologic examination. What is the most likely finding seen on his funduscopic examination?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-093301.png\" style=\"height:210px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q6044001",
    "question_audio": null,
    "question_video": null,
    "map_id": 19912,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Neovascularization</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The funduscopic image shows characteristic signs of proliferative diabetic retinopathy, the most significant of which is neovascularization. This is the growth of new blood vessels on the retina, which are fragile and prone to bleeding, leading to vision loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Microaneurysms:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While microaneurysms are an early sign of diabetic retinopathy,&nbsp;they are not the defining characteristic of proliferative retinopathy seen in this image.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Papilledema:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is swelling of the optic disc due to increased intracranial pressure and is not associated with diabetic retinopathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Retinal detachment:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While a potential complication of proliferative diabetic retinopathy,&nbsp;it is not directly visible in this image.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neovascularization is the hallmark of proliferative diabetic retinopathy, characterized by the growth of new blood vessels on the retina.</span></span></span></p>",
    "correct_choice_id": 79714,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 19939,
    "choices": [
      {
        "id": 79717,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase dose of statins </span></span></span></p>"
      },
      {
        "id": 79718,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add fenofibrate </span></span></span></p>"
      },
      {
        "id": 79719,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add Icosapent ethyl </span></span></span></p>"
      },
      {
        "id": 79720,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Change statins to PCSK9 inhibitor</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 44-year-old diabetic patient with CAD presents to you with routine blood tests. His LDL levels were within target (68 mg/dL) but his triglyceride levels were elevated (350 mg/dL). What can be done next to reduce his CV risk?</span></span></p>",
    "unique_key": "Q7771768",
    "question_audio": null,
    "question_video": null,
    "map_id": 19913,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Add Icosapent ethyl</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient has hypertriglyceridemia (triglycerides &gt;150 mg/dL) despite being on statin therapy and having LDL cholesterol under control. Icosapent ethyl is a highly purified form of eicosapentaenoic acid (EPA), an omega-3 fatty acid, that has been shown to significantly reduce cardiovascular risk in patients with elevated triglyceride levels, even when already on statin therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Increase dose of statins:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While statins can modestly lower triglycerides, their primary effect is on LDL cholesterol. Increasing the statin dose may not significantly reduce triglycerides and could increase the risk of side effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Add fenofibrate:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Fibrates can effectively lower triglycerides, but they have not been shown to reduce cardiovascular events in patients already on statin therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Change statins to PCSK9 inhibitor:</span></strong><span style=\"font-size:12.0pt\">&nbsp;PCSK9 inhibitors are potent LDL-lowering drugs but have limited effects on triglycerides. They would not be the most appropriate choice in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Icosapent ethyl, an omega-3 fatty acid, significantly reduces cardiovascular risk in patients with elevated triglycerides despite being on statin therapy.</span></span></span></p>",
    "correct_choice_id": 79719,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19940,
    "choices": [
      {
        "id": 79721,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rapid control of blood sugars </span></span></span></p>"
      },
      {
        "id": 79722,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fenofibrate </span></span></span></p>"
      },
      {
        "id": 79723,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pregnancy </span></span></span></p>"
      },
      {
        "id": 79724,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetic nephropathy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All of the following result in worsening of diabetic retinopathy except?</span></span></span></p>",
    "unique_key": "Q9762707",
    "question_audio": null,
    "question_video": null,
    "map_id": 19914,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Fenofibrate</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fenofibrate, a fibrate medication used to treat dyslipidemia, has been shown to have a potential beneficial effect on diabetic retinopathy. It may help reduce the progression of the disease by lowering triglyceride levels and improving blood lipid profiles.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Rapid control of blood sugars:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While tight glycemic control is essential for the long-term management of diabetic retinopathy,&nbsp;rapid improvement in blood sugar levels can sometimes lead to a temporary worsening of retinopathy in the short term (6-12 months). Individuals with known retinopathy may be candidates for prophylactic laser photocoagulation when initiating intensive therapy, and especially prior to pancreas or islet transplantation that can rapidly normalize glycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Pregnancy:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Hormonal changes and increased metabolic demands during pregnancy can exacerbate diabetic retinopathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Diabetic nephropathy:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Kidney disease in diabetes is often associated with worsened retinopathy due to shared microvascular damage and potential alterations in growth factors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fenofibrate may help reduce the progression of diabetic retinopathy by lowering triglyceride levels and improving blood lipid profiles.</span></span></span></p>",
    "correct_choice_id": 79722,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19941,
    "choices": [
      {
        "id": 79725,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased heart rate variability </span></span></span></p>"
      },
      {
        "id": 79726,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Orthostatic hypotension </span></span></span></p>"
      },
      {
        "id": 79727,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Resting tachycardia </span></span></span></p>"
      },
      {
        "id": 79728,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prolonged QT interval</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following does NOT occur in diabetic autonomic neuropathy (DAN)?</span></span></span></p>",
    "unique_key": "Q4075358",
    "question_audio": null,
    "question_video": null,
    "map_id": 19915,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Increased heart rate variability</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">DAN typically causes&nbsp;<strong>decreased</strong>&nbsp;heart rate variability due to impaired autonomic regulation of the heart.&nbsp;This is a significant finding that can be detected on electrocardiogram (ECG) or Holter monitoring.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Orthostatic hypotension:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is a common feature of DAN due to impaired sympathetic nervous system response,&nbsp;leading to a drop in blood pressure upon standing.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Resting tachycardia:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is also frequently seen in DAN due to parasympathetic dysfunction,&nbsp;leading to a faster resting heart rate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Prolonged QT interval:</span></strong><span style=\"font-size:12.0pt\">&nbsp;DAN can affect cardiac conduction,&nbsp;leading to a prolonged QT interval and increased risk of arrhythmias.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased heart rate variability is seen in DAN due to impaired autonomic regulation of the heart.</span></span></span></p>",
    "correct_choice_id": 79725,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19942,
    "choices": [
      {
        "id": 79729,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Most common form is DSPN (Distal Symmetric Polyneuropathy) </span></span></span></p>"
      },
      {
        "id": 79730,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glycemic control can worsen neuropathic pain initially </span></span></span></p>"
      },
      {
        "id": 79731,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients can be asymptomatic </span></span></span></p>"
      },
      {
        "id": 79732,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Loss of knee jerk is common</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is incorrect regarding diabetic neuropathy?</span></span></p>",
    "unique_key": "Q1441568",
    "question_audio": null,
    "question_video": null,
    "map_id": 19916,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Loss of knee jerk is common</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetic neuropathy often affects the longest nerves first, which are the peripheral nerves in the feet and legs. The loss of ankle jerk reflexes is a common finding, while the knee jerk reflex is typically preserved.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Most common form is DSPN:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is true.&nbsp;DSPN is the most prevalent form of diabetic neuropathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Glycemic control can worsen neuropathic pain initially:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is true.&nbsp;In some cases,&nbsp;rapid improvement in glycemic control can paradoxically worsen neuropathic pain in the short term.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Patients can be asymptomatic:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Many patients (up to 50%) with diabetic neuropathy,&nbsp;especially in the early stages,&nbsp;do not experience any symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetic neuropathy typically affects the peripheral nerves in the feet and legs first, with loss of ankle jerk reflexes being common.</span></span></span></p>",
    "correct_choice_id": 79732,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19943,
    "choices": [
      {
        "id": 79733,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Blood sugar of 340 mg/dL </span></span></span></p>"
      },
      {
        "id": 79734,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum bicarbonate of 22 mEq/L </span></span></span></p>"
      },
      {
        "id": 79735,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anion gap of 8 mEq/L </span></span></span></p>"
      },
      {
        "id": 79736,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta-hydroxybutyrate (&beta;-OHB) level of 5 mmol/L</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with type 1 diabetes presents with vomiting, abdominal pain and tachycardia. Which laboratory finding would be consistent with the diagnosis of euglycemic ketoacidosis (EDKA)?</span></span></p>",
    "unique_key": "Q5443871",
    "question_audio": null,
    "question_video": null,
    "map_id": 19917,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Beta-hydroxybutyrate (&beta;-OHB) level of 5 mmol/L</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Euglycemic ketoacidosis (EDKA) is a form of diabetic ketoacidosis (DKA) where ketone levels are elevated, leading to metabolic acidosis, but blood glucose levels are near normal or only slightly elevated.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">&beta;-OHB level of 5 mmol/L:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Elevated beta-hydroxybutyrate is a key ketone body and a hallmark of ketoacidosis.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">The symptoms</span></strong><span style=\"font-size:12.0pt\">&nbsp;of vomiting and abdominal pain are common in DKA and EDKA.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Blood sugar of 340 mg/dL:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is a high blood sugar level,&nbsp;typical of DKA,&nbsp;not EDKA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Serum bicarbonate of 22 mEq/L:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is a normal HCO3- level and wouldn&#39;t indicate acidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Anion gap of 8 mEq/L:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is a normal anion gap and wouldn&#39;t indicate acidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated &beta;-OHB levels indicate ketoacidosis, even when blood glucose levels are near normal, characteristic of euglycemic ketoacidosis.</span></span></span></p>",
    "correct_choice_id": 79736,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19944,
    "choices": [
      {
        "id": 79737,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Malignant otitis externa </span></span></span></p>"
      },
      {
        "id": 79738,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">UTI </span></span></span></p>"
      },
      {
        "id": 79739,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Pneumonia </span></span></span></p>"
      },
      {
        "id": 79740,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Tuberculosis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following infection is a hallmark of diabetes mellitus?</span></span></p>",
    "unique_key": "Q1828756",
    "question_audio": null,
    "question_video": null,
    "map_id": 19918,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Malignant otitis externa</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Malignant (invasive) otitis externa is a severe, potentially life-threatening infection of the external ear canal. It is particularly associated with diabetes mellitus, especially in older adults. Invasive otitis externa is usually secondary to Pseudomonas aeruginosa infection. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Many common infections are more frequent and severe in the diabetic population, whereas several rare infections are seen almost exclusively in the diabetic population. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Examples of this latter category include rhinocerebral mucormycosis, emphysematous infections of the gallbladder and urinary tract, and &ldquo;malignant&rdquo; or invasive otitis externa. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. UTI:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While urinary tract infections (UTIs) are more common in people with diabetes,&nbsp;they are not considered a hallmark infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Pneumonia:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Pneumonia can occur in people with diabetes,&nbsp;but it&#39;s not specific to this condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Tuberculosis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Diabetes can increase the risk of tuberculosis (TB),&nbsp;but it&#39;s not a hallmark infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Malignant otitis externa, a severe ear infection often caused by Pseudomonas aeruginosa, is particularly associated with diabetes mellitus.</span></span></span></p>",
    "correct_choice_id": 79737,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 19946,
    "choices": [
      {
        "id": 79745,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Abscess/cellulitis</span></span></span></p>"
      },
      {
        "id": 79746,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Charcot neuroarthropathy </span></span></span></p>"
      },
      {
        "id": 79747,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetic foot osteomyelitis </span></span></span></p>"
      },
      {
        "id": 79748,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Traumatic fracture</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 56-year-old woman with diabetes, hypertension, retinopathy, and peripheral neuropathy presents with 6 weeks of dull aching foot pain. Examination reveals bounding pulses and elevated temperature in the left foot, but no ulcers. What is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q9658973",
    "question_audio": null,
    "question_video": null,
    "map_id": 19920,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Charcot neuroarthropathy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Charcot neuroarthropathy is a degenerative joint disease often associated with diabetes and neuropathy. It presents with chronic, dull pain, bounding pulses, and increased temperature in the affected foot, even without ulcers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Abscess/cellulitis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Typically presents with acute pain,&nbsp;redness,&nbsp;and swelling.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Diabetic foot osteomyelitis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Usually associated with fever and elevated inflammatory markers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Traumatic fracture:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Requires a history of trauma and would present with more acute pain.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Charcot neuroarthropathy presents with chronic dull pain, bounding pulses, and increased temperature in the foot, often associated with diabetes and neuropathy.</span></span></span></p>",
    "correct_choice_id": 79746,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19948,
    "choices": [
      {
        "id": 79753,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Administer intravenous regular insulin at 0.1 units/kg/hour</span></span></span></p>"
      },
      {
        "id": 79754,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Correct hypokalemia with intravenous potassium chloride before initiating insulin therapy</span></span></span></p>"
      },
      {
        "id": 79755,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Administer intravenous sodium bicarbonate to correct acidosis</span></span></span></p>"
      },
      {
        "id": 79756,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Obtain a head CT scan to rule out cerebral edema</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 17-year-old boy with type 1 diabetes presents with vomiting, abdominal pain, lethargy and drowsiness. His blood glucose is 350 mg/dL, and ABG shows the following &ndash; pH 7.24, S. Na 130 mEq/L, S. K 3.0 mEq/L, S. HCO3- 14 mEq/L and S. Cl 88 mEq/L. His BP is 90/60 mm Hg and IV fluids were started. Which of the following is the most appropriate next step in management?</span></span></span></p>",
    "unique_key": "Q5464208",
    "question_audio": null,
    "question_video": null,
    "map_id": 19922,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Correct hypokalemia with intravenous potassium chloride before initiating insulin therapy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient presents with DKA and hypokalemia. Hypokalemia is a common complication of DKA and can be life-threatening if not corrected before initiating insulin therapy. Insulin drives potassium into cells, potentially worsening hypokalemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Administer intravenous regular insulin at 0.1 units/kg/hour:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While insulin is necessary for DKA management,&nbsp;it should not be initiated before correcting hypokalemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Administer intravenous sodium bicarbonate to correct acidosis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Sodium bicarbonate is generally not recommended in DKA unless the pH is less than 6.9 or there is significant cardiac instability.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Obtain a head CT scan to rule out cerebral edema:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Cerebral edema is a rare but serious complication of DKA,&nbsp;but it is not the most appropriate next step in management in this patient with hypokalemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Correct hypokalemia before initiating insulin therapy in DKA to prevent further potassium depletion and cardiac complications.</span></span></span></p>",
    "correct_choice_id": 79754,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19950,
    "choices": [
      {
        "id": 79761,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alcohol-induced hypoglycemia </span></span></span></p>"
      },
      {
        "id": 79762,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypoglycemia in type 1 diabetes </span></span></span></p>"
      },
      {
        "id": 79763,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sulfonylurea-related hypoglycemia </span></span></span></p>"
      },
      {
        "id": 79764,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypoglycemia due to insulinoma</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which among the following situations is glucagon most effective?</span></span></p>",
    "unique_key": "Q1889006",
    "question_audio": null,
    "question_video": null,
    "map_id": 19924,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Hypoglycemia in type 1 diabetes</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucagon works by stimulating glycogenolysis &gt; gluconeogenesis, causing blood sugar levels to rise. Glucagon also stimulates insulin release from &beta; cells; however, since patients with type 1 diabetes lack insulin production, glucagon can effectively raise blood glucose levels without an increase in insulin. Hence, it is an effective treatment for hypoglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Alcohol-induced hypoglycemia:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Alcohol impairs gluconeogenesis and most patients will be glycogen depleted (due to malnutrition) limiting the effectiveness of glucagon.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Sulfonylurea-related hypoglycemia:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Glucagon stimulate insulin release which can have a synergistic effect with sulfonylureas and can cause rebound severe hypoglycemia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Hypoglycemia due to insulinoma:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Glucagon stimulate excessive insulin release from insulinoma which can result in dangerous hypoglycemia and hence contraindicated. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucagon effectively raises blood glucose levels in hypoglycemia by stimulating glycogenolysis, especially in type 1 diabetes where there is no insulin production.</span></span></span></p>",
    "correct_choice_id": 79762,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 54044,
    "choices": [
      {
        "id": 215645,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CECT Abdomen </span></span></span></p>"
      },
      {
        "id": 215646,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Selective arterial calcium stimulation </span></span></span></p>"
      },
      {
        "id": 215647,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Measure serum IGF 2 levels</span></span></span></p>"
      },
      {
        "id": 215648,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Test for insulin autoantibodies</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old man presents with weight gain and recurrent hypoglycemia. Laboratory investigations reveal a low beta-hydroxybutyrate (&beta;-OHB) level (0.2 mmol/L). His C-peptide and plasma insulin levels are elevated. Urine and blood sulfonylurea screen is negative. What is the next step?</span></span></p>",
    "unique_key": "Q8729471",
    "question_audio": null,
    "question_video": null,
    "map_id": 25637,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) CECT Abdomen</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation and laboratory results strongly suggest an insulinoma, a neuroendocrine tumor of the pancreas that secretes insulin, leading to hypoglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Weight gain and hypoglycemia:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Classic symptoms of insulinoma.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Low &beta;-OHB:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Indicates the body is not breaking down fats for energy due to excess insulin.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Elevated C-peptide and insulin:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Confirms endogenous insulin overproduction.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Negative sulfonylurea screen:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Rules out medication-induced hypoglycemia.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">The next step is to localize the tumor with imaging.</span></strong><span style=\"font-size:12.0pt\"> CECT Abdomen (contrast-enhanced computed tomography of the abdomen) is the most sensitive imaging modality for detecting insulinomas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Selective arterial calcium stimulation:</span></strong><span style=\"font-size:12.0pt\">&nbsp;SACST (selective arterial calcium stimulation test) can be used if biochemical profile suggests endogenous hyperinsulinism but imaging is normal (to differentiate small insulinomas vs nesidioblastosis). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Measure serum IGF 2 levels:</span></strong><span style=\"font-size:12.0pt\">&nbsp;IGF-2 elevation would result in reflex suppression of endogenous insulin (hence insulin levels would be low).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Test for insulin autoantibodies:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This test is used for diagnosing autoimmune hypoglycemia,&nbsp;which is not supported by the clinical and laboratory findings in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CECT Abdomen is the most sensitive imaging modality for detecting insulinomas in patients presenting with weight gain, hypoglycemia, and elevated insulin/C-peptide levels.</span></span></span></p>",
    "correct_choice_id": 215645,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 53940,
    "choices": [
      {
        "id": 215229,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">5 years </span></span></span></p>"
      },
      {
        "id": 215230,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">8 years </span></span></span></p>"
      },
      {
        "id": 215231,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">20 years </span></span></span></p>"
      },
      {
        "id": 215232,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">15 years</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Screening for Parathyroid disorder in MEN 1 should begin at the age of?</span></span></p>",
    "unique_key": "Q8666884",
    "question_audio": null,
    "question_video": null,
    "map_id": 25534,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) 8 years</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary hyperparathyroidism (PHPT) is the most common and often the earliest manifestation of MEN1. While it usually manifests in adulthood, cases have been reported in children as young as 4 years old. Therefore, current guidelines recommend starting biochemical screening for PHPT with annual serum calcium and PTH measurements at 8 years of age.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-175419.png\" style=\"height:454px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. 5 years:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is when screening for anterior pituitary tumours &amp; insulinomas begin in MEN1. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. 20 years:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is when screening for gastrinomas begin in MEN 1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. 15 years:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is when screening for carcinoids (thymic/bronchial) begin in MEN 1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Screening for primary hyperparathyroidism in MEN1 should begin at 8 years of age.</span></span></span></p>",
    "correct_choice_id": 215230,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 39117,
    "choices": [
      {
        "id": 156203,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dexamethasone suppression </span></span></span></p>"
      },
      {
        "id": 156204,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CT of adrenals </span></span></span></p>"
      },
      {
        "id": 156205,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Plasma renin and aldosterone </span></span></span></p>"
      },
      {
        "id": 156206,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Urine metanephrines</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 36-year-old man presents to the clinic reporting ankle swelling. On examination, his blood pressure is elevated at 162/86, and he has bilateral ankle edema. Laboratory studies show a potassium of 2.9 and normal creatinine. Which of the following studies is recommended next?</span></span></p>",
    "unique_key": "Q9578795",
    "question_audio": null,
    "question_video": null,
    "map_id": 24092,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Plasma renin and aldosterone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient presents with hypertension, hypokalemia, and edema, which are classic signs of hyperaldosteronism. Plasma renin and aldosterone levels are the initial screening tests for primary aldosteronism. This test helps to determine if the aldosterone excess is due to an adrenal problem (primary aldosteronism) or if it&#39;s a result of another issue stimulating the adrenal glands to produce aldosterone (secondary aldosteronism).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Dexamethasone suppression:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This test is used to diagnose Cushing&#39;s syndrome (excess cortisol production). While Cushing&#39;s syndrome can cause hypertension, it is not typically associated with hypokalemia and edema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. CT of adrenals:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This imaging study can be useful to identify adrenal tumors, but it should be performed after biochemical confirmation of hyperaldosteronism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Urine metanephrines:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This test is used to diagnose pheochromocytoma, a tumor that produces catecholamines. While pheochromocytoma can cause hypertension, it is not typically associated with hypokalemia and edema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s presentation (hypertension, hypokalemia, and edema) suggests hyperaldosteronism. The initial test should be measuring plasma renin and aldosterone levels to confirm the diagnosis and determine if the cause is primary (adrenal) or secondary.</span></span></span></p>",
    "correct_choice_id": 156205,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 53965,
    "choices": [
      {
        "id": 215329,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated 17-hydroxyprogesterone (17-OHP) levels </span></span></span></p>"
      },
      {
        "id": 215330,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased serum 11-deoxycorticosterone (11-DOC) levels </span></span></span></p>"
      },
      {
        "id": 215331,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated DHEA-S (dehydroepiandrosterone sulfate) levels </span></span></span></p>"
      },
      {
        "id": 215332,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreased plasma renin activity</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A newborn presents with ambiguous genitalia, clitoromegaly and partial fusion of the labio-scrotal folds. The newborn also shows hyperpigmentation and hypertension. Karyotype shows 46,XX. Which of the following laboratory findings would be most consistent with the diagnosis?</span></span></p>",
    "unique_key": "Q7774887",
    "question_audio": null,
    "question_video": null,
    "map_id": 25559,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Increased serum 11-deoxycorticosterone (11-DOC) levels</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The combination of ambiguous genitalia, hyperpigmentation, and hypertension in a 46,XX infant is highly suggestive of congenital adrenal hyperplasia (CAH). The presence of hypertension differentiates 11&beta;-hydroxylase deficiency from the more common 21-hydroxylase deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In 11&beta;-hydroxylase deficiency: <strong>11-deoxycorticosterone (11-DOC) levels are increased </strong>due to the enzymatic block in the conversion of 11-DOC to aldosterone. Increased 11-DOC results in hypertension with reflex suppression of RAAS. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Elevated 17-OHP levels:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is primarily seen in 21-hydroxylase deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Elevated DHEA-S levels:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While DHEA-S is elevated in CAH, it is not specific to 11&beta;-hydroxylase deficiency and is also seen in 21-hydroxylase deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Decreased plasma renin activity:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is correct for 11&beta;-hydroxylase deficiency, but it is not the most specific finding for this type of CAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated serum 11-deoxycorticosterone (11-DOC) levels are indicative of 11&beta;-hydroxylase deficiency in CAH.</span></span></span></p>",
    "correct_choice_id": 215330,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 19914,
    "choices": [
      {
        "id": 79617,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hold atenolol for 1 week and repeat testing </span></span></span></p>"
      },
      {
        "id": 79618,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hold sertraline for 1 week and repeat testing </span></span></span></p>"
      },
      {
        "id": 79619,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Start &alpha;-blockers and then &beta;-blockers</span></span></span></p>"
      },
      {
        "id": 79620,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CT of the abdomen and pelvis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 43-year-old man with episodic, severe hypertension is referred with mild depression and current medications including sertraline, atenolol, amlodipine, and enalapril. Urine 24-hour total metanephrines show a borderline (1.5x) elevation. What is the next most appropriate step? </span></span></p>",
    "unique_key": "Q2584867",
    "question_audio": null,
    "question_video": null,
    "map_id": 19888,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Hold atenolol for 1 week and repeat testing</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When the diagnosis of pheochromocytoma is entertained, the first step is measurement of catecholamines and/or metanephrines. Testing for total metanephrines has a high sensitivity and, therefore, is frequently used. A value of &ge; 3x ULN is highly suggestive of pheochromocytoma. Borderline elevations, like in this patient, are likely to be false positives. The next most appropriate step is to remove potentially confounding dietary or drug exposures and repeat the test. Likely culprit drugs include <em><u>levodopa, sympathomimetics, diuretics, tricyclic antidepressants, and alpha and beta blockers</u></em> (atenolol in this case). Sertraline is a selective serotonin reuptake inhibitor, not a TCA. Alternatively, a clonidine suppression test may be ordered.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Hold sertraline for 1 week and repeat testing:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Sertraline is a selective serotonin reuptake inhibitor, not a TCA. Hence its unlikely to affect the test. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Start &alpha;-blockers and then &beta;-blockers:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This may be the initial management of pheochromocytoma, once the diagnosis is established, but NOT appropriate in this case with borderline metanephrine elevations. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. CT of the abdomen and pelvis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This may be done to localize pheochromocytoma, once biochemical diagnosis is established. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Borderline elevated metanephrines can be influenced by certain medications, including beta-blockers like atenolol. The next step is to stop potentially interfering medications and repeat the test to confirm the diagnosis.</span></span></span></p>",
    "correct_choice_id": 79617,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 53949,
    "choices": [
      {
        "id": 215265,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cushing&#39;s syndrome </span></span></span></p>"
      },
      {
        "id": 215266,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Addison&#39;s disease </span></span></span></p>"
      },
      {
        "id": 215267,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperparathyroidism</span></span></span></p>"
      },
      {
        "id": 215268,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypothyroidism</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the most common endocrine manifestation of Carney complex?</span></span></p>",
    "unique_key": "Q8291041",
    "question_audio": null,
    "question_video": null,
    "map_id": 25543,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Cushing&#39;s syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carney complex (CNC) is a multiple endocrine neoplasia syndrome characterized by various endocrine tumors and other features. The most common endocrine manifestation is Cushing&#39;s syndrome, which is caused by primary pigmented nodular adrenocortical disease (PPNAD) in the majority of cases. PPNAD leads to excess cortisol production, resulting in the typical features of Cushing&#39;s syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Addison&#39;s disease:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is primary adrenal insufficiency, which is not a typical feature of Carney complex.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Hyperparathyroidism:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While parathyroid adenomas can occur in CNC, they are less common than PPNAD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Hypothyroidism:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Thyroid involvement in CNC is typically in the form of thyroid nodules or cancer, not hypothyroidism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Summary:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Carney Complex &ndash;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Features:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Spotty skin pigmentation, <em><u>myxomas</u></em>, <em><u>psammomatous melanotic schwannomas</u></em>, endocrine tumors (adrenal, Sertoli cells, somatotropes, thyroid, ovary).</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most common endocrine manifestation:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Cushing&#39;s syndrome due to primary pigmented nodular adrenal disease (PPNAD).</span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Atypical Cushing&#39;s presentation: Patients are often thin, have short stature, muscle/skin wasting, and osteoporosis.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Periodic Cushing&#39;s syndrome: Fluctuating cortisol levels over days or weeks.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Can have paradoxical elevation of cortisol after dexamethasone administration. </span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other endocrine manifestations:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Acromegaly, testicular tumors (Sertoli cell, Leydig cell), thyroid tumors, ovarian cysts, breast duct adenomas.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Genetics:</span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CNC1: Mutations in PRKAR1A gene (tumor suppressor) on chromosome 17q24.2.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CNC2: Gene on chromosome 2p16 (not yet identified).</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most common endocrine manifestation of Carney complex is Cushing&#39;s syndrome due to primary pigmented nodular adrenocortical disease (PPNAD).</span></span></span></p>",
    "correct_choice_id": 215265,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 19930,
    "choices": [
      {
        "id": 79681,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Give hydrocortisone 100mg IV. </span></span></span></p>"
      },
      {
        "id": 79682,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Start IV insulin infusion.</span></span></span></p>"
      },
      {
        "id": 79683,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Start IV NaHCO3.</span></span></span></p>"
      },
      {
        "id": 79684,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Start IV Insulin + Dextrose.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 20-year-old woman presents with abdominal pain, fever and vomiting. She takes insulin for type 1 diabetes. On examination, her mucosa is dry and the appearance is shown in the image. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">You order an ABG and the results are as follows -</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">pH &ndash; 7.29, Na &ndash; 129 mEq/L, K &ndash; 5.6 mEq/L, HCO3- 18 mEq/L, Cl &ndash; 101 mEq/L and her RBS is 89 mg/dL. Her ECG shows sinus tachycardia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Her BP is 80/40 mm Hg and her PR is 122/min. You give an IV fluid bolus and her BP slightly improves. What is the most important treatment?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-173002.png\" style=\"height:226px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q7220340",
    "question_audio": null,
    "question_video": null,
    "map_id": 19904,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Give hydrocortisone 100mg IV.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s clinical presentation, including abdominal pain, fever, vomiting, malaise, dry mucosa, and hyperpigmentation, alongside the lab findings of hyponatremia, hyperkalemia, metabolic acidosis (low bicarbonate), and hypotension, is strongly suggestive of an adrenal crisis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most crucial step in managing an adrenal crisis is to administer intravenous hydrocortisone (100mg) to replace the deficient cortisol. This is a life-saving intervention, as untreated adrenal crisis can rapidly progress to shock and death.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Start IV insulin infusion:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While the patient has type 1 diabetes, her current blood glucose is within the normal range, and insulin infusion is not the priority in this emergency situation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Start IV NaHCO3:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Correcting acidosis is important, but the primary concern is addressing the underlying adrenal insufficiency with hydrocortisone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Start IV Insulin + Dextrose:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is an initial therapy in hyperkalemia, to transiently lower serum potassium levels. But in adrenal crisis, correction of underlying cause is important by administering hydrocortisone. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></u></strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s presentation is strongly suggestive of an adrenal crisis. Administering intravenous hydrocortisone is the most important treatment to replace the deficient cortisol.</span></span></span></p>",
    "correct_choice_id": 79681,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 53963,
    "choices": [
      {
        "id": 215321,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pathologic examination of her gonads </span></span></span></p>"
      },
      {
        "id": 215322,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum thyroid-stimulating hormone level </span></span></span></p>"
      },
      {
        "id": 215323,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum prolactin level </span></span></span></p>"
      },
      {
        "id": 215324,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Karyotype</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 17-year-old female presents with Tanner stage IV breast development but no menses. Ultrasound confirms a blind vaginal vault and no uterus or cervix. What lab test would be most helpful in finding the etiology of her problem?</span></span></p>",
    "unique_key": "Q1642027",
    "question_audio": null,
    "question_video": null,
    "map_id": 25557,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Karyotype</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s presentation (normal breast development but absent uterus and cervix) suggests M&uuml;llerian agenesis (Mayer-Rokitansky-K&uuml;ster-Hauser syndrome). However, the most important differential diagnosis to consider is complete androgen insensitivity syndrome (CAIS), a disorder of sex development caused by a mutation in the androgen receptor gene. Individuals with CAIS are genetically male (46,XY) but have female external genitalia due to insensitivity to androgens.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A karyotype is the most helpful test in this scenario as it will definitively determine the patient&#39;s genetic sex and help differentiate between M&uuml;llerian agenesis (46,XX) and CAIS (46,XY).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Pathologic examination of her gonads:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While this can be informative, it is not the first-line test and may not be necessary if the karyotype confirms CAIS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Serum thyroid-stimulating hormone level:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Thyroid dysfunction is not a likely cause of this presentation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Serum prolactin level:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hyperprolactinemia is not associated with the absence of uterus and cervix.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A karyotype is the most helpful test for differentiating between M&uuml;llerian agenesis and complete androgen insensitivity syndrome (CAIS).</span></span></span></p>",
    "correct_choice_id": 215324,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 53964,
    "choices": [
      {
        "id": 215325,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Kallman syndrome </span></span></span></p>"
      },
      {
        "id": 215326,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Turner syndrome </span></span></span></p>"
      },
      {
        "id": 215327,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Congenital adrenal hyperplasia (CAH) d</span></span></span></p>"
      },
      {
        "id": 215328,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Swyer syndrome</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 16-year-old girl presents with primary amenorrhea. On examination, she is tall and lacks secondary sexual characteristics. Which of the following is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q8746460",
    "question_audio": null,
    "question_video": null,
    "map_id": 25558,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Swyer syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Swyer syndrome, also known as 46,XY gonadal dysgenesis, is a disorder of sex development where individuals have a female phenotype despite having a male karyotype (46,XY). This occurs due to mutations or deletions in the SRY gene, which is responsible for testis development.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The following features in the patient&#39;s presentation support the diagnosis of Swyer syndrome:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary amenorrhea:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is due to the absence of functional ovaries.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lack of secondary sexual characteristics:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is caused by a lack of estrogen production from non-functional gonads.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tall stature:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Due to delayed closure of epiphysis due to lack of sex hormones. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Kallman syndrome:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Characterized by delayed or absent puberty and anosmia (loss of smell). Individuals with Kallman syndrome typically have a normal female karyotype (46,XX).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Turner syndrome:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Characterized by short stature, webbed neck, and other features, with a karyotype of 45,X.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Congenital adrenal hyperplasia (CAH):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Typically presents with virilization (development of male sexual characteristics) in females due to excess androgen production. This is the opposite of what is seen in Swyer syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Swyer syndrome (46,XY gonadal dysgenesis) is characterized by a female phenotype with a male karyotype and lack of secondary sexual characteristics.</span></span></span></p>",
    "correct_choice_id": 215328,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19921,
    "choices": [
      {
        "id": 79645,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bilateral adrenal hyperplasia</span></span></span></p>"
      },
      {
        "id": 79646,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Unilateral adrenal adenoma</span></span></span></p>"
      },
      {
        "id": 79647,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adrenocortical carcinoma </span></span></span></p>"
      },
      {
        "id": 79648,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pheochromocytoma</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 38-year-old woman with resistant hypertension and muscle weakness has a serum potassium of 2.8 mEq/L. Her plasma renin activity (PRA) is very low and her aldosterone levels are elevated. What is the most common cause?</span></span></p>",
    "unique_key": "Q6447458",
    "question_audio": null,
    "question_video": null,
    "map_id": 19895,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Bilateral adrenal hyperplasia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The combination of resistant hypertension, hypokalemia, low PRA, and elevated aldosterone is highly suggestive of primary aldosteronism. Among the causes of primary aldosteronism, bilateral adrenal hyperplasia is the most common, accounting for approximately 60-70% of cases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Unilateral adrenal adenoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While a common cause of primary aldosteronism, it is less frequent than bilateral adrenal hyperplasia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Adrenocortical carcinoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a rare cause of primary aldosteronism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Pheochromocytoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a tumor of the adrenal medulla that secretes catecholamines. It is not associated with the typical findings of primary aldosteronism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></u></strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bilateral adrenal hyperplasia is the most common cause of primary aldosteronism, accounting for 60-70% of cases. It leads to elevated aldosterone and low plasma renin activity, causing hypertension and hypokalemia.</span></span></span></p>",
    "correct_choice_id": 79645,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 19918,
    "choices": [
      {
        "id": 79633,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inferior petrosal sinus sampling. </span></span></span></p>"
      },
      {
        "id": 79634,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">High dose Dexamethasone suppression test. </span></span></span></p>"
      },
      {
        "id": 79635,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CRH stimulation test. </span></span></span></p>"
      },
      {
        "id": 79636,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MRI of the pituitary.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the gold standard to differentiate Cushing&#39;s disease (ACTH-producing pituitary adenoma) from ectopic Cushing&#39;s syndrome?</span></span></p>",
    "unique_key": "Q5586498",
    "question_audio": null,
    "question_video": null,
    "map_id": 19892,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Inferior petrosal sinus sampling.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inferior petrosal sinus sampling (IPSS) is the gold standard test to differentiate between Cushing&#39;s disease and ectopic ACTH syndrome. This involves measuring ACTH levels in blood samples taken from the inferior petrosal sinuses (which drain the pituitary gland) and a peripheral vein before and after administration of CRH. A central-to-peripheral ACTH ratio greater than 2 at baseline or greater than 3 after CRH stimulation is indicative of Cushing&#39;s disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. High dose Dexamethasone suppression test:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While this test can help distinguish between different causes of Cushing&#39;s syndrome, it is not as specific as IPSS in differentiating pituitary from ectopic ACTH secretion. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cortisol suppression &gt;50% after q6h 2 mg DEX for 2 days is suggestive of Cushing&rsquo;s disease.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. CRH stimulation test:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This test can be helpful in the evaluation of Cushing&#39;s syndrome, but it is not the gold standard for differentiating between pituitary and ectopic sources of ACTH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ACTH increase &gt;40% at 15&ndash;30 min + cortisol increase &gt;20% at 45&ndash;60 min after CRH 100 &mu;g IV is suggestive of Cushing&rsquo;s disease.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. MRI of the pituitary:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> MRI can detect pituitary tumors, but not all ACTH-producing tumors are visible on MRI. Additionally, incidental pituitary lesions can be found in patients without Cushing&#39;s disease. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the presence of cortisol &amp; ACTH excess, a lesion &gt; 6 mm is suggestive of Cushing&rsquo;s disease.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inferior petrosal sinus sampling (IPSS) is the gold standard for differentiating Cushing&#39;s disease from ectopic ACTH syndrome by measuring ACTH levels from the inferior petrosal sinuses and comparing them with peripheral levels after CRH administration.</span></span></span></p>",
    "correct_choice_id": 79633,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 39116,
    "choices": [
      {
        "id": 156199,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cushing&#39;s syndrome </span></span></span></p>"
      },
      {
        "id": 156200,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Conn&#39;s syndrome </span></span></span></p>"
      },
      {
        "id": 156201,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liddle&#39;s syndrome </span></span></span></p>"
      },
      {
        "id": 156202,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Connshing syndrome</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old patient presents with dizziness. On examination, his BP is 180/110 mm Hg, and he has stretch marks in the trunk. His blood reports show a serum potassium (S. Potassium) of 2.7 mEq/L and HCO3- of 31 mEq/L. He also has elevated aldosterone levels, and after a dexamethasone suppression test, his serum cortisol was 60 nmol/L. What is the likely diagnosis?</span></span></span></p>",
    "unique_key": "Q4921804",
    "question_audio": null,
    "question_video": null,
    "map_id": 24091,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Connshing syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient has <strong>Hypertension, Hypokalemia, Metabolic alkalosis </strong>and elevated aldosterone confirming mineralocorticoid excess (Conn&rsquo;s syndrome). The presence of stretch marks and high cortisol (&gt; 50 nmol/L) after dexamethasone indicates cortisol excess (Cushing&rsquo;s syndrome).</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Some patients with Conn&rsquo;s syndrome can also have mild autonomous cortisol secretion &ndash; called as &lsquo;Connshing&rsquo; syndrome. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Cushing&#39;s syndrome:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Even though patient has features of Cushing&rsquo;s syndrome, he also has elevated aldosterone, hence it is not the accurate diagnosis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Conn&rsquo;s syndrome</strong>: Even though patient has features of Conn&rsquo;s syndrome, he also has elevated cortisol, hence it is not the accurate diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Liddle&#39;s syndrome:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a rare genetic disorder causing similar electrolyte abnormalities but with normal or low aldosterone levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The combination of features indicating both Conn&#39;s syndrome (mineralocorticoid excess with hypertension, hypokalemia, and metabolic alkalosis) and Cushing&#39;s syndrome (elevated cortisol levels after dexamethasone suppression) points towards Connshing syndrome, where both aldosterone and cortisol are elevated.</span></span></span></p>",
    "correct_choice_id": 156202,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 53946,
    "choices": [
      {
        "id": 215253,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">S. Calcium at 11 years </span></span></span></p>"
      },
      {
        "id": 215254,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immediate total thyroidectomy </span></span></span></p>"
      },
      {
        "id": 215255,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Plasma metanephrines at 16 years </span></span></span></p>"
      },
      {
        "id": 215256,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MRI pituitary at 5 years</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A couple comes for counseling regarding their newborn&#39;s health. The father of the child had an MTC, was operated on recently, and was known to have a RET codon 918 mutation. The newborn has been screened and carries the same mutation as well. What will be your advice regarding the newborn?</span></span></p>",
    "unique_key": "Q7092955",
    "question_audio": null,
    "question_video": null,
    "map_id": 25540,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Immediate total thyroidectomy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The RET codon 918 mutation is associated with Multiple Endocrine Neoplasia type 2B (MEN2B), which carries a very high risk of early-onset and aggressive medullary thyroid carcinoma (MTC). Prophylactic total thyroidectomy is recommended in the first year of life, ideally within the first 6 months, to prevent the development of MTC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-180531.png\" style=\"height:418px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. S. Calcium at 11 years:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Recommended for RET codon 634 or 883 mutations, where hyperparathyroidism is common. Hyperparathyroidism is not a feature of codon 918 mutations, hence screening is NOT recommended. For mutations other than For 663, 883 and 918 &ndash; screening can be started at 16 years. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Plasma metanephrines at 16 years:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Recommended for screening of pheochromocytoma for RET codon mutations (other than 663, 883 and 918). For 663, 883 and 918 mutations &ndash; screening should be started at 11 years. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. MRI pituitary at 5 years:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is the recommendations for screening pituitary tumors in case of MEN1. Pituitary tumors are not associated with MEN2B. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immediate total thyroidectomy is recommended for newborns with RET codon 918 mutation to prevent medullary thyroid carcinoma (MTC).</span></span></span></p>",
    "correct_choice_id": 215254,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 53960,
    "choices": [
      {
        "id": 215309,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">45X/46XY </span></span></span></p>"
      },
      {
        "id": 215310,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">45X/46XX </span></span></span></p>"
      },
      {
        "id": 215311,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">45XY/45XXY </span></span></span></p>"
      },
      {
        "id": 215312,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">46XX/46XY</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the karyotype most commonly associated with mixed gonadal dysgenesis (MGD)?</span></span></p>",
    "unique_key": "Q2629617",
    "question_audio": null,
    "question_video": null,
    "map_id": 25554,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) 45X/46XY</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mixed gonadal dysgenesis (MGD) is characterized by the presence of both testicular and ovarian tissue in an individual. The most common karyotype associated with MGD is 45, X/46, XY mosaicism. This means that some cells in the body have a missing X chromosome (45, X), while others have the typical male karyotype (46, XY). The degree of mosaicism and the distribution of the different cell lines can vary greatly, leading to a wide range of phenotypic presentations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most are assigned as males and may have asymmetry (streak gonad and hemiuterus on one side, dysgenetic testis and hemiscrotum on the other). </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased risk of germ cell cancer (up to 35% in intraabdominal gonads) &ndash; so prophylactic removal of intrabdominal gonads is warranted. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. 45X/46XX:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This karyotype is associated with Turner mosaics. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. 45XY/45XXY:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This karyotype combination is seen in Klinefelter mosaics. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. 46XX/46XY:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This karyotype may be seen in Ovotesticular DSD (but most common is 46XX).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most common karyotype associated with mixed gonadal dysgenesis is 45,X/46,XY.</span></span></span></p>",
    "correct_choice_id": 215309,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 19927,
    "choices": [
      {
        "id": 79669,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Radiodensity &gt; 20 HU </span></span></span></p>"
      },
      {
        "id": 79670,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Size &ge; 4cm </span></span></span></p>"
      },
      {
        "id": 79671,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated steroid precursors in urine </span></span></span></p>"
      },
      {
        "id": 79672,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Calcifications in the adrenal gland</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 54-year-old man presents with an incidental 6 cm adrenal lesion with a radiodensity of 45 HU. Which of the following is NOT predictive of adrenocortical cancer (ACC)?</span></span></p>",
    "unique_key": "Q8858234",
    "question_audio": null,
    "question_video": null,
    "map_id": 19901,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Calcifications in adrenal gland</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While calcifications can be present in adrenal lesions, they are more commonly associated with benign lesions like adrenal adenomas. The presence of calcifications does not necessarily predict malignancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Radiodensity &gt; 20 HU:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Adrenocortical carcinomas typically have higher radiodensity on unenhanced CT scans (&gt;20 HU) due to their lower fat content.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Size &ge; 4 cm:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Larger adrenal lesions are more likely to be malignant. A 6 cm lesion is highly suspicious for ACC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Elevated steroid precursors in urine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Adrenocortical carcinomas often produce excess steroid precursors, which can be detected in urine. This is a suggestive feature of malignancy.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A recently introduced diagnostic test, urine steroid metabolomics, has a 2x higher PPV than imaging in detecting ACC, based on a distinct &ldquo;steroid fingerprint&rdquo; with accumulating precursor steroids in 24-h urine.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Calcifications can be present in adrenal lesions but are more commonly associated with benign lesions like adrenal adenomas and do not necessarily predict malignancy.</span></span></span></p>",
    "correct_choice_id": 79672,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 19922,
    "choices": [
      {
        "id": 79649,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liddle syndrome </span></span></span></p>"
      },
      {
        "id": 79650,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gordon syndrome (PHA2) </span></span></span></p>"
      },
      {
        "id": 79651,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gitelman syndrome </span></span></span></p>"
      },
      {
        "id": 79652,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Apparent mineralocorticoid excess (SAME)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 24-year-old man presents with severe hypertension, hypokalemia, and metabolic alkalosis. His brother died of intracranial hemorrhage (ICH) at the age of 12. His plasma renin and aldosterone levels are low, and his blood pressure normalized after adding spironolactone. Which of the following is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q7976445",
    "question_audio": null,
    "question_video": null,
    "map_id": 19896,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Apparent mineralocorticoid excess (SAME)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SAME is an autosomal recessive disorder caused by a deficiency of 11&beta;-hydroxysteroid dehydrogenase type 2 (11&beta;-HSD2), which normally inactivates cortisol to cortisone. In SAME, cortisol acts as a potent mineralocorticoid, leading to sodium retention, potassium excretion, and hypertension.</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The positive response to spironolactone, a mineralocorticoid receptor antagonist, further supports the diagnosis of SAME, as it blocks the mineralocorticoid receptor, mitigating the effects of cortisol.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Liddle syndrome:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Response to spironolactone would be poor. Patients typically respond to amiloride (as this disorder is due to hyperfunctioning ENaC channels in the principal cells).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Gordon syndrome (PHA2):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Response to spironolactone would be poor and patients usually present with hypertension, hyperkalemia and metabolic acidosis. Patients typically respond to thiazides (as this disorder is due to hyperfunctioning Na-Cl transporters in the DCT).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Gitelman syndrome:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This syndrome can cause hypokalemia and metabolic alkalosis, but patients tend to be normotensive and renin/aldosterone levels would be elevated. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></u></strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SAME is caused by a deficiency of 11&beta;-hydroxysteroid dehydrogenase type 2, leading to cortisol acting as a potent mineralocorticoid. The patient&#39;s response to spironolactone supports this diagnosis.</span></span></span></p>",
    "correct_choice_id": 79652,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 19924,
    "choices": [
      {
        "id": 79657,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dexamethasone suppression test </span></span></span></p>"
      },
      {
        "id": 79658,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Saline infusion test </span></span></span></p>"
      },
      {
        "id": 79659,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CT scan of the abdomen </span></span></span></p>"
      },
      {
        "id": 79660,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Urinary metanephrines</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old man presents with resistant hypertension&gt; His serum potassium is 3 mEq/L, and his serum HCO3- is 29 mEq/L. His renin levels were low and aldosterone levels were elevated. What is the confirmatory test for the suspected diagnosis?</span></span></p>",
    "unique_key": "Q9366513",
    "question_audio": null,
    "question_video": null,
    "map_id": 19898,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Saline infusion test</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s presentation (resistant hypertension, hypokalemia, metabolic alkalosis, low renin, and high aldosterone) strongly suggests primary aldosteronism. The saline infusion test is the gold standard confirmatory test for primary aldosteronism. In this test, the patient receives a large volume of saline intravenously, and aldosterone levels are measured. Failure of aldosterone to suppress after saline infusion confirms the diagnosis of primary aldosteronism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Dexamethasone suppression test:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This test is used to diagnose Cushing&#39;s syndrome (excess cortisol production), not primary aldosteronism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. CT scan of the abdomen:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This imaging test can help visualize adrenal glands and identify tumors, but it does not confirm the functional diagnosis of primary aldosteronism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Urinary metanephrines:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This test is used to diagnose pheochromocytoma, which is not consistent with the patient&#39;s presentation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The saline infusion test is the confirmatory test for primary aldosteronism. It involves administering saline and measuring aldosterone levels, which should suppress if primary aldosteronism is present.</span></span></span></p>",
    "correct_choice_id": 79658,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19916,
    "choices": [
      {
        "id": 79625,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">PRKAR1A </span></span></span></p>"
      },
      {
        "id": 79626,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">USP8 </span></span></span></p>"
      },
      {
        "id": 79627,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">GNAS1 </span></span></span></p>"
      },
      {
        "id": 79628,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PRKACA</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the most common mutation found in ACTH-secreting pituitary adenomas?</span></span></p>",
    "unique_key": "Q4003198",
    "question_audio": null,
    "question_video": null,
    "map_id": 19890,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) USP8</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">USP8 mutations are the most frequent genetic alterations found in ACTH-secreting pituitary adenomas, responsible for Cushing&#39;s disease. These mutations lead to increased deubiquitination of the epidermal growth factor receptor (EGFR), resulting in its stabilization and activation. This in turn promotes the synthesis and secretion of ACTH, leading to the development of Cushing&#39;s disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. PRKAR1A:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Mutations in this gene are associated with Carney complex, which is usually associated with PPNAD (Primary pigmented Nodular Adrenal Disease).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. GNAS1:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Activating mutations in this gene can result in McCune-Albright syndrome (MAS). Cushing&rsquo;s syndrome in MAS is usually ACTH independent. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. PRKACA:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mutations in this gene are found in a subset (40%) of cortisol-producing adrenal adenomas and are not typically associated with ACTH-secreting pituitary adenomas.</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Another mutation in a tumor suppressor gene ARMC5 have been identified as a prevalent cause of Cushing&rsquo;s due to bilateral macronodular adrenal hyperplasia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></u></strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">USP8 mutations are the most frequent genetic alterations found in ACTH-secreting pituitary adenomas, leading to increased deubiquitination and stabilization of the EGFR, which promotes ACTH synthesis and secretion.</span></span></span></p>",
    "correct_choice_id": 79626,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53943,
    "choices": [
      {
        "id": 215241,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullated corneal nerve fibers </span></span></span></p>"
      },
      {
        "id": 215242,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intestinal dysfunction </span></span></span></p>"
      },
      {
        "id": 215243,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mutation in cysteine-rich domain of RET </span></span></span></p>"
      },
      {
        "id": 215244,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most common mutation is RET codon 918</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT a feature of MEN2B?</span></span></p>",
    "unique_key": "Q8529181",
    "question_audio": null,
    "question_video": null,
    "map_id": 25537,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Mutation in cysteine-rich domain of RET</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN2B (Multiple Endocrine Neoplasia type 2B) is characterized by (M&rsquo;s):</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullary thyroid carcinoma (MTC)</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pheochromocytoma</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mucosal neuromas</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Marfanoid habitus</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullated corneal nerve fibers</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Megacolon due to Intestinal ganglioneuromatosis</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most common mutation is RET codon 918</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> (M918T) in the tyrosine kinase domain of the RET proto-oncogene.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Medullated corneal nerve fibers:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a distinctive feature of MEN2B.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Intestinal dysfunction:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a common feature due to intestinal ganglioneuromatosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Most common mutation is RET codon 918:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is the characteristic mutation in MEN2B (seen in 95% cases). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN2B is characterized by mutations in the tyrosine kinase domain of RET, not the cysteine-rich domain.</span></span></span></p>",
    "correct_choice_id": 215243,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 53935,
    "choices": [
      {
        "id": 215209,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immediate surgical removal of the testicular masses </span></span></span></p>"
      },
      {
        "id": 215210,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Start high-dose glucocorticoid therapy </span></span></span></p>"
      },
      {
        "id": 215211,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Initiate testosterone replacement therapy </span></span></span></p>"
      },
      {
        "id": 215212,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Perform a biopsy of the testicular masses to rule out malignancy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 16-year-old boy with known Congenital Adrenal Hyperplasia (CAH) presents with bilateral testicular masses. His serum ACTH levels are elevated, and ultrasound reveals B/L hypoechoic lesions in the testes. Which of the following is the most appropriate next step?</span></span></p>",
    "unique_key": "Q7709339",
    "question_audio": null,
    "question_video": null,
    "map_id": 25529,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Start high-dose glucocorticoid therapy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a patient with CAH, bilateral testicular masses with elevated ACTH levels and hypoechoic lesions on ultrasound are highly suggestive of TART (Testicular Adrenal Rest Tissue). These are benign tumors composed of ectopic adrenal tissue that can develop in the testes due to chronic ACTH stimulation. TART can compromise sperm production and induce testicular fibrosis that may be irreversible.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most appropriate next step is to <strong>start high-dose glucocorticoid therapy</strong> to suppress ACTH production and induce regression of the adrenal rest tumors. This is the primary treatment for adrenal rest tumors in CAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Immediate surgical removal of the testicular masses:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Surgery is not the initial approach for adrenal rest tumors. Medical management with glucocorticoids is usually attempted first.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Initiate testosterone replacement therapy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Testosterone replacement is not indicated for adrenal rest tumors and may even worsen the condition by stimulating further tumor growth.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Perform a biopsy of the testicular masses to rule out malignancy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While biopsy can be considered in cases with atypical features or lack of response to glucocorticoids, it is not the most appropriate initial step. Adrenal rest tumors are typically benign, and the clinical presentation and imaging findings strongly suggest this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bilateral testicular masses in a patient with congenital adrenal hyperplasia (CAH) are likely due to testicular adrenal rest tumors (TART). High-dose glucocorticoid therapy suppresses ACTH production and induces regression of the tumors.</span></span></span></p>",
    "correct_choice_id": 215210,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19911,
    "choices": [
      {
        "id": 79605,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prazosin </span></span></span></p>"
      },
      {
        "id": 79606,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propranolol </span></span></span></p>"
      },
      {
        "id": 79607,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spironolactone</span></span></span></p>"
      },
      {
        "id": 79608,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Enalapril</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 34-year-old man presents with resistant hypertension and a serum potassium level of 2.9 mEq/L, with normal creatinine. Which of the antihypertensives need not be stopped prior to the test you are about to perform to screen for the disease?</span></span></p>",
    "unique_key": "Q5095351",
    "question_audio": null,
    "question_video": null,
    "map_id": 19886,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Prazosin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s presentation (resistant hypertension and hypokalemia) suggests possible primary aldosteronism. The most common test to screen for primary aldosteronism is the plasma aldosterone-to-renin ratio (ARR).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prazosin (&alpha; -1 blocker):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Does not significantly interfere with the renin-angiotensin-aldosterone system (RAAS) and can be continued.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Propranolol (beta-blocker):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Can lower plasma renin activity (PRA), potentially masking primary aldosteronism (false positive test). It should be stopped 2 weeks before the test.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Spironolactone (mineralocorticoid receptor antagonist):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Directly affects aldosterone levels (false positive test). and should be stopped 4 weeks before the test.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Enalapril (ACE inhibitor):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Can increase plasma renin activity, potentially leading to a false-negative result. It should be stopped 2 weeks before the test.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-165846.png\" style=\"height:275px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></u></strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prazosin (an &alpha;-1 blocker) does not significantly affect the renin-angiotensin-aldosterone system (RAAS) and can be continued during testing for primary aldosteronism. Other medications like beta-blockers, mineralocorticoid receptor antagonists, and ACE inhibitors should be stopped prior to testing.</span></span></span></p>",
    "correct_choice_id": 79605,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53954,
    "choices": [
      {
        "id": 215285,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Type 1 DM </span></span></span></p>"
      },
      {
        "id": 215286,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mucocutaneous candidiasis </span></span></span></p>"
      },
      {
        "id": 215287,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypoparathyroidism </span></span></span></p>"
      },
      {
        "id": 215288,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adrenal insufficiency</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the first manifestation of APS 1?</span></span></span></p>",
    "unique_key": "Q9460332",
    "question_audio": null,
    "question_video": null,
    "map_id": 25548,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Mucocutaneous candidiasis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic mucocutaneous candidiasis is the most common and often the first manifestation of autoimmune polyendocrine syndrome type 1 (APS-1). It usually appears in infancy or early childhood, often preceding the development of other components of the syndrome by years or even decades. It affects the mouth and nails more frequently than the skin and esophagus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Type 1 DM:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> It is uncommon in APS-1 but a common feature of APS-2. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Hypoparathyroidism:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hypoparathyroidism typically develops after mucocutaneous candidiasis in APS-1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Adrenal insufficiency:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Adrenal insufficiency is usually the last component of the classic triad to appear.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The first manifestation of APS-1 is typically mucocutaneous candidiasis, appearing in infancy or early childhood.</span></span></span></p>",
    "correct_choice_id": 215286,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 39114,
    "choices": [
      {
        "id": 156191,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Morning peak of plasma cortisol level </span></span></span></p>"
      },
      {
        "id": 156192,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Release of cortisol in response to stress </span></span></span></p>"
      },
      {
        "id": 156193,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sodium retention in response to hypovolemia </span></span></span></p>"
      },
      {
        "id": 156194,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Release of DHEA</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient has neurosurgery for a pituitary tumor that requires resection of the gland. Which of the following functions of the adrenal gland will be preserved in this patient immediately post-op?</span></span></p>",
    "unique_key": "Q5734169",
    "question_audio": null,
    "question_video": null,
    "map_id": 24089,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Sodium retention in response to hypovolemia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The pituitary gland controls the adrenal gland&#39;s production of cortisol and adrenal androgens through adrenocorticotropic hormone (ACTH). However, mineralocorticoid production (aldosterone) is primarily regulated by the renin-angiotensin-aldosterone system (RAAS), which is independent of the pituitary. Therefore, the ability of the adrenal gland to retain sodium in response to hypovolemia would be preserved immediately postoperatively.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Morning peak of plasma cortisol level:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is regulated by ACTH from the pituitary and would be impaired after pituitary resection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Release of cortisol in response to stress:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is also regulated by ACTH and would be impaired after pituitary resection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Release of DHEA:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is also regulated by ACTH and would be impaired after pituitary resection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aldosterone production and function, which regulate sodium retention in response to hypovolemia, are controlled by the renin-angiotensin-aldosterone system (RAAS) and not dependent on the pituitary gland. Therefore, this function will be preserved postoperatively.</span></span></span></p>",
    "correct_choice_id": 156193,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 39115,
    "choices": [
      {
        "id": 156195,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adrenocortical carcinoma </span></span></span></p>"
      },
      {
        "id": 156196,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cortisol-producing adenoma </span></span></span></p>"
      },
      {
        "id": 156197,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endocrine-inactive adenoma </span></span></span></p>"
      },
      {
        "id": 156198,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pheochromocytoma</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the most common cause of a unilateral adrenal mass?</span></span></p>",
    "unique_key": "Q9702738",
    "question_audio": null,
    "question_video": null,
    "map_id": 24090,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Endocrine-inactive adenoma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endocrine-inactive adenomas (60-85%) are the most common cause of unilateral adrenal masses. These are benign tumors that do not produce excess hormones and are often discovered incidentally on imaging studies performed for other reasons.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Adrenocortical carcinoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a rare, malignant tumor of the adrenal cortex. While it can present as a unilateral adrenal mass, it is far less common than benign adenomas (2-5%).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Cortisol-producing adenoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> These adenomas cause Cushing&#39;s syndrome due to excess cortisol production. They are less common than endocrine-inactive adenomas (5-10%).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Pheochromocytoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a tumor of the adrenal medulla that secretes catecholamines. While it can present as a unilateral adrenal mass, it is also less common than endocrine-inactive adenomas (5-10%).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endocrine-inactive adenomas are the most common type of unilateral adrenal mass, accounting for 60-85% of cases. They are usually benign and discovered incidentally on imaging.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-164523.png\" style=\"height:641px; width:1000px\" /></span></span></span></p>",
    "correct_choice_id": 156197,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 39118,
    "choices": [
      {
        "id": 156207,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adrenocorticotropic hormone-producing (ACTH) pituitary adenoma </span></span></span></p>"
      },
      {
        "id": 156208,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adrenocortical adenoma </span></span></span></p>"
      },
      {
        "id": 156209,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adrenocortical carcinoma </span></span></span></p>"
      },
      {
        "id": 156210,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ectopic ACTH secretion</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the most common cause of Cushing syndrome?</span></span></p>",
    "unique_key": "Q8912154",
    "question_audio": null,
    "question_video": null,
    "map_id": 24093,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Adrenocorticotropic hormone-producing (ACTH) pituitary adenoma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ACTH-producing pituitary adenomas, also known as Cushing&#39;s disease, are the most common cause of endogenous Cushing syndrome, accounting for approximately 75% of cases. These benign tumors secrete excess ACTH, which stimulates the adrenal glands to produce excessive cortisol.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Adrenocortical adenoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While adrenal adenomas can cause Cushing syndrome (5-10% cases), they are less common than pituitary adenomas. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Adrenocortical carcinoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a rare, malignant tumor of the adrenal cortex and is a less common cause of Cushing syndrome (15% cases).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Ectopic ACTH secretion:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Ectopic ACTH secretion from tumors outside the pituitary gland is a less common cause of Cushing syndrome compared to pituitary adenomas (25% cases).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ACTH-producing pituitary adenomas (Cushing&#39;s disease) are the most common cause of endogenous Cushing syndrome, accounting for about 75% of cases. These adenomas stimulate excess cortisol production by the adrenal glands.</span></span></span></p>",
    "correct_choice_id": 156207,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "Factual"
    ]
  },
  {
    "id": 19910,
    "choices": [
      {
        "id": 79601,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IVF bolus </span></span></span></p>"
      },
      {
        "id": 79602,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">100mg hydrocortisone </span></span></span></p>"
      },
      {
        "id": 79603,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Repeat CT scan of the chest, abdomen, and pelvis</span></span></span></p>"
      },
      {
        "id": 79604,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CT pulmonary angiogram</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An elderly man is admitted to the hospital after a car accident. A CT scan reveals a splenic laceration, and he undergoes urgent splenectomy. 2 hours post-surgery, his blood pressure is persistently 70/50 mmHg. He is obese and his abdomen is shown in the picture. Which of the following is inappropriate in this patient?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-165457.png\" style=\"height:327px; width:300px\" /></span></span></p>",
    "unique_key": "Q1075313",
    "question_audio": null,
    "question_video": null,
    "map_id": 19885,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) CT pulmonary angiogram</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient presents with persistent hypotension after splenectomy, raising concerns about ongoing hemorrhage or adrenal insufficiency (given the obesity and stretch marks, which could suggest Cushing&#39;s syndrome).<br />\r\nWhile pulmonary embolism is a potential cause of hypotension, it usually occurs 72h post-op and unlikely in this patient in the immediate post-op period. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. IVF bolus:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is appropriate to address hypovolemia, a common cause of hypotension after surgery. This is important in the setting of adrenal insufficiency as well. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. 100mg hydrocortisone bolus:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is appropriate if adrenal insufficiency is suspected, as it can rapidly replace deficient cortisol levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Repeat CT scan of the chest, abdomen, and pelvis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This could be helpful in identifying a missed site of bleeding (which can be vital in deciding on re-exploration of the abdomen/pelvis).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient is post-splenectomy with persistent hypotension, suggesting possible hemorrhage or adrenal insufficiency. A CT pulmonary angiogram for pulmonary embolism is unlikely to be the cause immediately post-op and is not appropriate. Managing hypovolemia and considering adrenal insufficiency are priorities.</span></span></span></p>",
    "correct_choice_id": 79604,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 19912,
    "choices": [
      {
        "id": 79609,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&beta;-Blockade is contraindicated. </span></span></span></p>"
      },
      {
        "id": 79610,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immediate surgical removal. </span></span></span></p>"
      },
      {
        "id": 79611,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Salt and fluid intake should be restricted. </span></span></span></p>"
      },
      {
        "id": 79612,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IV phentolamine is indicated for hypertensive crisis.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old man presents with tachycardia, headache, and flushing. His BP is 250/140 mm Hg and his plasma metanephrines are elevated. Which of the following statements is true regarding the management of this individual?</span></span></p>",
    "unique_key": "Q9277092",
    "question_audio": null,
    "question_video": null,
    "map_id": 19887,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) IV phentolamine is indicated for hypertensive crisis.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient is presenting with a hypertensive crisis likely due to pheochromocytoma, as evidenced by the elevated metanephrines. IV phentolamine, an alpha-adrenergic blocker, is the appropriate first-line treatment to rapidly lower blood pressure in this emergency situation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. &beta;-Blockade is contraindicated:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While &beta;-blockers should not be used before &alpha;-blockade, they can be added later to control tachycardia once the &alpha;-adrenergic effects have been controlled.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Immediate surgical removal:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Surgery is the definitive treatment for pheochromocytoma, but it should not be done emergently. The patient needs to be stabilized first with appropriate medical management to control blood pressure and heart rate before surgery is considered.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Salt and fluid intake should be restricted:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Adequate hydration is essential in managing pheochromocytoma to prevent hypovolemia and orthostatic hypotension.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient with pheochromocytoma presenting in a hypertensive crisis should be treated with IV phentolamine, an alpha-adrenergic blocker, to rapidly lower blood pressure. Beta-blockers should be used only after adequate alpha-blockade.</span></span></span></p>",
    "correct_choice_id": 79612,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 19915,
    "choices": [
      {
        "id": 79621,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">10% cases have an inherited condition.</span></span></span></p>"
      },
      {
        "id": 79622,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Biallelic gene inactivation in VHL gene can result in pheochromocytoma.</span></span></span></p>"
      },
      {
        "id": 79623,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">RET activation can result in pheochromocytoma.</span></span></span></p>"
      },
      {
        "id": 79624,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patients with inherited conditions tend to present early.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is false regarding genetics of pheochromocytoma?</span></span></span></p>",
    "unique_key": "Q7468998",
    "question_audio": null,
    "question_video": null,
    "map_id": 19889,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) 10% cases have an inherited condition.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">About 25&ndash;33% (not 10%) of patients with a pheochromocytoma or paraganglioma have an inherited syndrome. At diagnosis, patients with inherited syndromes are a mean of ~ 15 years younger than patients with sporadic tumors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Biallelic gene <em><u>inactivation</u></em>, a characteristic of tumor-suppressor genes, has been demonstrated for the VHL, NF1, SDHx, TMEM127, MAX, FH, PDH1, PDH2, MDH2, and KIF1B&beta; genes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In contrast, RET is a protooncogene, and mutations <em><u>activate</u></em> receptor tyrosine kinase activity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Biallelic gene inactivation in VHL gene can result in pheochromocytoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> VHL is a tumor suppressor gene and hence biallelic inactivation is required for tumorigenesis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. RET activation can result in pheochromocytoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Since RET is a proto-oncogene, activation is required for tumorigenesis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Patients with inherited conditions tend to present early:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Patients with inherited syndromes are a mean of ~ 15 years younger than patients with sporadic tumors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></u></strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Approximately 25-33% of patients with pheochromocytoma or paraganglioma have an inherited syndrome, not 10%. These inherited conditions often present at a younger age compared to sporadic cases.</span></span></span></p>",
    "correct_choice_id": 79621,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19917,
    "choices": [
      {
        "id": 79629,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Low levels of ACTH. </span></span></span></p>"
      },
      {
        "id": 79630,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated serum DHEAS. </span></span></span></p>"
      },
      {
        "id": 79631,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Absence of hyperpigmentation. </span></span></span></p>"
      },
      {
        "id": 79632,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cortisol &gt; 50nmol/L after dexamethasone.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman presents with weight gain, moon facies, and purple striae. She has a 1 cm adrenal mass in CT scan. Which of the following is unlikely in this patient? </span></span></p>",
    "unique_key": "Q7217887",
    "question_audio": null,
    "question_video": null,
    "map_id": 19891,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Elevated serum DHEAS. </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adrenal causes of Cushing syndrome generally has lower DHEAS and ACTH-dependent causes tend to have normal or increased DHEAS (ACTH stimulate DHEAS production). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Low levels of ACTH</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Adrenal masses producing Cushing&rsquo;s syndrome tend to be ACTH independent.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Absence of hyperpigmentation</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Since ATCH is lower in adrenal causes, hyperpigmentation is unlikely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Cortisol &gt; 50nmol/L after dexamethasone</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is a feature of Cushing&rsquo;s syndrome due to any cause.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></u></strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adrenal causes of Cushing&#39;s syndrome generally result in lower DHEAS levels. Elevated DHEAS is more commonly associated with ACTH-dependent causes.</span></span></span></p>",
    "correct_choice_id": 79630,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19919,
    "choices": [
      {
        "id": 79637,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Osilodrostat </span></span></span></p>"
      },
      {
        "id": 79638,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mitotane </span></span></span></p>"
      },
      {
        "id": 79639,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metyrapone</span></span></span></p>"
      },
      {
        "id": 79640,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pasireotide</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT a recommended treatment for Cushing&#39;s disease?</span></span></p>",
    "unique_key": "Q1040509",
    "question_audio": null,
    "question_video": null,
    "map_id": 19893,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Mitotane</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mitotane is primarily used in the treatment of adrenocortical carcinoma, a rare form of adrenal cancer. While it can lower cortisol levels, its use is not recommended in Cushing&#39;s disease (ACTH-producing pituitary adenoma) due to its limited efficacy and potential for significant side effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Osilodrostat:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a newer medication that directly inhibits 11&beta;-hydroxylase, the enzyme responsible for the final step of cortisol synthesis. It is also known to block aldosterone synthase to some extent and it is is approved for the treatment of Cushing&#39;s disease. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Metyrapone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This medication blocks cortisol synthesis by inhibiting 11&beta;-hydroxylase. It is often used in the diagnosis and treatment of Cushing&#39;s syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Pasireotide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a somatostatin analog that can suppress ACTH secretion from pituitary tumors, making it a treatment option for Cushing&#39;s disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mitotane is primarily used for adrenocortical carcinoma and is not typically recommended for treating Cushing&#39;s disease (ACTH-secreting pituitary adenomas). Osilodrostat, metyrapone, and pasireotide are used for managing Cushing&#39;s disease.</span></span></span></p>",
    "correct_choice_id": 79638,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 19920,
    "choices": [
      {
        "id": 79641,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Unilateral adrenalectomy. </span></span></span></p>"
      },
      {
        "id": 79642,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bilateral adrenalectomy.</span></span></span></p>"
      },
      {
        "id": 79643,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">High-dose dexamethasone suppression test. </span></span></span></p>"
      },
      {
        "id": 79644,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inferior petrosal sinus sampling.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with Cushing&#39;s syndrome has suppressed ACTH levels and multiple bilateral small nodules (&lt; 1cm) on adrenal imaging. What is the most appropriate next step in management?</span></span></p>",
    "unique_key": "Q3501344",
    "question_audio": null,
    "question_video": null,
    "map_id": 19894,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Bilateral adrenalectomy.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The combination of suppressed ACTH levels and bilateral adrenal nodules is highly suggestive of primary pigmented nodular adrenocortical disease (PPNAD), a rare cause of Cushing&#39;s syndrome. PPNAD is characterized by multiple, small cortisol-producing nodules in both adrenal glands. The definitive treatment for PPNAD is bilateral adrenalectomy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Unilateral adrenalectomy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This would not be effective in PPNAD, as both adrenal glands are involved.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. High-dose dexamethasone suppression test:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This test helps differentiate between different causes of Cushing&#39;s syndrome, but it is not necessary in this case, as the suppressed ACTH and bilateral nodules strongly suggest PPNAD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Inferior petrosal sinus sampling:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This test is used to differentiate between Cushing&#39;s disease (ACTH-producing pituitary tumor) and ectopic ACTH syndrome. Since ACTH is suppressed in this patient, IPSS is not indicated. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></u></strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Suppressed ACTH levels and multiple small nodules on bilateral adrenal imaging suggest primary pigmented nodular adrenocortical disease (PPNAD). The appropriate treatment is bilateral adrenalectomy.</span></span></span></p>",
    "correct_choice_id": 79642,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19923,
    "choices": [
      {
        "id": 79653,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spironolactone </span></span></span></p>"
      },
      {
        "id": 79654,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydrochlorothiazide </span></span></span></p>"
      },
      {
        "id": 79655,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phenoxybenzamine </span></span></span></p>"
      },
      {
        "id": 79656,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prednisolone</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 22-year-old patient presents with recurrent and sudden bouts of high blood pressure and headache. His serum potassium is 5.8 mEq/L and his serum bicarbonate is 17 mEq/L. His renin and aldosterone levels are low. Which of the following medications would be most effective in managing this patient&#39;s condition?</span></span></p>",
    "unique_key": "Q2424237",
    "question_audio": null,
    "question_video": null,
    "map_id": 19897,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Hydrochlorothiazide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s presentation is consistent with Gordon&#39;s syndrome (pseudohypoaldosteronism type II), a rare genetic disorder characterized by hypertension, hyperkalemia (high potassium), and metabolic acidosis (low bicarbonate).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydrochlorothiazide, a thiazide diuretic, is the most effective treatment for Gordon&#39;s syndrome as it promotes potassium excretion and helps correct hyperkalemia. It can also help lower blood pressure and improve metabolic acidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Spironolactone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> An effective treatment in case of patients who have mineralocorticoid excess. Ineffective in Gordon syndrome. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Phenoxybenzamine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is an alpha-blocker used in the treatment of pheochromocytoma. It is not effective in Gordon&#39;s syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Prednisolone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Can be used in case of GRA (glucocorticoid remediable aldosteronism). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s symptoms are consistent with Gordon&#39;s syndrome, which is characterized by hypertension, hyperkalemia, and metabolic acidosis. Hydrochlorothiazide is effective in this condition by promoting potassium excretion and lowering blood pressure.</span></span></span></p>",
    "correct_choice_id": 79654,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 19925,
    "choices": [
      {
        "id": 79661,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bilateral adrenalectomy. </span></span></span></p>"
      },
      {
        "id": 79662,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adrenal vein sampling.</span></span></span></p>"
      },
      {
        "id": 79663,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spironolactone. </span></span></span></p>"
      },
      {
        "id": 79664,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FNAC/Biopsy of the adrenals.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 52-year-old man with primary hyperaldosteronism is referred to you by a colleague. You order a CECT of the abdomen which shows bilateral micronodular hyperplasia in the adrenals. What is the most appropriate next step?</span></span></p>",
    "unique_key": "Q2681655",
    "question_audio": null,
    "question_video": null,
    "map_id": 19899,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Spironolactone.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In cases of bilateral micronodular hyperplasia in primary aldosteronism, the preferred treatment is medical management with a mineralocorticoid receptor antagonist (MRA) like spironolactone. This is because surgery is not curative in this type of primary aldosteronism. Spironolactone helps control blood pressure and correct hypokalemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Bilateral adrenalectomy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is not indicated for bilateral hyperplasia, as it would result in permanent adrenal insufficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Adrenal vein sampling:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This procedure is used to differentiate between unilateral adenoma and bilateral hyperplasia. Since the diagnosis is already established by imaging, AVS is unnecessary.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. FNAC/Biopsy of the adrenals:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Biopsy is generally not recommended for primary aldosteronism as it carries the risk of bleeding and adrenal crisis. The diagnosis is usually made based on biochemical testing and imaging.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For bilateral adrenal hyperplasia, the preferred treatment is medical management with a mineralocorticoid receptor antagonist like spironolactone, as it helps control blood pressure and corrects hypokalemia.</span></span></span></p>",
    "correct_choice_id": 79663,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19926,
    "choices": [
      {
        "id": 79665,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Weiss score </span></span></span></p>"
      },
      {
        "id": 79666,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ki-67 </span></span></span></p>"
      },
      {
        "id": 79667,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">p53 mutations </span></span></span></p>"
      },
      {
        "id": 79668,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Steroid overproduction</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the most important prognostic marker of Adrenocortical carcinoma (ACC)?</span></span></p>",
    "unique_key": "Q3973813",
    "question_audio": null,
    "question_video": null,
    "map_id": 19900,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Ki-67</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Ki-67 proliferation index is the most important prognostic marker for ACC. A higher Ki-67 index indicates a more aggressive tumor with a higher risk of recurrence and poorer overall survival. A Ki-67 index of &lt;10% is associated with slow to moderate growth velocity, while a Ki-67 &ge;10% indicates a higher risk of recurrence and rapid progression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Weiss score:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While the Weiss score is a useful tool for diagnosing ACC, it is not the most important prognostic marker. It utilizes the following parameters (&ge; 3 = ACC) - high nuclear grade, mitotic rate (&gt;5/HPF), atypical mitosis, &lt;25% clear cells, diffuse architecture, presence of necrosis, venous invasion, and invasion of sinusoidal structures and tumor capsule. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. p53 mutations:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Somatic TP53 mutations are found in 25% of sporadic ACC &amp; germline TP53 mutations (also causes Li- Fraumeni syndrome) are found in 25% of pediatric ACC cases. TP53 mutations are not related to ACC prognosis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Steroid overproduction:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While steroid overproduction is a common feature of ACC (seen in 60-70% cases), it does not directly correlate with prognosis. Excess production of glucocorticoids and adrenal androgen precursors are most common and indicative of malignancy. ACCs tend to have a distinct steroid fingerprint that can be picked up using urine &lsquo;steroid metabolomics&rsquo;.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Ki-67 proliferation index is the most important prognostic marker for adrenocortical carcinoma (ACC). A higher Ki-67 index indicates a more aggressive tumor with a higher risk of recurrence and poorer overall survival.</span></span></span></p>",
    "correct_choice_id": 79666,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 19928,
    "choices": [
      {
        "id": 79673,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Weight loss </span></span></span></p>"
      },
      {
        "id": 79674,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Loss of pubic hair in women </span></span></span></p>"
      },
      {
        "id": 79675,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fever </span></span></span></p>"
      },
      {
        "id": 79676,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyponatremia</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with confirmed primary adrenal insufficiency presents with fatigue, weight loss, and salt craving. Which of the following would not be attributed to loss of cortisol?</span></span></p>",
    "unique_key": "Q5643917",
    "question_audio": null,
    "question_video": null,
    "map_id": 19902,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Loss of pubic hair in women </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Loss of axillary and pubic hair in women is a feature of androgen loss.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\">&nbsp;</span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Features of adrenal androgen deficiency in women</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <em>Lack of energy</em>, Dry and itchy skin (, Loss of libido, Loss of axillary and pubic hair.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Features of cortisol deficiency:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Fatigue &amp; <em>lack of energy</em>, Weight loss &amp; anorexia, Myalgia &amp; joint pain, Fever, Hematological (Normochromic anemia, lymphocytosis, eosinophilia), Slightly increased TSH (due to loss of feedback inhibition of TSH release), Hypoglycemia (more frequent in children), <em><u>Low blood pressure, postural hypotension</u></em>, <em><u>Hyponatremia</u></em> (euvolemic, due to loss of feedback inhibition of AVP release).</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Features of Aldosterone deficiency</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Abdominal pain &amp; nausea/vomiting, Dizziness, Salt craving, <em><u>Low blood pressure, postural hypotension</u></em>, Increased serum creatinine (due to volume depletion), <em><u>Hyponatremia</u></em> (hypovolemic), Hyperkalemia. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Weight loss:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Feature of cortisol deficiency. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Fever:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Feature of cortisol deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Hyponatremia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Feature of cortisol &amp;/or aldosterone deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Loss of pubic hair in women is a feature of androgen loss. Weight loss, fever, and hyponatremia are features of cortisol deficiency.</span></span></span></p>",
    "correct_choice_id": 79674,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 19929,
    "choices": [
      {
        "id": 79677,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Change hydrocortisone to dexamethasone. </span></span></span></p>"
      },
      {
        "id": 79678,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Maintain the same dose of hydrocortisone. </span></span></span></p>"
      },
      {
        "id": 79679,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increase hydrocortisone dose to 30 mg/day. </span></span></span></p>"
      },
      {
        "id": 79680,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decrease hydrocortisone dose to 10 mg/day.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old woman with known adrenal insufficiency comes to visit after getting pregnant. She is currently 28 weeks into gestation. She is already on 20 mg of hydrocortisone per day. What should be your advice?</span></span></p>",
    "unique_key": "Q5107905",
    "question_audio": null,
    "question_video": null,
    "map_id": 19903,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Increase hydrocortisone dose to 30 mg/day.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During pregnancy, the body&#39;s demand for cortisol increases, and women with adrenal insufficiency require higher doses of glucocorticoid replacement therapy. A common approach is to increase the hydrocortisone dose by approximately 50% during the last trimester of pregnancy. Therefore, increasing the dose from 20 mg to 30 mg/day is the most appropriate recommendation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Change hydrocortisone to dexamethasone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Dexamethasone is a long-acting glucocorticoid that can cross the placenta and suppress fetal adrenal function. It is not the preferred glucocorticoid replacement during pregnancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Maintain the same dose of hydrocortisone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Maintaining the same dose would not be sufficient to meet the increased cortisol demands of pregnancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Decrease hydrocortisone dose to 10 mg/day:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This would be inadequate and could precipitate an adrenal crisis in the pregnant woman.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During pregnancy, the body&#39;s demand for cortisol increases, especially during the last trimester. Therefore, increasing the dose from 20 mg to 30 mg/day is appropriate.</span></span></span></p>",
    "correct_choice_id": 79679,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 53936,
    "choices": [
      {
        "id": 215213,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN2B </span></span></span></p>"
      },
      {
        "id": 215214,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">VHL (von Hippel-Lindau) </span></span></span></p>"
      },
      {
        "id": 215215,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">TMEM127 </span></span></span></p>"
      },
      {
        "id": 215216,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PGL4</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following familial syndromes has the highest rate of metastatic pheochromocytoma?</span></span></p>",
    "unique_key": "Q1791600",
    "question_audio": null,
    "question_video": null,
    "map_id": 25530,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) PGL4 </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PGL4, or SDHB-related paraganglioma syndrome, has the highest rate of metastatic pheochromocytoma among the listed familial syndromes. Approximately one-third of patients with PGL4 develop metastatic disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. MEN2B:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While pheochromocytoma is a feature of MEN2B, it is typically benign and rarely metastasizes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. VHL:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Pheochromocytomas associated with VHL have a lower risk of metastasis compared to PGL4.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. TMEM127:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Pheochromocytomas associated with TMEM127 mutations are generally benign and rarely metastasize.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SDHB-related paraganglioma syndrome (PGL4) has the highest rate of metastatic pheochromocytoma among the listed familial syndromes, with approximately one-third of patients developing metastatic disease.</span></span></span></p>",
    "correct_choice_id": 215216,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 53937,
    "choices": [
      {
        "id": 215217,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Weight loss </span></span></span></p>"
      },
      {
        "id": 215218,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diarrhea </span></span></span></p>"
      },
      {
        "id": 215219,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperglycemia </span></span></span></p>"
      },
      {
        "id": 215220,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypercalcemia</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT a typical feature of pheochromocytoma?</span></span></p>",
    "unique_key": "Q3234106",
    "question_audio": null,
    "question_video": null,
    "map_id": 25531,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Diarrhea</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diarrhea is not a typical feature of pheochromocytoma. In fact, constipation is more common due to the inhibitory effects of catecholamines on gastrointestinal motility.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Weight loss:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Increased metabolic rate and lipolysis caused by catecholamines can lead to weight loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Hyperglycemia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Catecholamines stimulate glycogenolysis and gluconeogenesis, leading to elevated blood glucose levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Hypercalcemia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While not common, hypercalcemia can occur in pheochromocytoma (mechanism uncertain &ndash; possibly due to secretion of PTHrP).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diarrhea is not a typical feature of pheochromocytoma. Constipation is more common due to the inhibitory effects of catecholamines on gastrointestinal motility.</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 215218,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 53938,
    "choices": [
      {
        "id": 215221,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gastrinoma</span></span></span></p>"
      },
      {
        "id": 215222,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">GH secreting pituitary adenoma </span></span></span></p>"
      },
      {
        "id": 215223,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adrenocortical tumours </span></span></span></p>"
      },
      {
        "id": 215224,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullated corneal nerve fibers</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT a feature of MEN1 syndrome?</span></span></p>",
    "unique_key": "Q9886025",
    "question_audio": null,
    "question_video": null,
    "map_id": 25532,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Medullated corneal nerve fibers</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is a feature of MEN2B syndrome, not MEN1. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Gastrinoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Gastrinomas (gastrin-secreting tumors) are a common manifestation of MEN1, often leading to Zollinger-Ellison syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. GH secreting pituitary adenoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Growth hormone-secreting pituitary adenomas can occur in MEN1, causing acromegaly (however prolactinomas are the most common).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Adrenocortical tumors:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> These are also associated with MEN1 (20-70%), although most of them non-functional.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullated corneal nerve fibers are a feature of MEN2B, not MEN1.</span></span></span></p>",
    "correct_choice_id": 215224,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 53939,
    "choices": [
      {
        "id": 215225,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rare feature of MEN1 </span></span></span></p>"
      },
      {
        "id": 215226,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Preoperative imaging is less helpful </span></span></span></p>"
      },
      {
        "id": 215227,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">More common in females </span></span></span></p>"
      },
      {
        "id": 215228,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Usually presents with severe hypercalcemia</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is true regarding hyperparathyroidism in MEN1?</span></span></p>",
    "unique_key": "Q2865474",
    "question_audio": null,
    "question_video": null,
    "map_id": 25533,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Preoperative imaging is less helpful</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In MEN1, hyperparathyroidism (and therefore hypercalcemia) is a common feature, arising from multiple parathyroid adenomas. This often necessitates the exploration of all parathyroid glands during surgery, making preoperative imaging (like ultrasound or sestamibi scan) less helpful in localizing a single adenoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Rare feature of MEN1:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hypercalcemia is a very common feature of MEN1, as the parathyroid glands are almost always affected.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. More common in females:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hyperparathyroidism in MEN1 has an equal male-to-female ratio, unlike sporadic hyperparathyroidism, which is more common in women.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Usually presents with severe hypercalcemia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hypercalcemia in MEN1 is usually mild, and severe hypercalcemia is rare.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></u></strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Preoperative imaging is less helpful in hyperparathyroidism due to multiple parathyroid adenomas in MEN1.</span></span></span></p>",
    "correct_choice_id": 215226,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 53948,
    "choices": [
      {
        "id": 215261,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">APS-1 </span></span></span></p>"
      },
      {
        "id": 215262,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">APS-2 (Schmidt&#39;s syndrome)</span></span></span></p>"
      },
      {
        "id": 215263,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">IPEX syndrome </span></span></span></p>"
      },
      {
        "id": 215264,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">POEMS syndrome</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">35-year-old woman with type 1 diabetes and celiac disease presents with fatigue, hair loss, constipation, dry skin, elevated TSH, and positive thyroid peroxidase antibodies. What is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q4426667",
    "question_audio": null,
    "question_video": null,
    "map_id": 25542,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) APS-2 (Schmidt&#39;s syndrome)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The combination of autoimmune thyroid disease (Hashimoto&#39;s thyroiditis), type 1 diabetes mellitus, and celiac disease, along with the presence of other autoimmune manifestations (dry skin), strongly suggests a diagnosis of APS-2.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. APS-1:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is characterized by chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency, none of which are present in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. IPEX syndrome:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a rare X-linked recessive disorder primarily affecting males and presenting in infancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. POEMS syndrome:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a paraneoplastic syndrome associated with plasma cell dyscrasia and is not relevant to this patient&#39;s presentation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">APS-2 (Schmidt&#39;s syndrome) includes autoimmune thyroid disease, type 1 diabetes mellitus, and celiac disease.</span></span></span></p>",
    "correct_choice_id": 215262,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53951,
    "choices": [
      {
        "id": 215273,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gastrointestinal stromal tumor (GIST) </span></span></span></p>"
      },
      {
        "id": 215274,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary chondroma </span></span></span></p>"
      },
      {
        "id": 215275,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Paraganglioma </span></span></span></p>"
      },
      {
        "id": 215276,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiac myxoma</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are features of Carney triad except:</span></span></p>",
    "unique_key": "Q7481131",
    "question_audio": null,
    "question_video": null,
    "map_id": 25545,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Cardiac myxoma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiac myxoma is a feature of Carney complex and NOT Carney triad. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Gastric GIST:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a hallmark of Carney triad. They originate from the interstitial cells of Cajal in the stomach wall.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Pulmonary chondroma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> These are benign cartilaginous tumors found in the lungs and are present in about 80% of cases. They can be unilateral or bilateral.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Paraganglioma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Usually extra-adrenal can occur in various locations, such as the head, neck, and abdomen.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carney triad includes gastrointestinal stromal tumor (GIST), pulmonary chondroma, and paraganglioma, but not cardiac myxoma.</span></span></span></p>",
    "correct_choice_id": 215276,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 53953,
    "choices": [
      {
        "id": 215281,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HLA-DR typing </span></span></span></p>"
      },
      {
        "id": 215282,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FOXP3 gene analysis </span></span></span></p>"
      },
      {
        "id": 215283,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">AIRE gene analysis </span></span></span></p>"
      },
      {
        "id": 215284,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">RET proto-oncogene sequencing</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 6-year-old girl presents with recurrent oral thrush, patchy hair loss, and fatigue. Laboratory findings reveal hypocalcemia and elevated parathyroid hormone (PTH). Which of the following genetic tests is most likely to confirm the suspected diagnosis?</span></span></p>",
    "unique_key": "Q7700988",
    "question_audio": null,
    "question_video": null,
    "map_id": 25547,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) AIRE gene analysis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The combination of recurrent oral thrush, hypocalcemia, and elevated PTH in a young child is highly suggestive of autoimmune polyendocrine syndrome type 1 (APS-1). APS-1 is caused by mutations in the AIRE gene, which is responsible for immune tolerance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">AIRE gene analysis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This test directly identifies the genetic cause of APS-1.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. HLA-DR typing:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> HLA-DR typing is used to identify genetic susceptibility to certain autoimmune diseases, but it is not specific to APS-1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. FOXP3 gene analysis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> FOXP3 mutations are associated with IPEX syndrome, a different type of immune dysregulation disorder.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. RET proto-oncogene sequencing:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> RET mutations are associated with multiple endocrine neoplasia type 2 (MEN2), not APS-1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">APS-1 is confirmed by AIRE gene analysis, given the presence of recurrent oral thrush, hypocalcemia, and elevated PTH.</span></span></span></p>",
    "correct_choice_id": 215283,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 53955,
    "choices": [
      {
        "id": 215289,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Onset in infancy </span></span></span></p>"
      },
      {
        "id": 215290,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Females &gt; males affected </span></span></span></p>"
      },
      {
        "id": 215291,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Autoantibodies to type 1 interferons and IL-17 and IL-22 </span></span></span></p>"
      },
      {
        "id": 215292,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Monogenic disorder</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are features of APS 1, except?</span></span></p>",
    "unique_key": "Q3841974",
    "question_audio": null,
    "question_video": null,
    "map_id": 25549,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Females &gt; males affected</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">APS-1 (Autoimmune Polyendocrine Syndrome type 1) affects both males and females equally. There is no gender predilection in this disorder, since it is a monogenic disorder. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Onset in infancy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is true. APS-1 often manifests in infancy or early childhood.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Autoantibodies to type 1 interferons and IL-17 and IL-22:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> These are characteristic autoantibody findings in APS-1, contributing to chronic mucocutaneous candidiasis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Monogenic disorder:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is true. APS-1 is caused by mutations in the AIRE gene, making it a monogenic disorder.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-181506.png\" style=\"height:461px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">APS-1 affects both males and females equally.</span></span></span></p>",
    "correct_choice_id": 215290,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 53956,
    "choices": [
      {
        "id": 215293,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FOXP3 </span></span></span></p>"
      },
      {
        "id": 215294,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">AIRE </span></span></span></p>"
      },
      {
        "id": 215295,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">WFS-1 </span></span></span></p>"
      },
      {
        "id": 215296,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">WASP</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 3-month-old male infant presents with severe diarrhea, failure to thrive, and eczematous dermatitis. Laboratory findings reveal autoimmune enteropathy and type 1 diabetes mellitus. Which of the following genes is responsible for the disease?</span></span></p>",
    "unique_key": "Q5587108",
    "question_audio": null,
    "question_video": null,
    "map_id": 25550,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) FOXP3</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The combination of early-onset enteropathy, type 1 diabetes mellitus, and eczema in a male infant strongly suggests Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) syndrome. IPEX is caused by mutations in the FOXP3 gene.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FOXP3:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This gene is essential for the development and function of regulatory T cells (Tregs), which are crucial for maintaining immune tolerance and preventing autoimmunity. Mutations in FOXP3 lead to a deficiency of Tregs, resulting in the autoimmune manifestations seen in IPEX.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. AIRE:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Mutations in the AIRE gene cause autoimmune polyendocrinopathy syndrome type 1 (APS-1), which is characterized by chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. WFS-1:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Mutations in the WFS1 gene cause Wolfram syndrome, a rare autosomal recessive disorder with diabetes mellitus, optic atrophy, deafness, and other neurological manifestations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. WASP:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Mutations in the WASP gene cause Wiskott-Aldrich syndrome, a rare X-linked recessive disorder characterized by thrombocytopenia, eczema, and recurrent infections.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IPEX syndrome is caused by mutations in the FOXP3 gene.</span></span></span></p>",
    "correct_choice_id": 215293,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53957,
    "choices": [
      {
        "id": 215297,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Breast cancer </span></span></span></p>"
      },
      {
        "id": 215298,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiovascular disease </span></span></span></p>"
      },
      {
        "id": 215299,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metabolic syndrome </span></span></span></p>"
      },
      {
        "id": 215300,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prostate cancer</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT a long-term health risk associated with Klinefelter syndrome?</span></span></p>",
    "unique_key": "Q6877572",
    "question_audio": null,
    "question_video": null,
    "map_id": 25551,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Prostate cancer</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Men with Klinefelter syndrome are at an increased risk of developing breast cancer, cardiovascular disease, metabolic syndrome, and osteoporosis. They are not, however, at an increased risk of developing prostate cancer. In fact, some studies suggest a slightly lower risk of prostate cancer in men with KS compared to the general population.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Breast cancer</strong>: Increased risk due to higher estrogen levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Cardiovascular disease</strong>: Increased risk due to various factors, including hormonal imbalances and metabolic abnormalities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Metabolic syndrome:</strong> Increased risk due to insulin resistance and dyslipidemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Men with Klinefelter syndrome are not at increased risk for prostate cancer.</span></span></span></p>",
    "correct_choice_id": 215300,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 53958,
    "choices": [
      {
        "id": 215301,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most commonly due to non-disjunction during spermatogenesis. </span></span></span></p>"
      },
      {
        "id": 215302,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most cases are diagnosed by puberty.</span></span></span></p>"
      },
      {
        "id": 215303,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androgen supplementation improve quality of life. </span></span></span></p>"
      },
      {
        "id": 215304,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most patients have enlarged testes.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is true regarding Klinefelter syndrome?</span></span></p>",
    "unique_key": "Q9579479",
    "question_audio": null,
    "question_video": null,
    "map_id": 25552,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Androgen supplementation improve quality of life.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androgen (testosterone) replacement therapy is a standard treatment for Klinefelter syndrome (KS). It has been shown to improve various aspects of quality of life, such as energy levels, libido, muscle mass, bone density, and overall well-being.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Most commonly due to non-disjunction during spermatogenesis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is incorrect. Non-disjunction during oogenesis (egg formation) is more common, accounting for about 60% of cases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Most cases are diagnosed by puberty:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is incorrect. Most cases are diagnosed in adulthood, often during fertility evaluations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Most patients have enlarged testes:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is incorrect. Most patients with KS have small, firm testes (median length 2.5 cm [4 mL volume] &amp; almost always &lt;3.5 cm [12 mL]). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androgen supplementation improves quality of life in Klinefelter syndrome.</span></span></span></p>",
    "correct_choice_id": 215303,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 53959,
    "choices": [
      {
        "id": 215305,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Only 50% tend to have 45, X karyotype </span></span></span></p>"
      },
      {
        "id": 215306,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pubertal development is common with mosaics </span></span></span></p>"
      },
      {
        "id": 215307,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most girls are 20cm short on average</span></span></span></p>"
      },
      {
        "id": 215308,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Type 1 Diabetes is common</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 16-year-old girl presents with primary amenorrhea, elevated FSH/LH levels, short stature, hypertension, and a bicuspid aortic valve on echocardiogram. Identify the incorrect statement regarding the patient&#39;s condition?</span></span></p>",
    "unique_key": "Q1312068",
    "question_audio": null,
    "question_video": null,
    "map_id": 25553,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Type 1 Diabetes is common</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s clinical presentation is highly suggestive of Turner syndrome (TS), a genetic disorder caused by the absence or abnormality of one X chromosome in females. Type 1 diabetes mellitus, theoretically can occur in TS but most cases are due to insulin resistance. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Autoimmune disorders common in TS: Thyroid disease, Celiac disease, IBD. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Only 50% tend to have 45X karyotype:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is true. Approximately half of women with TS have a 45,X karyotype, while others have mosaicism or structural abnormalities of the X chromosome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Pubertal development is common with mosaics:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is true. Girls with mosaic TS (45,X/46,XX) are more likely to experience spontaneous pubertal development than those with the classic 45,X karyotype.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Most girls are 20cm short on average:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is true. Short stature is a hallmark of TS, with average adult height being approximately 20 cm shorter than the general population. Height in non-mosaic TS (45 X) rarely exceeds 150cm. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Type 1 diabetes is uncommon in Turner syndrome, with most cases due to insulin resistance.</span></span></span></p>",
    "correct_choice_id": 215308,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 53961,
    "choices": [
      {
        "id": 215313,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Heart disease </span></span></span></p>"
      },
      {
        "id": 215314,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypertension </span></span></span></p>"
      },
      {
        "id": 215315,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Substance abuse disorder </span></span></span></p>"
      },
      {
        "id": 215316,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Suicide attempt</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following health conditions is most increased in transgender individuals compared with the general population?</span></span></p>",
    "unique_key": "Q1722165",
    "question_audio": null,
    "question_video": null,
    "map_id": 25555,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Suicide attempt</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transgender individuals face significant discrimination, stigma, and social challenges, which can lead to increased rates of mental health disorders like depression and anxiety. This, in turn, results in a much higher risk of suicide attempts compared to the general population. Research indicates that over 40% of transgender adults in the US have attempted suicide at some point in their lives. Summary of important issues in transgenders - </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Preventive Screenings: Lesbian and bisexual women receive fewer screenings.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cancer Rates: Higher (17x) HPV-associated anal cancer rates in men who have sex with men.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HIV and STIs: High rates of HIV and syphilis among gay and bisexual men.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mental Health: Elevated rates of depression, anxiety, substance abuse, and suicide attempts, particularly among transgender individuals and LGBT youth.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Youth at Risk: LGBT youth have significantly higher rates of suicide attempts and substance abuse (41% vs 1.6%).</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Heart disease:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Risk is increases slightly, but depends on a lot of other factors as well. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Hypertension:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Slightly higher than general population but suicide risk is the highest.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Substance abuse disorder:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> 2x more in LGBT youth but suicide risk is the highest. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transgender individuals have a significantly higher risk of suicide attempts compared to the general population.</span></span></span></p>",
    "correct_choice_id": 215316,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53962,
    "choices": [
      {
        "id": 215317,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A person&#39;s internal sense of their gender </span></span></span></p>"
      },
      {
        "id": 215318,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">How a person defines their own sexuality </span></span></span></p>"
      },
      {
        "id": 215319,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">How a person thinks of their physical or emotional attraction to others </span></span></span></p>"
      },
      {
        "id": 215320,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sex assigned at birth</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the accurate definition of a patient&#39;s &quot;gender identity&quot;?</span></span></span></p>",
    "unique_key": "Q7404339",
    "question_audio": null,
    "question_video": null,
    "map_id": 25556,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) A person&#39;s internal sense of their gender</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gender identity refers to a person&#39;s deeply felt, internal and individual experience of gender, which may or may not correspond with the sex assigned at birth. It is a fundamental aspect of a person&#39;s self-concept and can be male, female, both, neither, or somewhere along the gender spectrum.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. How a person defines their own sexuality:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Sexuality refers to a person&#39;s sexual orientation, attraction, and behavior, which is distinct from gender identity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. How a person thinks of their physical or emotional attraction to others:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This also refers to sexual orientation, not gender identity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Sex assigned at birth:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This refers to the biological sex assigned to an individual at birth based on their external genitalia, but it doesn&#39;t define their internal sense of gender.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gender identity refers to a person&#39;s internal sense of their gender.</span></span></span></p>",
    "correct_choice_id": 215317,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  }
];
        let quizName = 'Endocrinology';
        let hierarchy = ["Cerebellum", "qBank", "Pathology"];
        
        // Handle Custom Quiz Loading
        if (window.location.pathname.endsWith('custom_quiz.html')) {
            const customData = JSON.parse(localStorage.getItem('customQuizData'));
            if (customData) {
                questionsData = customData.questions;
                quizName = customData.name;
                hierarchy = customData.hierarchy;
                document.title = quizName + ' - QuizMaster Pro';
                document.getElementById('totalQuestions').textContent = questionsData.length;
                document.getElementById('quizHierarchy').textContent = hierarchy.join(' > ');
            }
        }

        let currentQuestionIndex = 0;
        let selectedOption = null;
        let currentMode = 'study';
        let timer = null;
        let timeRemaining = 0;
        let questionStartTime = Date.now();
        let quizStartTime = Date.now();
        let isQuizCompleted = false;
        
        let questionStates = new Array(questionsData.length).fill(null).map(() => ({
            status: 'not_attempted',
            bookmarked: false,
            markedForReview: false,
            selectedAnswer: null,
            timeSpent: 0
        }));
        
        let stats = {
            correctAnswers: 0,
            incorrectAnswers: 0,
            totalAttempted: 0,
            totalTime: 0,
            notAttempted: questionsData.length
        };

        const urlParams = new URLSearchParams(window.location.search);
        currentQuestionIndex = Math.min(parseInt(urlParams.get('startAt')) || 0, questionsData.length - 1);

        function goBack() {
            if (isQuizCompleted || confirm('Are you sure you want to leave the quiz? Your progress will be lost.')) {
                window.history.back();
            }
        }

        function selectMode(mode) {
            currentMode = mode;
            document.getElementById('modeModal').style.display = 'none';
            initializeQuiz();
        }

        function initializeQuiz() {
            quizStartTime = Date.now();
            
            const bookmarkBtn = document.getElementById('bookmarkBtn');
            const markReviewBtn = document.getElementById('markReviewBtn');
            const testModeReviewLegend = document.getElementById('testModeReviewLegend');
            const isTestMode = currentMode === 'test' || currentMode === 'timed_exam';
            
            document.getElementById('statsBar').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('studyModeLegend').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('testModeLegend').style.display = isTestMode ? 'block' : 'none';
            document.getElementById('submitSection').style.display = isTestMode ? 'block' : 'none';
            bookmarkBtn.style.display = isTestMode ? 'none' : 'flex';
            markReviewBtn.style.display = isTestMode ? 'flex' : 'none';
            testModeReviewLegend.style.display = isTestMode ? 'flex' : 'none';
            
            if (currentMode === 'timed_study' || currentMode === 'timed_exam') {
                document.getElementById('timerContainer').classList.remove('hidden');
            }
            
            loadBookmarkedQuestions();
            generateQuestionNav();
            updateStats();
            displayQuestion();
        }

        function generateQuestionNav() {
            const nav = document.getElementById('questionNav');
            nav.innerHTML = '';
            
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.createElement('button');
                btn.textContent = i + 1;
                btn.className = 'w-8 h-8 text-sm font-medium rounded transition-all duration-200';
                btn.onclick = () => jumpToQuestion(i);
                btn.id = `navBtn_${i}`;
                nav.appendChild(btn);
            }
            
            updateQuestionNav();
        }

        function updateQuestionNav() {
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.getElementById(`navBtn_${i}`);
                const state = questionStates[i];
                let className = '';
                
                if (i === currentQuestionIndex) {
                    className = 'nav-btn-current';
                } else if (state.bookmarked) {
                    className = 'nav-btn-bookmarked';
                } else if (state.markedForReview) {
                    className = 'nav-btn-marked-review';
                } else if (currentMode === 'study' || currentMode === 'timed_study') {
                    if (state.status === 'correct') className = 'nav-btn-correct';
                    else if (state.status === 'incorrect') className = 'nav-btn-incorrect';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                } else {
                    if (state.selectedAnswer !== null) className = 'nav-btn-answered';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                }
                btn.className = `w-8 h-8 text-sm font-medium rounded ${className}`;
            }
        }

        function jumpToQuestion(index) {
            if (index >= 0 && index < questionsData.length) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex = index;
                displayQuestion();
            }
        }

        function updateStats() {
            if (currentMode === 'study' || currentMode === 'timed_study') {
                document.getElementById('correctCount').textContent = stats.correctAnswers;
                document.getElementById('incorrectCount').textContent = stats.incorrectAnswers;
                document.getElementById('totalAttempted').textContent = stats.totalAttempted;
                
                const accuracy = stats.totalAttempted > 0 
                    ? Math.round((stats.correctAnswers / stats.totalAttempted) * 100)
                    : 0;
                document.getElementById('accuracy').textContent = accuracy + '%';
                
                stats.totalTime = questionStates.reduce((acc, state) => acc + state.timeSpent, 0);
                const timeSpent = Math.floor(stats.totalTime / 1000);
                const minutes = Math.floor(timeSpent / 60);
                const seconds = timeSpent % 60;
                document.getElementById('timeSpent').textContent = 
                    minutes + ':' + seconds.toString().padStart(2, '0');
            }
        }

        function setupVideo(videoElement, url) {
            if (Hls.isSupported()) {
                const hls = new Hls();
                hls.loadSource(url);
                hls.attachMedia(videoElement);
            } else if (videoElement.canPlayType('application/vnd.apple.mpegurl')) {
                videoElement.src = url;
            }
        }

        function displayQuestion() {
            if (!questionsData || questionsData.length === 0) {
                document.getElementById('questionText').innerHTML = 'No questions available for this quiz.';
                return;
            };
            
            const question = questionsData[currentQuestionIndex];
            questionStartTime = Date.now();
            
            selectedOption = questionStates[currentQuestionIndex].selectedAnswer;
            
            const progress = ((currentQuestionIndex + 1) / questionsData.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';
            document.getElementById('currentQuestion').textContent = currentQuestionIndex + 1;
            updateQuestionNav();
            
            document.getElementById('prevBtn').disabled = currentQuestionIndex === 0;
            
            document.getElementById('solutionContainer').classList.add('hidden');
            
            document.getElementById('questionText').innerHTML = question.text || 'No question text available';
            
            let mediaHtml = '';
            if (question.question_audio) mediaHtml += `<div class="glass-light p-4 mb-4"><audio src="${question.question_audio}" controls class="w-full"></audio></div>`;
            if (question.question_video) mediaHtml += `<div class="glass-light p-4 mb-4"><video src="${question.question_video}" controls class="w-full rounded-lg"></video></div>`;
            if (question.question_images) {
                question.question_images.forEach(imgSrc => {
                    if (imgSrc) mediaHtml += `<div class="glass-light p-4 mb-4"><img src="${imgSrc}" alt="Question Image" class="w-full rounded-lg"></div>`;
                });
            }
            document.getElementById('questionMedia').innerHTML = mediaHtml;
            
            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';
            optionsContainer.classList.remove('answered');
            
            if (question.choices && Array.isArray(question.choices)) {
                question.choices.forEach((choice, index) => {
                    const optionLetter = String.fromCharCode(65 + index);
                    const isSelected = selectedOption === index;
                    
                    const optionDiv = document.createElement('div');
                    optionDiv.innerHTML = `
                        <button type="button" class="option-button ${isSelected ? 'selected' : ''}" data-option-index="${index}">
                            <div class="option-letter">${optionLetter}</div>
                            <div class="option-text">${choice.text || 'Option ' + (index + 1)}</div>
                        </button>
                    `;
                    optionsContainer.appendChild(optionDiv);
                });
                
                optionsContainer.addEventListener('click', function(e) {
                    const optionButton = e.target.closest('.option-button');
                    if (optionButton) {
                        const optionIndex = parseInt(optionButton.getAttribute('data-option-index'));
                        selectOption(optionIndex);
                    }
                });
            }
            
            updateBookmarkButton();
            updateMarkReviewButton();

            if ((currentMode === 'timed_study' || currentMode === 'timed_exam') && !isQuizCompleted) {
                startTimer();
            }
        }

        function selectOption(index) {
            const optionsContainer = document.getElementById('optionsContainer');
            if (optionsContainer.classList.contains('answered')) return;

            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                questionStartTime = Date.now();
            }
            
            selectedOption = index;
            questionStates[currentQuestionIndex].selectedAnswer = index;
            
            document.querySelectorAll('.option-button').forEach((btn, i) => {
                btn.classList.toggle('selected', i === index);
            });
            
            if (currentMode === 'study' || currentMode === 'timed_study') {
                setTimeout(processAnswer, 300);
            } else {
                if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                    questionStates[currentQuestionIndex].status = 'answered';
                    stats.totalAttempted++;
                    stats.notAttempted--;
                }
                updateQuestionNav();
            }
        }

        function processAnswer() {
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            
            if(selectedOption === null) return;

            const selectedChoice = question.choices[selectedOption];
            const isCorrect = selectedChoice.id === correctChoiceId;
            
            if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                stats.totalAttempted++;
                stats.notAttempted--;
                if(isCorrect) stats.correctAnswers++; else stats.incorrectAnswers++;
            }
            questionStates[currentQuestionIndex].status = isCorrect ? 'correct' : 'incorrect';
            
            updateStats();
            showInlineFeedback(isCorrect);
            updateQuestionNav();
        }

        function showInlineFeedback(isCorrect) {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;

            const optionsContainer = document.getElementById('optionsContainer');
            const optionButtons = optionsContainer.querySelectorAll('.option-button');
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            let correctOptionIndex = question.choices.findIndex(c => c.id === correctChoiceId);

            optionsContainer.classList.add('answered');

            optionButtons.forEach((btn, index) => {
                btn.classList.remove('selected');
                if (index === correctOptionIndex) btn.classList.add('correct');
                else if (index === selectedOption && !isCorrect) btn.classList.add('incorrect');
            });

            setTimeout(showSolution, 1500);
        }


        function showSolution() {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;
            
            const question = questionsData[currentQuestionIndex];
            document.getElementById('solutionText').innerHTML = question.solution || 'No solution provided';
            
            const videoContainer = document.getElementById('solutionVideo');
            const videoPlayer = document.getElementById('explanationVideoPlayer');
            const explanationVideo = question.explanation_video;
            
            if (explanationVideo) {
                videoContainer.classList.remove('hidden');
                if (explanationVideo.includes('.m3u8')) setupVideo(videoPlayer, explanationVideo);
                else videoPlayer.src = explanationVideo;
            } else {
                videoContainer.classList.add('hidden');
            }

            const audioContainer = document.getElementById('solutionAudio');
            audioContainer.innerHTML = '';
            if (question.explanation_audio_eng) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English Explanation:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
            }
            if (question.explanation_audio_hin) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish Explanation:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;
            }
            
            const imagesContainer = document.getElementById('solutionImages');
            imagesContainer.innerHTML = '';
            if (question.explanation_images) {
                 question.explanation_images.forEach(imgSrc => {
                    if(imgSrc) imagesContainer.innerHTML += `<div class="mt-4"><img src="${imgSrc}" alt="Explanation Image" class="w-full rounded-lg"></div>`;
                });
            }

            document.getElementById('solutionContainer').classList.remove('hidden');
        }

        function submitQuiz() {
            if (timer) clearInterval(timer);
            if (!confirm('Are you sure you want to submit the quiz?')) return;
            
            isQuizCompleted = true;
            let correct = 0, incorrect = 0;
            const totalTime = Date.now() - quizStartTime;
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                if (state.selectedAnswer !== null) {
                    if (question.choices[state.selectedAnswer].id === question.correct_choice_id) {
                        correct++;
                        state.status = 'correct';
                    } else {
                        incorrect++;
                        state.status = 'incorrect';
                    }
                }
            });
            
            // Save performance data
            const performanceData = JSON.parse(localStorage.getItem('quizPerformanceData')) || [];
            performanceData.push({
                quizName: quizName,
                hierarchy: hierarchy,
                timestamp: Date.now(),
                totalTime: totalTime,
                stats: {
                    correct: correct,
                    incorrect: incorrect,
                    notAttempted: questionsData.length - (correct + incorrect)
                }
            });
            localStorage.setItem('quizPerformanceData', JSON.stringify(performanceData));

            showPerformanceAnalysis(correct, incorrect, questionsData.length - (correct + incorrect), totalTime);
        }

        function showPerformanceAnalysis(correct, incorrect, notAttempted, totalTime) {
            const modal = document.getElementById('performanceModal');
            const accuracy = (correct + incorrect) > 0 ? Math.round((correct / (correct + incorrect)) * 100) : 0;
            
            const circumference = 2 * Math.PI * 65;
            const scoreCircle = document.getElementById('scoreCircle');
            scoreCircle.style.strokeDasharray = `${circumference} ${circumference}`;
            scoreCircle.style.strokeDashoffset = circumference - (accuracy / 100) * circumference;
            
            document.getElementById('accuracyScore').textContent = `${accuracy}%`;
            document.getElementById('totalQuestionsResult').textContent = questionsData.length;
            document.getElementById('correctResult').textContent = correct;
            document.getElementById('incorrectResult').textContent = incorrect;
            document.getElementById('notAttemptedResult').textContent = notAttempted;
            
            const totalMinutes = Math.floor(totalTime / 60000);
            const totalSeconds = Math.floor((totalTime % 60000) / 1000);
            document.getElementById('totalTimeResult').textContent = `${totalMinutes}:${totalSeconds.toString().padStart(2, '0')}`;
            
            const avgTime = totalTime / questionsData.length;
            const avgMinutes = Math.floor(avgTime / 60000);
            const avgSeconds = Math.floor((avgTime % 60000) / 1000);
            document.getElementById('avgTimeResult').textContent = `${avgMinutes}:${avgSeconds.toString().padStart(2, '0')}`;
            
            modal.classList.remove('hidden');
        }

        function closePerformanceModal() { document.getElementById('performanceModal').classList.add('hidden'); }

        function reviewQuestions() {
            document.getElementById('questionReviewSection').classList.remove('hidden');
            const container = document.getElementById('reviewQuestionsContainer');
            container.innerHTML = '';
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                const correctChoiceId = question.correct_choice_id;
                
                let statusClass = 'not-attempted', statusText = 'Not Attempted';
                if (state.selectedAnswer !== null) {
                    const selectedChoice = question.choices[state.selectedAnswer];
                    if (selectedChoice.id === correctChoiceId) { statusClass = 'correct'; statusText = 'Correct'; }
                     else { statusClass = 'incorrect'; statusText = 'Incorrect'; }
                }
                
                const reviewDiv = document.createElement('div');
                reviewDiv.className = `review-question ${statusClass}`;
                
                let optionsHtml = (question.choices || []).map((choice, choiceIndex) => {
                    const isSelected = state.selectedAnswer === choiceIndex;
                    const isCorrect = choice.id === correctChoiceId;
                    let borderClass = 'border-gray-600';
                    if(isCorrect) borderClass = 'border-green-500';
                    else if(isSelected) borderClass = 'border-red-500';
                    
                    return `<div class="p-3 rounded-lg border ${borderClass}"><span class="font-bold mr-3">${String.fromCharCode(65 + choiceIndex)}</span><span>${choice.text}</span></div>`;
                }).join('');

                const videoHtml = question.explanation_video ? `<div class="mt-4"><video id="review-video-${index}" data-src="${question.explanation_video}" class="w-full rounded-lg" controls></video></div>` : '';
                
                let audioHtml = '';
                if(question.explanation_audio_eng) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
                if(question.explanation_audio_hin) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;

                let imagesHtml = (question.explanation_images || []).map(src => src ? `<div class="mt-4"><img src="${src}" alt="Explanation Image" class="w-full rounded-lg"></div>` : '').join('');

                reviewDiv.innerHTML = `
                    <div class="mb-4">
                        <div class="flex justify-between items-center mb-3">
                            <h4 class="text-lg font-bold text-white">Question ${index + 1}</h4>
                            <span class="text-sm px-3 py-1 rounded-full bg-${statusClass === 'correct' ? 'green' : statusClass === 'incorrect' ? 'red' : 'gray'}-600 text-white">${statusText}</span>
                        </div>
                        <div class="text-white mb-4">${question.text}</div>
                    </div>
                    <div class="space-y-2 mb-4">${optionsHtml}</div>
                    <div class="bg-green-900 bg-opacity-20 p-4 rounded-lg border border-green-700">
                        <h5 class="text-green-400 font-bold mb-2">Explanation:</h5>
                        <div class="text-white text-opacity-90">${question.solution || 'No solution available.'}</div>
                        ${videoHtml}
                        ${audioHtml}
                        ${imagesHtml}
                    </div>`;
                container.appendChild(reviewDiv);
            });
            initializeReviewVideos();
        }

        function initializeReviewVideos() {
            document.querySelectorAll('video[data-src]').forEach(videoEl => {
                const src = videoEl.dataset.src;
                if (src && src.includes('.m3u8')) {
                    setupVideo(videoEl, src);
                } else if (src) {
                    videoEl.src = src;
                }
            });
        }

        function retakeQuiz() {
            if (confirm('Are you sure you want to retake the quiz? This will reset all your answers.')) {
                if (window.location.pathname.endsWith('custom_quiz.html')) {
                    localStorage.removeItem('customQuizData');
                }
                location.reload();
            }
        }

        function loadBookmarkedQuestions() {
            const bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            bookmarks.forEach(bookmark => {
                if (bookmark.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-'))) {
                    if (bookmark.questionIndex < questionsData.length) {
                        questionStates[bookmark.questionIndex].bookmarked = true;
                    }
                }
            });
        }

        function toggleBookmark() {
            const isBookmarked = !questionStates[currentQuestionIndex].bookmarked;
            questionStates[currentQuestionIndex].bookmarked = isBookmarked;
            
            let bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            
            if (isBookmarked) {
                const bookmarkData = {
                    quizName: quizName,
                    quizFile: window.location.pathname.split('/').pop(),
                    questionIndex: currentQuestionIndex,
                    question: questionsData[currentQuestionIndex],
                    hierarchy: hierarchy,
                    timestamp: Date.now()
                };
                bookmarks.push(bookmarkData);
            } else {
                bookmarks = bookmarks.filter(b => 
                    !(b.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-')) && b.questionIndex === currentQuestionIndex)
                );
            }
            
            localStorage.setItem('bookmarkedQuestions', JSON.stringify(bookmarks));
            updateBookmarkButton();
            updateQuestionNav();
        }

        function updateBookmarkButton() {
            const btn = document.getElementById('bookmarkBtn');
            const text = document.getElementById('bookmarkText');
            const isBookmarked = questionStates[currentQuestionIndex].bookmarked;
            
            btn.className = isBookmarked ? 'gradient-yellow px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isBookmarked ? 'Bookmarked' : 'Bookmark';
        }
        
        function toggleMarkForReview() {
            questionStates[currentQuestionIndex].markedForReview = !questionStates[currentQuestionIndex].markedForReview;
            updateMarkReviewButton();
            updateQuestionNav();
        }

        function updateMarkReviewButton() {
            const btn = document.getElementById('markReviewBtn');
            const text = document.getElementById('markReviewText');
            const isMarked = questionStates[currentQuestionIndex].markedForReview;
            
            btn.className = isMarked ? 'gradient-purple px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isMarked ? 'Marked' : 'Mark for Review';
        }

        function previousQuestion() {
            if (currentQuestionIndex > 0) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex--;
                displayQuestion();
            }
        }

        function nextQuestion() {
            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
            }
            
            if (currentQuestionIndex < questionsData.length - 1) {
                currentQuestionIndex++;
                displayQuestion();
            } else {
                if (currentMode === 'test' || currentMode === 'timed_exam') {
                    if (confirm('You have reached the end of the quiz. Would you like to submit your answers now?')) {
                        submitQuiz();
                    }
                } else {
                    if (confirm('You have completed all questions. Would you like to review from the beginning?')) {
                        currentQuestionIndex = 0;
                        displayQuestion();
                    }
                }
            }
        }

        function startTimer() {
            if (timer) clearInterval(timer);
            timeRemaining = 120; // 2 minutes per question
            updateTimerDisplay();
            
            timer = setInterval(() => {
                timeRemaining--;
                updateTimerDisplay();
                
                if (timeRemaining <= 0) {
                    clearInterval(timer);
                    if (currentMode === 'timed_exam') {
                        submitQuiz();
                    } else {
                        nextQuestion();
                    }
                }
            }, 1000);
        }

        function updateTimerDisplay() {
            const minutes = Math.floor(timeRemaining / 60);
            const seconds = timeRemaining % 60;
            document.getElementById('timeDisplay').textContent = 
                minutes + ':' + seconds.toString().padStart(2, '0');
        }

        function toggleSidebar() {
            document.getElementById('quizSidebar').classList.toggle('open');
        }

        document.addEventListener('DOMContentLoaded', () => {
             if (!window.location.pathname.endsWith('custom_quiz.html')) {
                document.getElementById('modeModal').style.display = 'flex';
             } else {
                initializeQuiz();
             }
        });
        
        document.addEventListener('keydown', function(e) {
            if (document.getElementById('modeModal').style.display !== 'none') return;
            if (document.getElementById('performanceModal').classList.contains('hidden') === false) return;
            
            if (e.key >= '1' && e.key <= '4') {
                const optionIndex = parseInt(e.key) - 1;
                const options = document.querySelectorAll('.option-button');
                if (optionIndex < options.length) selectOption(optionIndex);
            } else if (e.key === 'ArrowLeft') {
                previousQuestion();
            } else if (e.key === 'ArrowRight' || e.key === ' ') {
                e.preventDefault();
                nextQuestion();
            } else if (e.key.toLowerCase() === 'b' && (currentMode === 'study' || currentMode === 'timed_study')) {
                toggleBookmark();
            } else if (e.key.toLowerCase() === 'm' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                toggleMarkForReview();
            } else if (e.key.toLowerCase() === 's' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                submitQuiz();
            }
        });
    </script>
</body>
</html>